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Peripartum Cardiomyopathy (PPCM) is a rare and potentially life-threatening form 
of dilated cardiomyopathy that strikes previously healthy women in the last month of 
pregnancy or up to 5 months after delivery and can have a profound effect on the young 
women as well as their families. The cause of PPCM is not fully understood, but is most 
likely multifactorial and driven by a vasculotoxic environment caused by late pregnancy 
hormones. Factors such as oxidative stress, inflammation, infection, and anti-angiogenic 
molecules may also increase susceptibility to PPCM. Based on the known associations 
between PM2.5 exposure and cardiovascular disease as well as potential mechanistic 
overlaps in pathophysiology including oxidative stress and inflammation, exposure to 
PM2.5 during pregnancy and post-delivery may increase the risk of developing PPCM. 
For this thesis project we created a new cohort from the Rochester Epidemiology 
Project (REP) because the REP provides a unique opportunity to study relationships 
between environmental exposures, such as PM2.5, and disease outcomes including PPCM 
at a population level with increased generalizability and reduced misclassification by using 
medical record review to confirm diagnosis. A case control study was designed to examine 
whether exposure to PM2.5 during or after pregnancy increases susceptibility to PPCM. 
The results from the case study suggest that in this rural area traffic-based 
surrogates for PM2.5 are not good measures of exposure and PM2.5 air monitoring would be 
the most accurate exposure metric. However, we found that the current level of monitoring 
in rural areas is not sufficient to assess relationships between PM2.5 exposure and potential 
resulting health effects such as PPCM. Increased funding to develop and implement a 
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monitoring system based on scientific and not just compliance measurement needs would 
allow the US EPA to increase protection of human health from air pollution including 
PM2.5 for pregnant women. Without these changes the US EPA may fail to meet its duty to 
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Chapter 1: Introduction 
 
Cardiomyopathies are a group of diseases affecting the heart muscle, or 
myocardium, characterized by ventricular dysfunction typically due to hypertrophy, 
inflammation or dilation. This group of diseases contributes significantly to the global 
burden of cardiovascular disease (CVD). In 2015, approximately 640,000 individuals were 
diagnosed with cardiomyopathy globally with a reported mortality of more than 350,000 
persons.1 The most common form of cardiomyopathy is dilated cardiomyopathy (DCM), 
which affects one in 2,500 adults in the United States (US) and presents with the same 
symptoms as other types of chronic heart failure2 DCM is the 3rd leading cause of death 
due to heart failure in the US and the most common cause of heart failure leading to a heart 
transplant.3 
One rare and potentially life-threatening type of DCM is peripartum 
cardiomyopathy (PPCM), which strikes previously healthy women in the last month of 
pregnancy or up to 5 months after delivery. PPCM is characterized by systolic dysfunction 
of the left ventricle (LV) leading to dilation and heart failure. PPCM is unique from other 
cardiomyopathies in that while patients with PPCM have a high morbidity and mortality, 
these patients can also experience complete recovery of heart function4,5 with reported 
recovery rates ranging from 23-90%.6,7 Early diagnosis and treatment are essential to 
decrease mortality and increase the potential for full recovery of LV function. However, 
the symptoms of PPCM (orthopnea, dyspnea, on are very similar to the cardiophysiological 
changes that occur in a normal pregnancy, making timely diagnosis challenging.8,9 
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Many hypotheses have been suggested regarding the etiology and pathophysiology 
of PPCM including viral myocarditis leading to DCM, autoimmunity, fetal chimerism, 
genetics, hemodynamic stresses of pregnancy, nutritional deficiencies and angiogenic 
imbalance, but the exact causes remain unknown.10-12 Current research suggests that PPCM 
may be triggered by hormones secreted by the placenta and pituitary during late gestation 
that cause a vasculotoxic environment that leads to cardiac dilation and heart failure in 
susceptible women.10,13-16 However, why only a small number of women develop 
cardiomyopathy/ DCM during pregnancy remains unclear and requires further 
investigation. Other factors that may increase susceptibility to PPCM include oxidative 
stress, inflammation, viral infection, and antiangiogenic molecules.17 
There is a well-established relationship between ambient air pollution exposure and 
the development of CVD.18-23 Numerous studies have found relationships between elevated 
criteria air pollutant levels, including particulate matter, ozone, nitrogen dioxide, carbon 
monoxide, and/or sulfur dioxide, and the development of CVDs including heart failure, 
stroke, myocardial infarction (MI), coronary artery disease (CAD), hypertension (HT), and 
cardiac arrhythmias.19-21,23,24 However, the evidence is strongest for particulate matter sized 
2.5 micrometers and smaller (PM2.5), which is now recognized as a risk factor for 
cardiovascular morbidity and mortality.18,21,22,24,25 Both short- and long-term exposure to 
PM2.5 have been associated with an increased risk of ischemic heart disease, MI, stroke, 
arrhythmia, and heart failure as well as increased cardiovascular hospitalizations and 
mortality.18,22  
One of the main proposed pathways of how exposure to PM2.5 leads to heart failure 
and mortality begins with inflammation and oxidative stress leading to impaired vascular 
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function, similar to the proposed pathways for the development of PPCM.22 However, 
while there is a large amount of evidence that PM2.5 exposure contributes to the 
development and worsening of heart failure there are no studies specifically examining 
PM2.5 exposure and the development of cardiomyopathy or PPCM. In addition to the 
biological plausibility due to overlapping proposed pathways, multiple systematic reviews 
and meta-analysis provide epidemiological evidence of a relationship between the two by 
demonstrating strong positive relationships between exposure to PM2.5 and hypertensive 
disorders of pregnancy, one of the strongest known risk factors for PPCM.26-28 Based on 
the known relationship between exposure to PM2.5 and CVDs, overlapping potential 
biological mechanisms, and recent evidence for a relationship between PM2.5 exposure and 
hypertension during pregnancy, we hypothesize that it is possible that PM2.5 exposure could 
be a risk factor for PPCM. If PM exposure is found to be associated with PPCM, this may 
help us understand why some women are more susceptible to PPCM and why the highest 
incidence of PPCM occurs in less developed regions of the world like Nigeria, Togo, Haiti, 
and Pakistan,6 where indoor cooking and heating involve burning of organic material that 
releases large amounts of PM. The following aims were developed to test the hypothesis 
that exposure to elevated levels of air pollution/ PM2.5 during and post pregnancy increases 
the risk of developing PPCM: 
Aim 1: Use data from the Rochester Epidemiological Project (REP) to conduct a 
population-level epidemiological study to determine the incidence and risk factors for 
PPCM using a well-characterized population in order to estimate the incidence of PPCM 
among residents of a) Olmsted County, Minnesota from 1970 to 2014 (we refer to this part 
of the study as REP) and b) the 27 county area including and surrounding Olmstead County 
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from 1976 to 2014 (we refer to this part of the study as REP Expanded Region) in order to 
determine potential risk factors for PPCM and to determine short- and long-term survival 
among PPCM patients. 
Aim 2: Examine whether an association exists between exposure to air pollution and the 
incidence of PPCM using either a) U.S. Environmental Protection Agency (U.S. EPA) 
monitored levels of PM2.5 or b) proxies for air pollution such as traffic density and/or 
distance from major roadways. 
Aim 3: Discuss the a) public health implications and b) potential policy opportunities that 
arise from the research results found in Aim 1 and 2. 
The rest of this dissertation is laid out as follows: Chapter Two presents a recently 
published literature review of PPCM by Douglass and Blauwet,6 a that describes the case 
definition, epidemiology, pathophysiology, genetics and risk factors, diagnosis, 
biomarkers, treatment, outcomes, subsequent pregnancy, additional clinical concerns, 
knowledge gaps, and clinical care points. The reasons for developing a new cohort, of 
PPCM patients and controls, to test the hypothesis of this dissertation and for using the 
Rochester Epidemiology Project as the source of this cohort are described in Chapter 
Three. Chapter Four presents the results of Aim 1a, which are found within a published 
manuscript but are described in this chapter in more detail.7 The results from Aim 1b are 
presented in Chapter Five as a third manuscript which has been published in the Journal of 
Cardiac Failure.7 Chapter Six examines the relationship of PM2.5 exposure and the 
development of CVD and presents the literature foundation and a proposed mechanism for 
a relationship between PM2.5 exposure and the development of PPCM as well as how Aim 
2 had to be reframed due to limitations of available data. And finally, Chapter Seven 
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presents a case study titled “Clean Air Act: Peripartum Cardiomyopathy and the Rochester 
Epidemiology Project” which provides results from the modified Aim2 as well as 
discussion points from Aim 3. This chapter examines the ability of three commonly 
available methodologies (air monitoring, traffic density, and distance to major roadways) 
to ascertain the role of PM2.5 exposure on our study cohort, highlights the issues 
preventing each method from being fully applied, presents policy-based recommendations 
that would allow studies to successfully determine whether PM2.5 exposure leads to 
increased susceptibility to developing PPCM, and makes policy recommendation that 
could strengthen the human health protection required by the Clean Air Act. The final 
chapter of this dissertation, Chapter Eight, makes overall conclusions about the research 
project, identifies knowledge and research gaps, and discusses the environmental health 
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Peripartum cardiomyopathy (PPCM) is a form of heart failure with no known other cause 
that occurs towards the end of pregnancy or in the months following pregnancy and is 
marked by left ventricular systolic dysfunction. The cause of PPCM remains unknown and 
there is no diagnostic test specific to PPCM. Outcomes vary and include complete left 
ventricular recovery, persistent cardiac dysfunction, transplant, and death. Numerous 
advances have been made in understanding the etiology, pathophysiology and natural 
history of this disease, but many knowledge gaps remain. This article reviews the most 
recent data and recommendations for clinical practice in addition to highlighting the 





• Diagnosing peripartum cardiomyopathy (PPCM) requires a high degree of 
suspicion, because presenting signs and symptoms tend to mimic those of normal 
pregnancy and the early postpartum period. 
• Guideline-directed medical therapy for heart failure, with special considerations for 
use during pregnancy and lactation, is recommended, although efficacy and optimal 
duration of therapy have not been established. 
• Outcomes of both mother and child are generally good, although a subset of women 
experience chronic heart failure, transplant and/or cardiac death. 
• Subsequent pregnancy is not contraindicated in all women with history of PPCM, 
because risk of cardiac complications associated with future pregnancy varies 






ACE-I, angiotensin-converting enzyme-inhibitor 
AHA, American Heart Association 
ARB, angiotensin receptor blockers 
ARNI, angiotensin receptor neprilysin inhibitor 
BMI, body mass index 
BNP, brain natriuretic peptide 
CCS, Canadian Cardiovascular Society 
CRP, C-reactive protein 
DCM, dilated cardiomyopathy 
ECG, electrocardiogram 
Fas/Apo1, Fas/apoptosis antigen 1 
GDMT, guideline directed medical therapy 
HDP, hypertensive diseases of pregnancy 
HFA ESC WG PPCM, Heart Failure Association of the European Society of Cardiology 
Working Group on Peripartum Cardiomyopathy 
HFrEF, heart failure with reduced ejection fraction 
IL-1β, interleukin 1 beta 
IL-6, interleukin 6 
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INF-γ, interferon gamma 
IPAC, Investigations of Pregnancy Associated Cardiomyopathy 
kDa, kilodalton 
LDL, low-density lipoprotein 
LV, left ventricular 
LVAD, left ventricular assist device 
LVEDD, left ventricular end diastolic diameter 
LVEF, left ventricular ejection fraction 
MCS, mechanical circulatory support 
MRA, mineralocorticoid receptor antagonist 
MRI, magnetic resonance imaging 
NHLBI, National Heart, Lung and Blood Institute 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide 
NYHA, New York Heart Association 
PPCM, peripartum cardiomyopathy 
RV, right ventricular 
sFlt-1, soluble fms-like tyrosine kinase-1 
TNFα, tumor necrosis factor alpha 
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US, United States 





Peripartum cardiomyopathy (PPCM) is a form of heart failure with no known cause 
that occurs toward the end of pregnancy or in the months following pregnancy and is 
marked by left ventricular (LV) systolic dysfunction. Outcomes vary, because most women 
experience complete LV recovery, but a significant minority experience persistent cardiac 
dysfunction, transplant, or death. 
 
Case Definition 
The National Heart, Lung, and Blood Institute (NHLBI) and the Heart Failure 
Association (HFA) of the European Society of Cardiology (ESC) Working Group (WG) 
on PPCM have both published definitions for PPCM.1,2 (Box 2.1) These two definitions 
differ in terms of timing of diagnosis and the cutoff for LV ejection fraction (LVEF). 
Further investigation is needed to determine potential differences between women 
diagnosed with PPCM using the NHLBI criteria and (1) women who present with 
previously undiagnosed cardiomyopathy before 1 month before delivery or greater than 5 
months postdelivery, and (2) women who present with an initial LVEF greater than 45%, 
to determine whether or not pathophysiology and outcomes are similar. Having a clear and 
accurate definition of PPCM is crucial for determining optimal management strategies and 
prognosis and facilitating collaborative research. 
 
Epidemiology 
Estimates of PPCM incidence vary widely around the world, with many of the 
estimates coming from retrospective single-center cohort studies. Fig. 2.1 presents selected 
incidence estimates from several countries. The highest reported rates occur in Nigeria, 
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with 995 cases per 100,000 deliveries, and Togo, with 781 cases per 100,000 deliveries.3,4 
In the United States, nationwide estimates vary from 18 to 103 per 100,000 live births or 
deliveries.5-9 Risk factors associated with increased risk of developing PPCM include black 
African descent, hypertensive diseases of pregnancy (HDPs), multifetal pregnancies, and 
advanced maternal age.6,7,10-13 
 
Pathophysiology, Genetics, and Risk Factors 
The cause of PPCM is not fully understood but is most likely multifactorial. Current 
research suggests that hormones of late pregnancy cause a vasculotoxic environment that, 
in susceptible women, leads to the development of PPCM.14,15 High levels of prolactin are 
secreted from the pituitary gland and can be cleaved into the vasculotoxic, 
proinflammatory, and proapoptotic 16-kDa form.16 At the same time, antiangiogenic 
soluble fms-like tyrosine kinase-1 (sFlt-1) is secreted from the placenta, inhibiting vascular 
endothelial growth factor and placental growth factor. Both the 16-kDa form of prolactin 
and sFlt-1 have been shown to cause PPCM in mouse models.17,18 sFlt-1 levels are 
significantly increased in women with PPCM, and higher levels at diagnosis are associated 
with worse out- comes.19 Women with preeclampsia also have significantly increased sFlt-
1 levels, which may at least partially explain why HDP increases risk for PPCM.20 
A small percentage of women with PPCM have a family history of dilated 
cardiomyopathy (DCM). Family clustering has also been observed.21-26 Studies have also 
shown that a subset of women with PPCM have genetic mutations linked to DCM, 
predominantly in the TTN gene, which encodes the titin protein, which is critical to cardiac 
muscle structure.27-29 The Investigations of Pregnancy Associated Cardiomyopathy (IPAC) 
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study found that 1 TTN mutation genotype was associated with lower LVEF at 6 and 12 
months, especially in black women, which may help explain why black women have worse 
outcomes compared with white women.30 High frequencies of mutations in the TTN gene 
have also been found in women with preeclampsia, which may help to explain the increased 
risk of PPCM in women diagnosed with HDP.31 However, only 15% to 20% of women 
with PPCM have TTN mutations, and greater than 90% of individuals in the general 
population that have TTN mutations never develop any form of cardiomyopathy,27-29,32 so 
the significance of TTN mutations in women with PPCM remains unclear. Other factors 
that may increase susceptibility for PPCM include oxidative stress, inflammation, viral 
infection, and antiangiogenic molecules.33 
 
Diagnosis 
Because the exact cause remains unknown and no single test currently exists to 
confirm the diagnosis, PPCM remains a diagnosis of exclusion. Women generally present 
with symptoms that are common to pregnancy (orthopnea, dyspnea on exertion, fatigue, 
edema, paroxysmal nocturnal exertion, and chest tightness), so the diagnosis of PPCM may 
be delayed or missed altogether. Late diagnosis has been linked to worse outcomes, 
including persistent cardiac dysfunction and increased mortality.13,34-40 
Diagnostic Tests 
Echocardiogram, electrocardiogram (ECG), chest radiograph, cardiac MRI, and 
laboratory testing may all be useful in the diagnosis of PPCM. Echocardiography is the 
most important imaging modality, because it is readily available in many health care 
centers and can easily and comprehensively assess cardiac structure and function. By the 
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NHLBI definition, LVEF must be less than 45%.1 The left ventricle is usually, but not 
always, dilated.33-35,41 Assessment of right ventricular (RV) function is essential, because 
3 recent articles have reported that many women with PPCM also have RV dysfunction 
and that these women are at higher risk for adverse outcomes.42-44 Additional 
echocardiographic findings may include RV dilatation, mitral and/or tricuspid valve 
regurgitation, atrial enlargement, increased pulmonary pressures, and intracardiac 
thrombus.33-35,41 Cardiac MRI may be useful for the evaluation of biventricular structure 
and function or when echocardiography is nondiagnostic, but gadolinium is not 
recommended for use during pregnancy.43,45,46 Suggested diagnostic testing is outlined in 
Table 2.1. 
Biomarkers 
Many biomarker levels have been shown to be abnormal in women with PPCM and 
may thus be useful in diagnosing PPCM (Table 2.2). Markers of cardiac function such as 
N-terminal prohormone of brain natriuretic peptide (NT-proBNP), brain natriuretic peptide 
(BNP), and cardiac troponin are likely the most clinically useful. No biomarkers can be 




Initial management strategies vary depending on pregnancy status (Table 2.3). A 
multidisciplinary team approach to management is recommended, particularly if the 




Women diagnosed with PPCM should be treated with guideline-directed medical 
therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), bearing in mind 
the safety of specific medications during pregnancy and breastfeeding. Recommended 
medications may include b- blockers, angiotensin-converting enzyme inhibitors (ACE-
Is)/angiotensin receptor II blocker (ARBs), angiotensin receptor neprilysin inhibitor 
(ARNIs), hydralazine/nitrates, mineralocorticoid receptor antagonists (MRAs), and 
diuretics. Anticoagulation should be initiated if LV thrombus is present and may be 
considered in women with LVEF less than 35%. 
Whether or not initiating GDMT for HFrEF is necessary in all women with PPCM 
remains unclear, because some women recover LV function quickly and completely while 
taking only minimal to low doses of heart failure medications. Note that there has never 
been a randomized clinical trial testing the efficacy and safety of any heart failure 
medications in women with PPCM. Information regarding specific medications and their 
compatibility with pregnancy and breast feeding is reviewed Karen L. Florio and 
colleagues’ article, “Cardiovascular Medications in Pregnancy: A Primer.”47 
Bromocriptine 
Bromocriptine, which inhibits the nursing hormone prolactin, has been proposed as 
a novel treatment of PPCM in response to the hypothesis that the development of PPCM is 
driven by the antiangiogenic and proapoptotic 16-kDa cleaved form of prolactin. A small 
proof-of-concept study with 20 women in South Africa found that the addition of 
bromocriptine led to greater recovery of LVEF and lower mortality at 6 months.48 A second 
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study in Burkina Faso showed that treatment with bromocriptine was associated with 
increased LVEF at 2 weeks and at 3, 6, and 12 months, as well as decreased mortality.49 
However, both studies had unusually high rates of mortality in the control groups, limiting 
the ability to generalize the results. A multicenter randomized study with no control group 
conducted in Germany compared 2 dosing regimens (1 week vs 8 weeks) of bromocriptine 
in addition to GDMT for heart failure.50 Both study groups had similar outcomes, with no 
women undergoing heart transplant and no mortality in either group. The lack of a control 
group limits the applicability of these results in current clinical practice. 
In addition to the lack of rigorous clinical research showing the efficacy of 
bromocriptine for treatment of acute PPCM, concern regarding potential serious adverse 
effects has limited routine administration of bromocriptine in clinical practice. Treatment 
with bromocriptine has been associated with stroke, myocardial infarction, and seizures 
and, as a result, it is no longer marketed for elective lactation suppression in the United 
States.34 If bromocriptine is used, anticoagulation should be administered for the duration 
of therapy because women are already in a hypercoagulable state during the peripartum 
period and bromocriptine may further increase hypercoagulability. 
Of particular importance, women treated with bromocriptine cannot breastfeed 
their infants. The World Health Organization recommends exclusive breastfeeding for 6 
months and continued breastfeeding for at least 1 to 2 years because of the importance of 
breastfeeding to the health of both mother and infant. Not breast- feeding is associated with 
increased risk of diabetes, ovarian and breast cancer, and postpartum depression for 
mothers, and higher rates of mortality, infections, eczema, asthma, childhood obesity, type 
2 diabetes, leukemia, and lower intelligence in children.51,52 Results of the IPAC study and 
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two retrospective cohort studies suggest that breastfeeding has no detrimental effect on 
outcomes for women with PPCM.53-55 
The most recent statement on PPCM by the HFA ESC WG PPCM lists treatment 
with bromocriptine as a class IIb recommendation.41 In contrast, the American Heart 
Association (AHA) and the Canadian Cardiovascular Society (CCS) both recommend that 
bromocriptine should not routinely be used in the treatment of PPCM until more rigorous 
data that support the safety and effectiveness of its use are available.33,56 
Chronic Management 
Most experts agree that GDMT for HFrEF should be continued indefinitely in 
women with PPCM who have persistent cardiac dysfunction. The optimal duration of 
treatment of women who recover normal LV function is unknown. A 2016 AHA scientific 
statement on the diagnosis and treatment of dilated cardiomyopathies recommended 
indefinite continuation of treatment in women with PPCM, including those with recovered 
cardiac function, as well as yearly clinical follow-up and assessment of LV function even 
after recovery.35 More recent articles suggest that treatment duration should be considered 
on a case-by-case basis, with changes to or discontinuation of any cardiac medications to 
be completed slowly using a stepwise approach with frequent clinical and 
echocardiographic monitoring and follow-up.34,41 The HFA ESC WG PPCM has published 
recommendations for women diagnosed with PPCM who have recovered LV function 
(LVEF>55%) and are New York Heart Association (NYHA) functional class I as follows: 
continuation of all cardiac drugs for at least 12 to 24 months after full recovery and then 
discontinue them in a stepwise fashion (first MRA, second ACE-I/ARB/ ARNI, and then 
-blocker) with frequent monitoring of symptoms and LV function.41 Thus, although both 
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the AHA and HFA ESC WG PPCM guidelines agree that diuretics can be tapered and 
discontinued if there are no signs of fluid over- load, there is no consensus regarding 
duration of other cardiac medications in individual women. 
Several studies and case reports have shown that some women with PPCM who 
have recovered LV function can safely be tapered off medical therapy.36,57-59 In one study, 
5 women were tapered off all cardiac medications and none experienced deterioration of 
LV function over an average follow-up duration of 29 months (range, 5– 63 months).59 
Another report found that 2 women who had fully recovered LV function had deterioration 
of LVEF after discontinuation of all cardiac medications, with deterioration occurring at 
24 and 34 months after diagnosis.58 Two more recent studies found that women with LV 
recovery may have high rates of LV diastolic dysfunction and reduced exercise capacity60 
as well as ongoing angiogenic imbalance and residual myocardial injury,61 suggesting that 
women who recover may benefit from long-term GDMT for HFrEF. 
Long-term cardiology follow-up of women with history of PPCM who have 
recovered LV function is recommended regardless of whether or not LV recovery occurs 
and/or cardiac medications are discontinued (see Table 2.1). 
Advanced Heart Failure Therapies 
Women with PPCM who have severe myocardial disease may benefit from a 
wearable or implant- able cardiac defibrillator, left ventricular assist de- vice (LVAD), 
mechanical circulatory support (MCS), and/or transplant. Multiple factors affect the rates 
of each of these types of advanced heart failure therapy, including time to diagnosis, race, 
and availability. Rates of use of each of these advanced therapies in women with PPCM 
are difficult to discern, because studies often do not list these therapies separately and have 
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combined these outcomes differently for reporting. A nation- wide study conducted in the 
United States reported that, between 2004 and 2011, 1.5% of patients with PPCM required 
MCS and 0.5% of patients underwent transplant.9 Study specific rates in the United States 
vary between 0% and 7.8% for defibrillator implantation, 0% to 17.2% for MCS (intra-
aortic balloon pump, LVAD, and extracorporeal membrane oxygenation), and 0% to 8.8% 
for transplant.11,36,40,62-64 Rates in other countries vary widely, often depending on the 




Women with PPCM tend to have lower mortalities than women with other forms 
of DCM.73,74 Re- ported mortalities related to PPCM vary widely both within and between 
countries and within similar follow-up durations (Table 2.4). A recent systematic review 
and meta-analysis by Kerpen and colleagues75 found the overall PPCM mortality to be 9%, 
with higher rates in developing countries (14%) compared with more advanced countries 
(4%). Fig. 2.2, which includes 9 countries in addition to the 13 included in the meta-
analysis by Kerpen and colleagues,75 shows a similar trend of higher mortalities in 
developing countries. The higher PPCM mortalities in developing countries are most likely 
related to the impact of social determinants of health, including reduced access to care in 
general and access to advanced heart failure therapies in particular. 
Mortalities in Taiwan and the United States seem to be exceptions among advanced 
countries, whereas rates in The Philippines, China, and Singapore do not follow the trend 
among developing countries. Small sample sizes76-78 and differences in methodologies and 
15 
 
populations, particularly among the US reports,7-9,11-13,36,38,40,43,59,62,63,73,74,79-88may account 
for these variations. 
Left Ventricular Recovery 
Similar to mortality, women with PPCM tend to have higher rates of LV recovery 
than women with other forms of DCM.73,74 Recovery rates differ between countries, from 
28% in Haiti89 to 43% in Israel,72 48% in Turkey,90 47% in Germany,29 55% in South 
Africa,91 63% in Japan,68 and 67% in Denmark.65 There is a wide variation in recovery 
rates within the United States as well, with reported rates ranging between 23% and 
72%.38,40,59,62,79,85,87,92,93 Lack of consensus in the definition of LV recovery (LVEF>45% 
vs 50%, vs 55%, or any recovery vs a specific percentage increase in LVEF) and follow-
up time (6 months vs 12 months vs longer) contributes to the large range in reported LV 
recovery rates among studies across the globe. 
Timing of LV recovery varies, with some women recovering in days to weeks, 
whereas other women require months to years. An article from Israel reported that 22% of 
women with PPCM achieved full recovery (LVEF ≥50%) within 2 weeks, a further 30.1% 
recovered by 1 year, and an additional 13.8% recovered between 1 and 10 years.72 The 
mean time to recovery in a study of 44 women in the United States was 54 months.87 In 
Haiti, reported recovery time ranged from 3 to 38 months and in Turkey from 3 to 42 
months (mean, 19.3 months).70,94 One study completed in the United States found that 83% 
of women who recovered did so after more than 6 months of follow-up, whereas another 
study re- ported that 25% of women who recovered did so between 2 and 8 years after 
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diagnosis.85,95 The wide range of time to LV recovery underlines the importance of long-
term cardiac follow-up of women with PPCM. 
Predictors of Outcome 
Many factors have been evaluated for their potential to predict outcomes in PPCM, 
particularly the risks for persistent myocardial dysfunction and death. The most reliable 
predictor has been found to be LVEF at diagnosis, with studies consistently reporting that 
women with lower LVEF (particularly <30%) at diagnosis are less likely to recover and 
more likely to experience adverse outcomes, including 
death.29,36,38,40,58,59,62,79,81,84,87,92,93,96,97 Studies have also reported that the degree of LV 
dilatation may be a useful predictor, with larger LV end- diastolic diameter (LVEDD) 
being associated with lack of LV recovery and death.29,40,58,59,79,93,97,98 LV dilatation and 
LVEF were combined as predictors in the IPAC study, which found that 91% of women 
with LVEF greater than or equal to 30% and LVEDD less than 60 mm recovered.40 The 
IPAC study also reported that LV global longitudinal strain at presentation was associated 
with clinical outcomes and may be useful for risk stratification in addition to LVEF.99 RV 
fractional area change at diagnosis was shown to be a strong predictor of outcomes in the 
IPAC study,44 whereas another study in the United States found that moderate to severe 
RV dysfunction was associated with more severe disease and higher risk of adverse 
outcomes.43 T-wave abnormalities on ECG have been suggested as a useful tool for 
predicting adverse outcome in PPCM, which could be advantageous in resource-poor 
settings in which echocardiographic evaluation may not be readily available.91,100 
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Other factors that also seem to affect outcomes include race, HDP, and body mass 
index (BMI). Studies in the United States show that, compared with nonblack women, 
black women have worse outcomes, including slower and less complete recovery of LV 
function and higher rates of defibrillator use, transplant, and mortality.36,40,62,92,101-104 A 
recent meta-analysis found that studies with higher rates of African women tend to have 
higher mortalities.75 History of HDP during index pregnancy may also be important, with 
multiple studies finding an association between HDP and improved rates of recovery and 
reduced mortality.29,40,53,65,68,95,98,105 The IPAC study found that higher BMI is associated 
with less cardiac recovery at 6 and 12 months,106 whereas a study including predominantly 
black African women in South Africa found that lower BMI was associated with a worse 
combined end point of death, LVEF less than 35%, or remaining in NYHA functional class 
III/IV at 6 months.107 Women with multiple predictors of poor outcome may be at increased 
risk of persistent cardiac dysfunction and death, but this re- mains speculative because of 
limited data. Multiple biomarkers have been investigated for their potential usefulness in 
predicting which women are more likely to experience adverse out- comes, but none have 
been validated for clinical use (see Table 2.2). 
 
Subsequent Pregnancy 
Many women with history of PPCM desire to become pregnant again. One recent 
study found that 74% of women diagnosed with PPCM desire to have more children and 1 
in 4 women with PPCM who are sexually active were not using birth control.108 All women 
with PPCM are at risk of declining LV function during subsequent pregnancy, but the risk 
is not necessarily prohibitive. Although some women experience worsening LV function 
or even death with subsequent pregnancy, others are able to complete a subsequent 
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pregnancy without cardiac complications. Having 1 subsequent pregnancy without heart 
failure relapse does not ensure that a woman will not experience worsening heart function 
during a future subsequent pregnancy and vice versa.84,109-111 At present, there is no clear 
method to identify with certainty which women will experience adverse cardiac events with 
subsequent pregnancies. The risk of heart failure relapse is highest in women who have 
persistent LV dysfunction at the onset of a subsequent pregnancy, with up to 50% having 
further decline in LV function during subsequent pregnancies.112-115 Women with 
recovered LV function have an approximately 20% chance of heart failure relapse as 
defined in various studies by either experiencing heart failure symptoms and/or decrease 
in LVEF.109,112-115 
The AHA, the CCS, and the HFA ESC WG PPCM stratify recommendations 
regarding sub- sequent pregnancy based on LV function, recommending that women with 
partial or fully recovered LV function be advised that they may consider subsequent 
pregnancy, whereas women with lack of LV recovery should be advised against subsequent 
pregnancy.35,56,114 Despite these recommendations, studies show that only 59% to 75% of 
women diagnosed with PPCM report receiving counseling on the risk of subsequent 
pregnancy.108,116 Importantly, qualitative studies have shown that women report feeling 
that the counseling provided tends to be limited, with women simply being told that they 
should not get pregnant again rather than engaging in an informed discussion with a health 
care provider.117,118 These findings indicate that discussions regarding contraception and 
potential risks of subsequent pregnancy should occur with informed health care providers 




All women considering or undergoing subsequent pregnancy, regardless of cardiac 
function before conception, should be closely monitored by a multidisciplinary team from 
before conception through to several months postpartum in order to identify potential 
cardiac compromise as early as possible so as to optimize management and improve 
outcomes.35,112,114 Recommended cardiac monitoring includes clinical evaluation, BNP or 
NT-proBNP, and echocardiogram either just before conception or within the first trimester, 
at 6 months’ gestation, 9 months’ gestation, before hospital discharge after delivery, and 1 
month after delivery, with the timeline and type of follow-up adjusted according to the 
patient’s clinical status. 
 
Additional Clinical Concerns 
Infant Outcomes 
The few studies of PPCM that include infant outcomes suggest that PPCM diagnosis in 
mothers is related to increased adverse outcomes in the infants, including higher rates of 
preterm and premature birth,13,88,119,120 increased risk of being born small for gestational 
age,13,119 increased rates of low birth weight,13,88,119,120 and lower Apgar scores at both 1 
and 5 minutes.13,88,119 In women with PPCM, rates of premature birth (<37 weeks’ 
gestation) vary between 25% and 60%13,38,88,105,120 and are significantly increased 
compared with controls (25.4% vs 8.6% P<.01119 and 27.9% vs 7.3%; P<.00113). Mean 
birthweight for infants born to mothers with PPCM ranged between 2378 and 3178 
g,13,38,57,65,72,77,79,85,88,119,120 and two studies with controls found that birth weights were 
significantly lower in infants born to mothers with PPCM (2697 vs 3165 g, P<.002119; and 
3188 vs 3331 g, P<.01120). Two studies that examined Apgar scores at 1 and 5 minutes 
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found both to be significantly lower in infants born to mothers with PPCM compared with 
those born to mothers without PPCM.13,119 
Premature birth, low birth weight, and lower Apgar scores are all known to be 
associated with greater risk of infant mortality and a variety of early and late developmental 
and other medical issues.121 However, information regarding these outcomes in children of 
women with PPCM remains limited because infant outcomes in PPCM have only rarely 
been assessed in research studies. 
Mental Health 
Depression is a well-known risk factor for heart disease, and depression and anxiety 
are linked to worse outcomes in heart failure.122,123 Women diagnosed with PPCM tend to 
be young mothers who were previously in the prime of their lives and now must juggle a 
diagnosis of heart failure while caring for a newborn, a household, and possibly other 
children. These stresses increase the risk for mood disorders. High levels of generalized 
anxiety, cardiac anxiety, and quality-of-life concerns are present in more than 50% of 
women with PPCM, and 56% of women with PPCM never return to their baseline 
emotional states after PPCM diagnosis.116 Although only 3% to 7% of women with PPCM 
have a history of depression before PPCM diagnosis,9,65,81 the rate of depression in women 
after diagnosis with PPCM has been reported to be 32.3%,124 which is higher than the 
reported rate of 11.5% among postpartum women in the United States.125 Notably, there 
has been an association reported between depression and lower adherence to appointments 
for PPCM.124 Qualitative studies suggest that an underlying issue for ongoing emotional 
and mental distress is lack of inclusion of the women and their partners in discussions and 
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decisions related to the women’s care and prognosis, with 35% of women in one study 
thinking that they had not been adequately counseled and another 33% thinking they were 
left with unaddressed questions.116-118,124,126,127 
The HFA ESC WG PPCM and AHA both advise that each woman with PPCM be 
assessed and followed during subsequent pregnancy by a multidisciplinary team including 
cardiology, obstetrics, maternal-fetal medicine, neonatology, anesthesiology, and possibly 
other specialties.35,114 Given the high incidence of mood disorders in women with history 
of PPCM, including mental health specialists or social workers on the multidisciplinary 
team to help address the long lasting emotional and psychological impact of PPCM would 
be beneficial, not only during subsequent pregnancy but after initial diagnosis as well. 
 
Summary 
Although rare, PPCM can have a profound effect on previously healthy young 
women. Numerous advances have been made in understanding the cause, pathophysiology, 
and natural history of this disease, but many knowledge gaps remain (Box 2.2). Large 
prospective studies and randomized clinical trials are needed to address these knowledge 
gaps and to facilitate development of evidence-based guidelines regarding the diagnosis 
and management of PPCM. In addition, it is of utmost importance that management 
decisions regarding women with PPCM be formulated among a multidisciplinary team 
using a shared decision-making approach with the patients and their families in order to 




Clinical Care Points 
• Women diagnosed with PPCM benefit from evaluation and treatment by a 
multidisciplinary team including members from cardiology, maternal fetal medicine, 
obstetrics, social work, mental health and other specialties as indicated. 
• Obtaining a complete patient and family cardiac history is important in order to 
establish the diagnosis of PPCM, as PPCM is a diagnosis of exclusion. 
• Clinicians should have a low threshold for obtaining cardiac testing, including an ECG, 
echocardiogram, and B-type natriuretic pep- tide (BNP) or N-terminal proBNP, in 
pregnant/postpartum women who present with signs/symptoms suggestive of heart 
failure, even though the signs/symptoms may seem typical for women who are pregnant 
or postpartum. 
• No biomarkers, including troponin T, troponin I, B-type natriuretic peptide (BNP) or 
N-terminal proBNP, are specific for the diagnosis or PPCM. 
• Bromocriptine may be helpful for treatment of acute PPCM, particularly in postpartum 
women with severely depressed LVEF, but the safety and efficacy of this medication 
for treatment of PPCM has not yet been established. 
• Clinicians must be cognizant of which of the guideline directed mediations for heart 
failure are safe to use during pregnancy and which are safe to use during lactation. 
• Contraceptive counseling during the post- partum period and on a regular basis there- 
after is imperative in order to prevent unplanned pregnancy. 
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• Women with history of PPCM should be counseled about the risk of subsequent 
pregnancy, bearing in mind that women who have recovered normal LV function are 
generally able to complete a subsequent pregnancy without significant complications. 
• Screening women with PPCM for anxiety and depression in both in the acute and 
chronic care setting is essential for optimizing management of their mental and physical 
health. 
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1Table 2.1 Suggested evaluation for women with peripartum cardiomyopathy 
 
 highly recommended,  recommended in certain circumstance,  considered in certain circumstances 
Abbreviations: CTA, computed tomography angiography; ECG, electrocardiogram; ECHO, echocardiogram. 
aTiming of follow-up may vary according to presentation and clinical course. 
bSuggested laboratory tests include complete blood count, basic metabolic panel, and brain natriuretic peptide (BNP) or N-terminal 
prohormone of BNP (NT-proBNP) at all times points plus aspartate aminotransferase, alanine aminotransferase, cardiac troponin, and 
thyroid stimulating hormone at baseline and during follow-up, if indicated. 
cUrinalysis is especially important for women presenting with increased blood pressure during pregnancy or the first 6 weeks 
postpartum to assess for preeclampsia. 
dConsider chest CTA to assess for pulmonary embolism in patients presenting during pregnancy or the first 6 weeks postpartum. 
eConsider cardiac MRI if patient presents during the postpartum period and echocardiography results are inconclusive. 
















Diagnosis         
3 months         
6 months         
12 months         
18 months         
24 months         
>24monthsf         
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2Table 2.2 Biomarkers in peripartum cardiomyopathy 
 
Biomarkers of Cardiac Function 
NT-ProBNP May be 
increased29,138,154 
Failure to decrease levels by 6 mo 
is associated with 
persistent LV dysfunction138 
BNP May be increased104 Higher levels at diagnosis are 
associated with persistent LV 
dysfunction104,138 
Higher levels at 6 mo are 
associated with persistent LV 
dysfunction104 
Higher levels at 6 mo may predict 
mortality89,138 
Increased levels at 3 and 6 mo may 
predict persistent dysfunction69 
Lower levels at 3 and 6 mo are 
associated with faster recovery69 
Cardiac troponin May be increased154 Higher levels at diagnosis are 
associated with persistent LV 
dysfunction156 
Biomarkers of Inflammation 
C-reactive protein May be 
increased95,138,154,157 
Higher levels at baseline may 
predict mortality157 
Higher levels at baseline are 
correlated with worse disease95 
Increased levels at 3 and 6 mo may 
predict persistent dysfunction69 
IL-6 May be 
increased138,157 










IL-1b May be increased138 — 
Interferon gamma May be increased138 Failure to decrease levels by 6 mo 
is associated with persistent LV 
dysfunction138 
Pregnancy and Nursing Hormones 
Relaxin-2 May be 
decreased158,159 
Higher levels at diagnosis are 
associated with recovery at 2 mo19 
Prolactin May be increased138 Failure to decrease levels by 6 mo 
is associated with persistent LV 
dysfunction138 





Failure to decrease levels by 6 mo 






Higher levels at baseline may 
predict mortality95 
sFlt-1 May be increased18 Higher levels at diagnosis are 
associated with more severe 




May be increased29 — 
PlGF May be increased159 — 




May be increased160 — 
MicroRNAs 
miR-146a May be 
increased29,161 
— 
miR-1991 May be increased162 —  
Biomarkers of Fibrosis and Remodeling 
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Galectin-3 May be increased102 High baseline levels are associated 
with poor outcomes102 
Soluble ST2 May be increased102 High baseline levels are associated 
with poor outcomes102 
Cleaved osteopontin May be increased102 High baseline levels are associated 
with poor outcomes102 
Matrix-metallo-
proteinase-2 
May be increased138 — 
Abbreviations: IL, interleukin; PIGF, placental growth factor. 


























Consult Cardio-Obstetrics specialist 
    
Consult High-Risk Obstetrics (Maternal 
Fetal Medicine) specialist   
─ ─ 
Form multidisciplinary team to prepare 
delivery plan   
─ ─ 
Consider early delivery ─ 
 
─ ─ 
Arrange for fetal monitoring during labor 
and delivery   
─ ─ 
Initiate selected oral heart failure 
medications (e.g., diuretics, nitrates, 
hydralazine, digoxin)   
─ ─ 
Initiate oral GDMT for HFrEF [e.g., beta 
blocker, ACE-I, ARB, ARNI, MRA, 









Initiate anticoagulation if LV thrombus 
    
Consider anticoagulation if LVEF <35% ─ ─ 
  
Plan for vaginal delivery 
 
─ ─ ─ 
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Plan for probable Cesarean delivery ─ 
 
─ ─ 
Provide supplemental oxygen and/or 










Consider advanced heart failure therapiesa 






Discuss lactation preferences ─ ─ 
 
─ 
Discuss contraception ─ ─ 
  
aMechanical circulatory support/ventricular assist device/cardiac transplant 
Abbreviations: ACE-I, ACE inhibitor; ARB, angiotension receptor blocker; ARNI, angiotension receptor neprolysin inhibor; GDMT, 





















Kolte et al,9 2014 NA NA United States 





Krisnamoorthy et al,80 2016 NA NA United States 





Lee et al,136 2018 NA NA South Korea 





Masoomi et al,8 2018 NA NA United States 
Nationwide Readmission 
database 
2013 568 1.2% 
Kao et al,11 2013 NA NA United States 
Inpatient administrative 




Mielniczuk et al,7 2006 NA NA United States 






Azibani et al,102 2020 6 months actual Germany 1 hospital Missing 73 0.0% 
Dhesi et al,119 2017 6 months actual Canada 
Multiple databases linked 












Libhaber et al,97 2015 6 months actual South Africa 2 hospitals Missing 206 12.6% 
Blauwet et al,106 2013 6 months actual South Africa 1 hospital Missing 162 13.0% 
Azibani et al,102 2020 6 months actual South Africa 1 hospital Missing 56 14.3% 
Sliwa et al,95 2006 6 months actual South Africa 1 hospital Missing 100 15.0% 
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7-12 Months  
Kamiya et al,67 2011 9.6 months mean Japan 










Phan et al,79 2020 1 year actual United States 









Danish National Patient 
Register, Medical Birth 





McNamara et al,40 2015 1 year actual United States 









Wu et al,39 2017 1 year actual Taiwan 





Elkayam et al,38 2015 1.9 years mean United States 
Survey mailed to doctors 
nationwide & data from 1 
hospital 
Missing 100 9.0% 
Sliwa et al,140 2011 2 years actual South Africa 1 hospital Missing 60 36.7% 
>2 Years 


















Gunderson et al,13 2011 3 years actual United States 









Brar et al,81 2007 4.7 years mean United States 





































Abbreviations: NA, not available 




Figure 2.1  
  
1Figure 2.1 Incidence of peripartum cardiomyopathy (per 100,000 live births or deliveries.) 
Measurements using live births: Hati127, USA9, Singapore77, India128, Canada119, Martinique129, Japan130, Malaysia131. Measurements 






2Figure 2.2 Percent mortality estimates for peripartum cardiomyopathy. 
Twenty-four countries are represented 12 of which only had one estimate available while each of the other 10 countries had between 2 
and 25 estimates available. For countries with only 1 estimate available, that value is indicated. For the countries with multiple 
estimates available ranges are presented showing the highest and lowest estimate for each country. Data from References:7–9,11–13,36,38–
40,42,43,47,56–58,61,62,64–70,73,75–87,95,97,99,102,106,119,131,136–155b References: US7-9,11-13,36,38,40,43,58,61,62,72,73,78-87, Turkey57,66,69,85,96,99,137, Taiwan39,75, 
Sweden56, South Korea136, South Africa47,65,95,97,102,106,138-141, Singapore77, Philippines76, Pakistan142,143, Nigeria42,144, Malaysia131, 
Japan67, Israel71, Ireland68, India145-148, Haiti149-151, Germany102,152, Demark64, China153,154, Canada119, Brazil155, Argentina70. 
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1Box 2.1 Current peripartum cardiomyopathy definitions 
National Heart Lung and Blood Institute (NHLBI)1 
• Development of cardiac failure in the last month of pregnancy or within 5 
 months of delivery 
• Absence of an identifiable cause for the cardiac failure 
• Absence of recognizable heart disease before the last month of pregnancy 
• LV systolic dysfunction identified by classic echocardiographic criteria, 
 such as ejection fraction < 45% or fractional shortening < 30%, or both 
 
 
European Society of Cardiology (ESC)2 
• Heart failure secondary to LV systolic dysfunction with an LV ejection 
fraction < 45% 
 
• Occurrence toward the end of pregnancy or in the months following 
 delivery (mostly in the months following delivery) 
 
• No other identifiable cause of heart failure 
 
Data from Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum 
cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare 
Diseases (National Institutes of Health) workshop recommendations and review. 
Jama. 2000;283(9):1183-1188 and Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. 
Current state of knowledge on aetiology, diagnosis, management, and therapy of 
peripartum cardiomyopathy: a 
position statement from the Heart Failure Association of the European Society of 
Cardiology Working Group on peripartum cardiomyopathy. European journal of 






2Box 2.2 Knowledge gaps in peripartum cardiomyopathy requiring 
further evidence-based investigation 




• How can women who are susceptible to developing PPCM be identified 
before pregnancy? 
Pathophysiology and genetics 
• What is the exact pathophysiology/pathophysiologies of PPCM? 
• To what extent to do genetic variations contribute to the development of 
PPCM and influence outcomes? 
Diagnosis 
• Is there a PPCM-specific biomarker, or set of biomarkers, that can be used to 
diagnose PPCM with a high degree of certainty? 
Treatment 
• Which, if any, typical heart failure medications are beneficial for treating all 
women with PPCM? 
• How long should GDMT for HFrEF be continued in women with PPCM who 
have completely recovered LV function? 
• Is bromocriptine safe and effective for treatment of acute PPCM? 
• When is the use of wearable defibrillators indicated? 
• When should an implantable cardioverter defibrillator be recommended? 
• What is the most appropriate type and timing of follow-up in women who 
have recovered LV function versus those who have not? 
Outcomes 
• What are the best clinical predictors of outcome for women with PPCM that 
could be available in various health care resource settings? 
• What are the very-long-term (ie, decades after diagnosis) outcomes for women 
with history of PPCM? 
• Do women with history of PPCM have higher risk of developing other types 
of cardiac disease as they age? 
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Subsequent pregnancy 
• What are the risks of cardiac deterioration and death with subsequent 
pregnancy with women with history of PPCM and those who have recovered 
LV function versus those who have not? 
• Are there management strategies that are useful to reduce the risk of adverse 
outcomes in women during a subsequent pregnancy? 
Infant outcomes 
• What are the short-term and long-term health risks for infants born of mothers 
with PPCM? 
• Are there strategies than can mitigate these risks? Mental and emotional health 
• Are there safe and effective strategies that can be used to decrease the burden 
of mental and emotional health issues affecting women with PPCM and their 
families? 
Issues to be addressed in order for future research to adequately address 
knowledge gaps 
• Global agreement on the definition of PPCM 
• Global agreement on the definition of LV recovery 
• Global agreement on the definition of relapse during subsequent pregnancy 
• Funding for large, multicenter, well-designed, and well-adjudicated 
prospective registries and clinical trials 
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Chapter 3: The Rochester Epidemiology Project and the 
Study Cohort 
 To further study PPCM and the role possible environmental exposures might play 
we created a case-control cohort using the Rochester Epidemiology Project (REP).1 
Previously published studies of PPCM in the US included single or multi-institution 
cohorts and a few population level studies using nationwide databases with limited data 
sets such as the National Hospital Discharge Survey, The National Inpatient Survey from 
the Healthcare Cost and Utilization Survey.2,3  
 The population level studies are limited by the use of diagnosis codes for 
identifying cases, which can lead to misclassification, as well as by what data was available 
as part of the databases. The institution-based studies were more likely to use medical 
records review to confirm cases, but were limited to data available through their 
institution(s). To overcome these limitations for our study we chose to create a new cohort 
using the REP, which to our knowledge, is the first population level incidence study with 
complete medical record review to confirm cases and abstract data. 
 The REP is a unique resource in that it is one of the few places that allows for 
“population-based” research to be conducted and true population level incidence estimates. 
The REP, which had been federally funded for over 50 years, is a collaboration between 
health care providers, medical facilities, and community members that links medical 
records from almost all health care providers in Olmsted County, including Mayo Clinic 
and Olmsted Medical Center, and their affiliated hospitals as well as local private 
providers.4-6 The healthcare providers who have agreed to participate in the REP share 
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medical records which are all assembled in a large database. The results is a databased 
linking medical records form essentially all source of medical care available to, and utilized 
by, the Olmsted County population as well as a large portion of the care available to, and 
utilized by, residents of the surrounding counties. These records therefore contain the 
details of every inpatient hospitalization, every outpatient visit to the offices, clinics or 
emergency rooms in the county, every physician visit to nursing homes or private homes, 
as well as every laboratory result, pathology report (including autopsies), imaging report 
and correspondence pertaining to individual patients. The REP also has electronic indexes 
that include demographic information, diagnostic and procedure codes, health services use 
data, outpatient drug prescriptions, laboratory test results, imaging and procedure reports, 
and information about smoking, height, weight, and body mass index.5,7 Both paper and 
electronic medical records are accessible with a system that lists all record available for 
each resident of the area.8 This is an incredibly rich data source allowing for high quality 
medical research at a population level that has been shown to be generalizable to all of the 
Minnesota/Wisconsin area, as well as a large segment of the US population.7,9 
 The REP covers 27 counties in southern Minnesota (MN) and western Wisconsin 
(WI) and can be broken into three overlapping, areas with varying levels of coverage of 
medical records. (Figure 3.1) The first is Olmsted County alone, which has near complete 
coverage (99.9%) allowing for very accurate population level incidence estimates, where 
98% of residents have agreed to participate in the REP and 90-96% off all health care 
received by county residents is provided by participating providers with data available from 
January 1, 1970 through December 31, 2020.7 The second area is a 7-county region which 
includes Olmsted County and 6 surround counties and has a 93.8% coverage rate (data 
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available from January 1 1976 through December 31, 2020) and the largest area (all 27 
counties including Olmsted County) has a 60.9% coverage rate (data available from 
January 1, 2010 through December 31, 2020).7 The lower coverage rates in the 27-country 
region is predominantly due to not all health care facilities in the region collaboration with 
the REP.7 
 Using the REP as our data source we were able to create, to our knowledge, the 
first population level incidence study with complete medical record review to confirm 
cases and abstract data. Using the REP data we first conducted a study of cases of PPCM 
in Olmsted County diagnosed between January 1, 1970 and December 31, 2014 and 
identified 15 unique cases resulting in an incidence of 20.3 cases per 100,000 live births. 
This result is reported in a published manuscript Douglass EJ, et al. A Case-Control Study 
of Peripartum Cardiomyopathy Using the Rochester Epidemiology Project. J Card Fail. 
2021 Feb;27(2):132-142.doi: 10.1016/j.cardfail.2020.12.021. Epub 2021 Jan 1. PMID: 
33388468.10 More information on the collection of the data from this population level 
cohort is presented in Chapter 4 of this dissertation. We then expanded the study to include 
the entire 27 county region of the REP in order to increase the number of cases (48 total) 
and add controls matched 2:1 on age, race, and number of infants delivered during index 
pregnancy (pregnancy when diagnosed with PPCM or matched pregnancy in controls). The 
results from the 48 cases and 96 controls are described in Chapter 5 as a manuscript that 
has been published in the Journal of Cardiac Failure: Douglass EJ, et al. A Case-Control 
Study of Peripartum Cardiomyopathy Using the Rochester Epidemiology Project. J Card 
Fail. 2021 Feb;27(2):132-142.doi: 10.1016/j.cardfail.2020.12.021. Epub 2021 Jan 1. 
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3Figure 3.1 Map of the Rochester Epidemiology Project.  
Geographical map of the 27-county region showing the geographical location and the 
percentage capture for each county (black numbers or white numbers). The region can be 
subdivided into a maximum capture segment, Olmsted County (blue border), a high capture 
segment, including Olmsted County and six additional contiguous counties (pink border), 
and the overall 27-county region. The color shading of the counties is proportional to the 
percentage capture of the E-REP as compared with the US Census estimates 
Figure and legend from: Rocca, WA. et al. Data Resource Profile: Expansion of the 
Rochester Epidemiology Project medical records-linkage system (E-REP). Int J Epidemiol, 





Chapter 4: A Population Level Study of Peripartum 
Cardiomyopathy using the Rochester Epidemiology 
Project* 
 
*Unpublished, incidents results reported in Douglass EJ, Blauwet LA, Cooper LT, 
Fairweather D. A Population Level Study of Peripartum Cardiomyopathy using the 




• Incidence peripartum cardiomyopathy in Olmsted County, MN 20.3/100,000 live 
births 
• Infection, migraine, allergy and mental health diagnoses identified as novel risk 
factors 
• All patients with follow-up available (93%) recovered heart function (LVEF 
≥45%) 
• No cardiac devices, transplants, mechanical circulatory support or deaths 





Objective: To estimate at the population level the incidence, clinical characteristics, 
presentation and outcomes of women with peripartum cardiomyopathy (PPCM) in a well-
defined geographical region of the United States. 
Methods: A retrospective cohort study using the Rochester Epidemiology Project was 
conducted to identify all incident cases of PPCM occurring in residents of Olmsted County, 
Minnesota between January 1, 1970 and December 31, 2014. Demographics, clinical 
information, disease characteristics and outcome data were obtained by individual medical 
record review. 
Results: A total of 15 PPCM cases were identified and confirmed. The incidence of PPCM 
in Olmsted County, Minnesota during the time of the study was 20.3 per 100,000 live 
births. All cases recovered cardiac function to a left ventricular ejection fraction of ≥50%. 
There was a 26% rate of recurrent PPCM in subsequent pregnancies, but all recovered 
cardiac function. No index or subsequent pregnancy was complicated by ventricular assist 
device implantation, transplant or death. 
Conclusions: PPCM occurred in approximately 20.3 per 100,000 live births in Olmsted 
County, Minnesota. A history of infections, migraines, allergies and mental health 
diagnoses were identified as potential novel risk factors. 
 




ACE, angiotensin converting enzyme 
BMI, body mass index 
BPM, beats per minute 
ECHO, echocardiogram 
GBS, group B strep 
GED, general educational development or general education diploma 
HDP, hypertensive disorders of pregnancy or hypertensive diseases of pregnancy  
LA, left atrial 
LV, left ventricle/ventricular 
LVEF, LV ejection fraction 
LVEDD, LV end diastolic diameter 
LVESD, LV end systolic diameter 
MDMA, 3,4-methylenedioxy-methamphetamine  
mmHg, millimeters of mercury 
OCD, obsessive compulsive disorder 
PPCM, peripartum cardiomyopathy 
PTSD, post-traumatic stress disorder 
REDCap, Research Electronic Data Capture 
REP, Rochester Epidemiology Project 
RV, right ventricle 




Peripartum cardiomyopathy (PPCM) is a potentially life-threatening form of 
cardiac failure that strikes women with no history of heart disease in the last month of 
pregnancy or within 5 months of delivery1,2. PPCM is characterized by left ventricular (LV) 
systolic dysfunction, with LV ejection fraction (LVEF) confirmed by echocardiography as 
≤45%,3 leading to heart failure symptoms. Patients with PPCM can experience complete 
recovery of heart function.4,5 Early diagnosis and treatment decrease mortality and increase 
the potential for full recovery of LV function. However, timely diagnosis is challenging, 
as the symptoms of PPCM are similar to the physiological changes that occur with normal 
pregnancy.6,7 
Incidence estimates of PPCM vary widely between countries and within the United 
States from 25 per 100,000 live births in the United States8 to 333 per 100,000 live births 
in Haiti.9 Within the United States, rates vary from 25 per 100,000 live births in southern 
California to 185 per 100,000 live births in Augusta, Georgia.7,8,10-14 The first population 
level estimate of PPCM incidence within the United States used the National Hospital 
Discharge Survey and reported 31 per 100,000 live births.15 However, to our knowledge, a 
population level incidence study of PPCM that involved complete medical record review 
to confirm cases and abstract data has not previously been published. This study provides 
the first population level epidemiological study of incidence, clinical characteristics, 
presentation and outcomes of PPCM using complete medical record review available 




The project was approved by both the Mayo Clinic and Olmsted Medical Center 
Institutional Review Boards and conformed to the principles set forth in the Helsinki 
Declaration of 1975, as revised in 2013. All patients involved in the study provided written 
informed consent to allow the use of their medical records for research purposes as part of 
the Rochester Epidemiology Project (REP). Any patients who had not previously 
consented to participate in research through REP were excluded from the study. 
The REP can be used to conduct population level epidemiologic research in 
Olmsted County, Minnesota, as previously described.16 Briefly, the database links the 
medical record of most health care providers in the county including Mayo Clinic, Olmsted 
Medical Center and its affiliated hospital and a few private providers.17 Together, these 
providers cover 90-96% of all health care to Olmsted County residents.16 In Olmstead 
County, 98% of residents have agreed to participate in the REP.18 The health care providers 
who participate in the REP use a unit (or dossier) medical record system where all medical 
data are assembled in one database.17 The result is the linkage of medical records from 
essentially all sources of medical care available to, and utilized by, the Olmsted County 
population. These records therefore contain the details of every inpatient hospitalization, 
every outpatient visit to the offices, clinics or emergency rooms in the county, every 
physician visit to nursing homes or private homes, as well as every laboratory result, 
pathology report (including autopsies), imaging report and correspondence pertaining to 
individual patients. The medical details are collected by physicians providing subspecialty 
level medical care and are of high quality. 
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Data were collected for all Olmsted County, Minnesota residents diagnosed with 
PPCM from January 1, 1970 to December 31, 2014. Fifteen PPCM cases were identified 
from a list of 866 women 15 to 55 years of age living in Olmsted County, Minnesota from 
1970-2014 with either a PPCM diagnosis code (ICD-9 674.5X, HICDA 4251610, 425310, 
BRK 0234X1) or a heart failure code (ICD-9 428.X, HIC 4270110, 4279133, BRK 23452). 
The case definition for PPCM was based on the criteria proposed by the National Heart, 
Lung and Blood Institute and the Office of Rare Diseases of the National Institutes of 
Health Workshop on Peripartum Cardiomyopathy3 and included 1) development of cardiac 
failure in the last month of pregnancy or within 5 months of delivery, 2) absence of an 
identifiable cause for the cardiac failure, 3) absence of recognizable heart disease before 
the last month of pregnancy, and 4) LV systolic dysfunction demonstrated by classical 
echocardiographic criteria with a LVEF ≤45%. 
Data of confirmed PPCM cases were individually abstracted from electronic and 
paper medical records available through the REP and entered into a Research Electronic 
Data Capture (REDCap) database.19 
Data were analyzed using Microsoft Excel and StataIC 15.20 Incidence was 
calculated for all female Olmsted County residents that were 15 to 55 years of age and 
considered to be at risk for PPCM. Annual birth rates for Olmsted County residents were 
obtained from the Minnesota Health Statistics Annual Summary Reports.21,22 For primary 
diagnosis the outcomes of interest included cardiac assist device implantation, transplant 
and death. In addition, recurrence of disease was assessed, and the same outcomes of 




From January 1970 to December 2014, 15 cases of PPCM were confirmed to have 
occurred in Olmsted County, Minnesota. Based on vital statistics data from the Minnesota 
Department of Health,21,22 the incidence of PPCM from 1970 to 2014 in Olmsted County, 
Minnesota was determined to be 20.3 cases per 100,000 live births.21,22 
Table 4.1 lists the demographic characteristics of the 15 PPCM cases from Olmsted 
County that were identified. The mean age was 29 (range, 17-39 years). Two thirds (66.7%, 
n=10) of the cases were white and 33.3% (n=5) black, with 4 of the 5 black women being 
recent immigrants from Africa (Table 4.1). There were no PPCM cases among women of 
Asian, Native American or Hispanic race/ethnicity. Seven of the cases (46.7 %) were 
overweight or obese prior to the index pregnancy (Table 4.1). 
Socioeconomic factors varied widely among women in the study (Table 4.1). 
Eighty percent (n=12) of the women were married or living with a partner who was co-
parenting with them, while 20% (n=3) were single parents. Education levels ranged from 
those who had not completed high school to those who had obtained graduate degrees. The 
women with the lowest level of education were African immigrants (data not shown). Sixty 
percent (n=9) of the cases had private insurance while 40% (n=6) were on medical 
assistance. Seven of the women (46.6%) had a history of tobacco use (current at diagnosis 
or past) and 53.3% (n=8) had a history of alcohol use. Only 1 woman had a history of 
illegal drug use (i.e., marijuana and 3,4-methylenedioxy-methamphetamine/MDMA). 
Table 4.2 describes the medical history of the women from Olmsted County prior 
to their index pregnancy and diagnosis of PPCM. Only 1 woman had a history of 
hypertension. Three had a history arrhythmia with 1 case of tachycardia, 1 case of 
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tachycardia and palpitations, and 1 case of non-symptomatic supraventricular tachycardia. 
No further types of cardiovascular diseases were recorded. Mental health diseases were 
common (66.7%, n=10), with 60% (n=9) of the women diagnosed with depression, 20% 
(n=3) with anxiety, and 40% (n=6) having other mental health diagnoses. A history of 
migraine was found in 10 cases (66.7%), but none were taking migraine medications during 
their index pregnancy or at diagnosis of PPCM. Nine (60%) cases had a history of 
infectious diseases. Two cases had a history of unusual or specific exposure to chemicals 
during their lives, 1 to pesticides weekly as a child and the other to black mold as an adult. 
Eight cases (53.3%) had a history of allergies. Two women, both Caucasian, had past 
diagnoses of cancer. Both women had melanoma treated with surgical excision. No one in 
the cohort had been treated with chemotherapy agents or chest radiation. No cases had a 
history of diabetes. 
Table 4.3 describes the obstetric and gynecological history (prior to the index 
pregnancy) of women with PPCM from Olmsted County. The majority of the women 
(73.3%, n=11) in the cohort were nulliparous, 2 (13.3%) primiparous and 2 (13.3%) 
multiparous, each with ≥4 previous live births. Of the 4 women with previous live births, 
75% (n=3) had a history of some type of hypertensive disorder of pregnancy (HDP) during 
at least one of their previous pregnancies that carried to term, with some women diagnosed 
with more than one type of HDP in separate pregnancies. All three women with previous 
live births and history of a HDP were diagnosed with gestational hypertension. Two were 
also diagnosed with preeclampsia, and the third had an additional diagnosis of an unknown 
type of HDP. 
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Table 4.4 describes the characteristics of the index pregnancies of the 15 PPCM 
cases. Twelve (80%) women had singleton pregnancies and 3 (20%) had twin pregnancies. 
Eighteen infants were born to the cohort cases, with 13 (72.2%) of the offspring being 
female and 5 (27.8%) male. Seven (46.7%) of the 15 index PPCM cases in the study had 
emergency C-sections and 2 (13.3%) needed device assistance during vaginal delivery. The 
mean gestational age was 37 weeks (range 32-42 weeks) and the mean birthweight was 
2,907 grams (range 1,635-4,760 grams). Seven (38.9%) of the 18 infants were classified as 
low birthweight (<2,500 grams) and there were 5 premature births (before the 37th weeks 
of gestation). Breastfeeding rates in PPCM patients were initially 60% (n=9) and decreased 
to at least 40% (n=6) after diagnosis, but may have been even lower as breastfeeding status 
post diagnosis was missing for four cases. The majority of the women (86.7%, n=13) had 
access to standard medical care during their pregnancy. Two thirds (66.7%, n=10) of the 
women had a diagnosis of some type of HDP, with the most common diagnosis (46.7%, 
n=7) being preeclampsia. In addition, 6 (40%) women were placed on bedrest during their 
index pregnancy, 1 (7%) had gestational diabetes, 1 (7%) was treated with tocolytic 
therapy, and 10 (66.7%) completed at least one course of antibiotics during pregnancy, 
with 3 (20%) women prescribed 4 or more courses of antibiotics. 
Table 4.5 presents characteristics including physical exams at diagnosis, 
echocardiogram results, treatments and outcomes for the 15 women with PPCM. Thirteen 
(86.7%) women presented with significantly elevated blood pressure (data not shown). 
Symptoms of heart failure (i.e., rales, wheezing, pulmonary edema, peripheral edema, 
jugular venous distention, and/or ascites) were present in 13 (86.7%) women, left heart 
failure only in 3 (20%), right heart failure only in 3 (20%), and symptoms of both right and 
79 
 
left sided heart failure in 7 (46.7%) women (data not shown). At diagnosis, the mean LVEF 
was 35% (range 20-45%) and the mean LV end diastolic diameter (LVEDD) was 5.5 cm 
(range 4.0-6.4 cm). 
Figure 4.1 shows the trends in LVEF over the first 5 years of the study period for 
the 15 PPCM cases, although some women had data available up to 14 years post diagnosis. 
The 14 women with follow-up echocardiography data available all recovered (LVEF 
≥50%) with 13 recovering by year 4. Timing of recovery ranged widely: 7 (46.6%) women 
recovered by 6.5 months, 2 (13.3%) recovered between 1 and 2 years, and 4 (26.6%) 
recovered by 4 years. Timing of recovery for the remaining patient is unknown, as she had 
no follow-up echocardiogram until year 12, at which point she had recovered (Table 4.5, 
Figure 4.2). All 15 patients in this cohort were treated with guideline directed medical 
therapy for heart failure, with the most common medications being angiotensin converting 
enzyme (ACE) inhibitors (93.3%, n=14), diuretics (80%, n=12) and beta blockers (73.3%, 
n=11) (Table 5). No pacemakers or internal cardiac defibrillators were implanted, no 
patients underwent ventricular assist device implantation or transplantation, and there were 
no deaths in this cohort during a mean follow up time of 13.7 years (Table 4.5, Figure 4.2). 
Post diagnosis, 6 (50%) of the 12 women for whom contraception records were available 
underwent sterilization after receiving counseling by medical providers regarding the risk 
of PPCM relapse during subsequent pregnancy. The sterilizations occurred at various time 
points including 1 at index delivery, 1 shortly after diagnosis, 3 at subsequent pregnancy 
(each after termination of that pregnancy), and 2 after subsequent delivery. 
Table 4.6 summarizes the data on subsequent pregnancies in this cohort. Nine 
(60%) women had a total of 15 subsequent pregnancies, and 2 (13.3%) women may have 
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had further subsequent pregnancies after they were lost to follow-up. Of the 15 subsequent 
pregnancies, 7 (46.6%) resulted in live birth, 3 (20%) in spontaneous abortion and 5 
(33.3%) were terminated. The relapse rate in this cohort was (26.7%) but all 4 women who 
relapsed recovered their LV function post relapse (Table 4.6 and Figure 4.2). 
 
Discussion 
The estimate of the incidence of PPCM in Olmstead County from 1970-2014 was 
20.3 per 100,000 live births, which is lower than previous estimates of 25 to 185 per 
100,000 live births. 7-9,11,15,23 Our findings may reflect a more accurate population level 
incidence estimate for several reasons. All PPCM cases in a defined geographical area were 
confirmed using REP data instead of relying on diagnosis codes. Although 58 women had 
a diagnosis code for PPCM in their medical record, after record review, only 15 (26%) met 
the diagnostic criteria for PPCM.3 Thus, previously published epidemiologic studies of 
PPCM may have overestimated the disease incidence by including women who had the 
diagnosis code for PPCM in their medical record but did not actually meet diagnostic 
criteria for PPCM. 
Previous studies of PPCM reported that black women have the highest rate of 
PPCM followed by white women, while Hispanics and Asians have the lowest rate.7-
9,11,15,23 Similar race/ethnicity patterns were observed in this study (Table 4.1). Differences 
in demographics may have led to a lower overall incidence of PPCM in this study compared 
with previous studies.24 Olmsted County is, in general, less racially diverse than some other 
regions of the US. Based on the 2010 US Census, the US population was 76.6% white and 
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13.4% Black or African American whereas Olmsted County was 84.7% white and 6.1% 
Black or African American.24,25 Based on these Census numbers the incidence of PPCM 
was higher than expected in Blacks and lower than expected in all other racial groups.  
The women in this study were evenly divided above and below 30 years of age, 
differing from previous studies where PPCM was associated with increased maternal age, 
reporting that over half of the cases occurred in women >30 years of age.8,10,11,15 The 
majority of women in our study were nulliparous, which differs from previous studies that 
reported multi-parity as a risk factor for PPCM.7,10-14 Similar to previous studies,26 there 
was an increased rate (20%) of multifetal gestations among women diagnosed with PPCM 
in our cohort, compared with 2.1-3.5% births nationwide.27  
Hypertensive disease of pregnancy, especially preeclampsia, is known to be a risk 
factor for the development of PPCM.26,28,29 The cohort in this study had high rates of HDP 
during the index pregnancy, with the most common diagnosis being preeclampsia. Seven 
of the 15 women with PPCM (46.6%) had preeclampsia (Table 4.4), a rate that is almost 
12x greater than the national prevalence of 4%.30 Thus, this study provides support for the 
hypothesis that preeclampsia and PPCM may have an overlapping pathophysiology with 
an anti-angiogenic milieu and inflammation linking the conditions.26,31-34 Research is 
needed to investigate this possibility. 
This study identified some possible novel risk factors for PPCM including one or 
more mental health diagnoses (primarily depression and anxiety), migraine and allergies 
(Table 4.2). Of note, migraine, depression, anxiety and allergies occur more often in 
women than men in the general population and mast cell activation and inflammation play 
a role in promoting migraine and allergic reactions.35-38 In this study, high rates of antibiotic 
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use during pregnancy (Table 4.4) suggest that viral/bacterial infection may play a role in 
the pathogenesis of PPCM. Several investigators have postulated that myocarditis, which 
is primarily caused by viral infections but also by bacterial infections, could cause 
PPCM.39-42 However, myocarditis occurs more often in men than women (3.5:1 men to 
women).43-45 Other possible risk factors for PPCM identified in this cohort include being a 
current or past smoker and alcohol use (Table 4.2). 
Another interesting and potential novel finding in this study was that of the 18 
infants born to the PPCM cases, 72.2% (n=13) were female and only 27.8% (n=5) were 
male. In Olmsted County, the average birth rate by sex during the years of the study were 
51% male and 49% female 21,22. Thus, the percentage of female neonates born to women 
diagnosed with PPCM appears to be higher than expected. A recent study showed a similar 
trend towards higher numbers of female sex in the offspring of women diagnosed with 
PPCM both in the index pregnancy (59% female) and in the subsequent pregnancies (63% 
female).46 Other studies have shown mixed results. 7,47-49 To our knowledge the role of fetal 
sex in the pathogenesis of PPCM has not been investigated. However, a recent study found 
that women carrying female fetuses had greater inflammatory responses after immune 
challenge compared to women carrying male fetuses. Results from other studies suggest 
that fetal sex may also play a role in maternal physiology during pregnancy including blood 
pressure.50-52 Overall, these findings suggest that fetal sex may play a role in the 
pathogenesis of PPCM and should be further investigated. 
Medical guidelines state that women with a diagnosis of PPCM should be 
counseled to avoid future pregnancies due to concern that the mother may develop heart 
failure relapse.4,53 However, all women in this study who had follow-up echocardiograms 
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available regained normal cardiac function with time (Table 4.5 and Figure 4.1). While 
past studies reported adverse outcomes in women with PPCM who pursue subsequent 
pregnancy including the need for cardiac devices, mechanical support, transplantation and 
death,11,15,54-59 none of these poor outcomes were observed in this cohort (Table 4.5, Table 
4.6, and Figure 4.2). The results from this study suggest that women diagnosed with PPCM 
that obtain special cardiac monitoring can have safe subsequent pregnancies. 
Using diagnosis codes to identify cases has limitations and can lead to over or under 
estimation of cases. This study screened all women living in the study area whose medical 
records included the diagnoses codes for heart failure in an attempt to identify cases that 
were miscoded. But no additional cases were found. A major strength of the study was the 
use of the REP to create a population level cohort from a specific geographical region 
isolated from other large medical centers with almost complete availability of medical 
records for the study. Importantly, only 26% of women who had a diagnosis code of PPCM 
in their medical record met the case definition. We were not able to screen all women who 
had pregnancies due to the large sample size. It is also possible that cases may have been 
missed as medical professionals were not as aware of PPCM in the past; however, by 
screening all women diagnosed with heart failure we minimized this possibility. A strength 
of the study was the ability to individually examine all medical records of potential cases 
without relying on diagnosis codes for inclusion of cases so that only confirmed cases were 
included in the study. Due to the methodology of the study, it is possible a few very mild 
cases may have been missed, but all women miscoded for PPCM were excluded from the 
study making our incidence calculation more accurate than studies that did not use medical 
records to confirm cases. Other inherent limitations included the small sample size, the 
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lack of racial/ethnic diversity in Olmsted County, and the retrospective cohort design that 
limited data to what was available in the medical record.  
 
Conclusion 
A population level epidemiological study of PPCM in Olmsted County, Minnesota 
found 20.3 cases per 100,000 live births. Women with PPCM had complete cardiac 
recovery and multiple subsequent pregnancies with no enduring cardiac dysfunction 
despite a 26% relapse rate. We identified potential novel risk factors for PPCM including 
depression, anxiety, infections, migraine and allergies. These potential risk factors should 
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5Table 4.1 Maternal characteristics (n=15) 
Characteristic Value 
Age (y) 29 (17-39) 
Pre-pregnancy BMI (kg/m2)* 
 
 < 18.5 0 (0.0) 
 18.5-24.9 7 (46.7) 
 25.0-29.9 2 (13.3) 
 ≥ 30 5 (33.3) 
Race/Ethnicity 
 
 White 10 (66.7) 
 Black 5 (33.3) 
  African American 1(6.7) 
  African Immigrant 4 (26.6)  
Hispanic 0 (0.0) 
Marital Status 
 
 Single 3 (20.0) 
 Married 8 (53.3) 
 Domestic Partner 4 (26.7) 
Education 
 
 < High school 2 (13.3) 
 High school or GED 3 (20.0) 
 Some college or associate degree 5 (33.3) 
 ≥ College degree 5 (33.3) 
Health Insurance 
 
 Private 9 (60.0) 
 Medical assistance 6 (40.0) 
Smoking 
 
 At diagnosis 2 (13.3) 
 Before pregnancy 5 (33.3) 
 Never 8 (53.3) 
Alcohol Use* 
 
 At diagnosis 2 (13.3) 
 Before pregnancy 6 (40.0) 
 Never 6 (40.0) 
Drug Use 
 
 Current 0 (0.0) 
 Past 1 (6.7) 
 Never 14 (93.3) 
Abbreviations: BMI, body mass index; GED, general educational development or general 
education diploma 
Data are n (%) or mean (range) unless otherwise specified. 
*One unknown.  
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6Table 4.2 Maternal medical history (n=15) 
Patient  Medical history 
1 Past smoker, current alcohol use*, depression, post-partum depression, 
adjustment disorder, 2 attempted suicides, alcohol abuse, >5 infections 
(mumps, trichomonas, genital herpes simplex II, Molluscum contagiosum, 
condylomata, chorioamnionitis) 
2 Past alcohol use, migraine 
3 Past smoker, past alcohol use, depression, oppositional disorder, dysthymia, 
1 environmental allergy, 1 infection (herpes simplex), migraine, 
environmental exposure (repetitive pesticide exposure as a child) 
4 Past smoker, past alcohol use, obesity, melanoma - no chemotherapy, 
adjustment disorder with mixed emotional features, 1 drug allergy 
5 Current smoker, past alcohol use, depression, 2 drug allergies, >5 
infections (pyelonephritis, frequent and recurrent bladder infections), 
migraine 
6 Past smoker, unknown alcohol use, obesity, depression, anxiety, asthma, 1 
drug allergy, 1 infection (appendicitis), migraine 
7 Current smoker, current alcohol use, past drug use, obesity, depression, 
adjustment disorder with mixed disturbance of emotions and conduct, parent-
child problems, PTSD, alcohol abuse, dysthymic disorder, borderline 
personality traits, 1 environmental allergy, >5 infections (gonorrhea, 
chlamydia x2, recurrent urinary tract infections, bacterial vaginosis) 
8 Past smoker, migraine 
9 Obesity, tachycardia, palpitations, depression, anxiety, OCD, panic attacks, 
panic disorder with agoraphobia, dysthymia, asthma, multiple allergies (drugs, 
food, environmental, other), 1 infection (recurrent cystitis), migraine 
10 Overweight, arrhythmia, tachycardia, depression, anxiety, PTSD, 5 infections 
(GBS, herpes labials, hepatitis A, hepatitis B, latent tuberculosis) 
11 Overweight, 3 infections (hepatitis B, malaria, infection of unknown type) 
12 Past alcohol use, obesity, hypertension, melanoma - no chemotherapy, 3 drug 
allergies, migraine 
13 Supraventricular tachycardia, migraine 
14 Depression, asthma, migraine 
15 Past alcohol use, depression, multiple allergies (food, drug, environmental, 
other), 2 infections (scarlet fever, recurrent otitis media), migraine, 
fibromyalgia, chronic fatigue syndrome, environmental exposure (black mold) 
Abbreviations: OCD, obsessive compulsive disorder; PTSD, post-traumatic stress 
disorder; GBS, group B strep 
*Of the 15 women in this study 10 (66.7%) had a history of current or past smoking and/or 
alcohol use, 10 (66.7%) a history of migraines, 9 (60.0%) had past infections, 10 (66.7%) 




7Table 4.3. Obstetric history prior to index pregnancy (n=15) 
Obstetric history Value 
Live Births  
 0 11 (73.3) 
 1 2 (13.3) 
 2-3 0 (0.0) 
 4-5 1 (6.7) 
 >5 1 (6.7) 
Multifetal gestations 0 (0.0) 
Hypertensive disease of pregnancy 3 (20.0) 
 Chronic hypertension 0 (0.0) 
 Pre-eclampsia 2 (13.3) 
 Gestational hypertension 3 (20.0) 
 Unknown type 1 (6.7) 
Gestational Diabetes 0 (0.0) 




8Table 4.4 Index pregnancy obstetrics and neonatal characteristics (n=15) 
Characteristic Value 
Assisted reproduction 2 (13.3) 
Access to standard medical care during pregnancy 13 (86.7) 
Hypertensive disease of pregnancy 10 (66.7) 
 Chronic hypertension 0 (0.0) 
 Gestational hypertension 3 (20.0) 
 Preeclampsia* 7 (46.7) 
 Eclampsia 0 (0.0) 
 Pre-eclampsia superimposed on chronic 
hypertension 
1 (6.7) 
 Unspecified 1 (6.7) 
Gestational diabetes 1 (6.7) 
Antibiotic use during pregnancy 10 (66.7) 
Bed rest 6 (40.0) 
Tocolytic therapy 1 (6.7) 
Method of delivery  
 Spontaneous vaginal 4 (26.7) 
 Assisted vaginal 2 (13.3) 
 Planned Cesarean section 2 (13.3) 
 Emergency Cesarean section 7 (46.7) 
Number of neonates  
 Single 12 (80.0) 
 Twins 3 (20.0) 
Neonate sex  
 Male 5 (27.8) 
 Female 13 (72.2) 
Breastfeeding  
 At delivery  
  Yes 9 (60.0) 
  Unknown 1 (6.7) 
 After diagnosis  
  Yes 2 (13.3) 
  Unknown 4 (26.7) 
Gestational age (wks) † 37 (32-42) 
 Premature (<37 weeks)  5 (35.7) 
Birthweight (g)† 2,907 (1,635 – 4,760) 
 Low birth weight (<2,500 g)  7 (38.9) 
Data are n (%) or mean (range) unless otherwise specified. 
*Two cases had diagnoses of both gestational hypertension and preeclampsia and are 





9Table 4.5. Index pregnancy maternal cardiovascular characteristics (n=15) 
Characteristic Value 
Clinical Features  
 Blood pressure  
  Systolic (mmHg) 145 (114-180) 
  Diastolic (mmHg) 94 (56-120) 
 Heart rate (bpm) 99 (70-150) 
 Murmur 7 (46.7) 
 Signs suggestive of left heart failure*,† 9 (60.0)  
Signs suggestive of right heart failure‡,§ 9 (60.0) 
Echocardiograph Parameters  
 LVEF (%) 35 (20 - 45) 
 LVEDD (cm) 5.5 (4.0 - 6.4) 
 LVESD (cm) 4.3 (3.1 – 5.6) 
 Ventricular septal wall thickness (cm) 1.0 (0.8 – 1.2) 
 Posterior wall thickness (cm) 0.9 (0.8 – 1.2) 
 RV enlargement 1 (6.7) 
 RV hypokinesis 3 (20.0) 
 LA volume index (mL/m2) 33 (15 – 70) 
 Valvular heart disease,§. ‖ 7 (46.7) 
 Pericardial effusion 9 (60.0) 
Treatment  
 Medication 15 (100) 
 ACE inhibitor 14 (93.3) 
 Angiotensin II receptor blocker 1 (6.7) 
 Beta blocker 11 (73.3) 
 Diuretic 12 (80.0) 
 Anticoagulant 6 (40.0) 
 Bromocriptine 0 (0.0) 
 Vasodilator 3 (20.0) 
 Antiarrhythmic 3 (20.0) 
 Calcium channel blocker 2 (13.3) 
 Nitroglycerin 1 (6.7) 
 Potassium 2 (13.3) 
 Magnesium sulfate 1 (6.7) 
 Mechanical circulatory support 0 (0.0) 
 Cardiac device implantation 0 (0.0) 
 VAD 0 (0.0) 
 Transplant 0 (0.0) 
 Death 0 (0.0) 
 Left ventricular recovery† 14 (93.3) 
 Sterilization 6 (40.0) 
Abbreviations: mmHg, millimeters mercury; bpm, beats per minute; LVEF, left ventricular 
ejection fraction; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular 
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end systolic diameter; RV, right ventricle; LA, left atrial; ACE, angiotensin-converting 
enzyme; VAD, ventricular assist device. 
Data are n (%) or mean (range) unless otherwise specified. 
*Rales, wheezing, pulmonary edema. 
†1 missing. 
‡ Jugular venous distension, ascites, peripheral edema. 
§2 missing. 
‖ Designation of valvular heart disease was based on echocardiogram interpretations and 
included disease categorized as mild/moderate, moderate, moderate/severe, or severe. 
Valvular disease involved the mitral and or tricuspid valves in all 7 patients. One patient 





10Table 4.6 Obstetric and cardiac outcomes of subsequent pregnancy (n=9) 
Data are n (%). 
*Nine women had a total of 15 subsequent pregnancies. Six of these women had 1 
subsequent pregnancy each, one woman had 4, one had 3, and one had 2. 
  
Outcomes Value 
Pregnancy outcome (n=15)*  
 Delivered 7 (46.7) 
 Spontaneous abortion 3 (20.0) 
 Terminated 5 (33.3) 
Maternal outcome   
 Relapse (n=4) 4 (26.7) 




4Figure 4.1 Trends in LVEF for confirmed cases of PPCM for the first 5 
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5Figure 4.2 Outcomes of the 15 patients with PPCM 
14/15 of the patients that had follow-up echocardiography data available recovered. There 
were no cardiac device implantations, transplants or deaths in this cohort. Nine of the 14 
recovered women had subsequent pregnancies. Four of the 9 relapsed, but all recovered. 
Confirmed Cases 
15
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Background: The incidence of peripartum cardiomyopathy (PPCM) is known through 
referral center databases that may be affected by referral, misclassification, and other 
biases. We sought to determine the community-based incidence and natural history of 
PPCM using the Rochester Epidemiology Project. 
Methods and Results: Incident cases of PPCM occurring between January 1, 1970, and 
December 31, 2014, were identified in Olmsted County, Minnesota. A total of 15 PPCM 
cases were confirmed yielding an incidence of 20.3 cases per 100,000 live births in 
Olmsted County, Minnesota. Clinical information, dis- ease characteristics, and outcomes 
were extracted from medical records in a 27-county region of the Rochester Epidemiology 
Project including Olmsted County and matched in a 1:2 ratio with pregnant women without 
PPCM. A total of 48 women were identified with PPCM in the expanded 27-county region. 
There was 1 death and no transplants over a median of 7.3 years of follow-up. Six of the 
23 women with subsequent pregnancies developed recurrent PPCM, all of whom 
recovered. Migraine and anxiety were identified as novel possible risk factors for PPCM. 
Conclusions: The population-based incidence of PPCM was 20.3 cases per 100,000 live 
births in Olmsted County, Minnesota. Cardiovascular outcomes were generally excellent 
in this community cohort.  
 




Peripartum cardiomyopathy (PPCM) is defined as the development of cardiac 
failure in the last month of pregnancy or within 5 months of delivery in women with no 
history of heart disease and no other identifiable cause for cardiac failure. PPCM is 
characterized by left ventricular (LV) systolic dysfunction with an LV ejection fraction 
(LVEF) of 45% and confirmed by echocardiography,1 as well as heart failure symptoms. 
Women with PPCM can experience complete recovery of heart function2,3 with early 
diagnosis and treatment. Timely diagnosis is challenging because the symptoms of PPCM 
are similar to the physio- logical changes that occur during normal pregnancy and 
postpartum.4,5 
The incidence estimates of PPCM vary widely between countries and within the 
United States from 25 cases per 100,000 live births in the United States6 to 333 per 100,000 
live births in Haiti.7 Within the United States, rates vary from 25 cases per 100,000 live 
births in southern California to 185 per 100,000 live births in Georgia.5,6,8-13 The first 
population-level estimate of PPCM incidence in the United States used the National 
Hospital Discharge Survey, relying on International Classification of Diseases (ICD) 
codes to confirm the diagnosis, and reported 31 cases per 100,000 live births.13 A 
population-level study of PPCM with a complete medical record review for data 
abstraction has not been published previously. This study provides the first population-
level epidemiologic study describing the incidence and outcomes of PPCM using a 
comprehensive medical record review through the Rochester Epidemiology Project (REP) 
using a case-control design to examine demographic and clinical characteristics, 






This project was approved by both the Mayo Clinic and Olmsted Medical Center 
Institutional Review Boards and conformed to the principles set forth in the Declaration of 
Helsinki 1975, as revised in 2013. All patients involved in the study provided written 
informed consent to allow the use of their medical records for research purposes as part of 
the REP. Patients who had not previously consented to participate in research through the 
REP were excluded from the study. 
Source of Data 
The REP has been used to conduct population-level epidemiologic research in 
Olmsted County, Minnesota, as described previously.14 Briefly, the database links the 
medical record of most health care providers in the county, including Mayo Clinic and 
Olmsted Medical Center and their affiliated hospitals as well as a few private providers 
who provide 90% 96% of all health care to Olmsted County residents.14-16 Data for this 
study was available from 3 regions: Olmsted County (1 county), a 7-country region that 
included Olmsted County and 6 other surrounding counties, and a 27-county region that 
incorporated the 7 counties as well as other counties in southern Minnesota and western 
Wisconsin.17 Olmsted County has a coverage rate of 99.9% from January 1, 1970, through 
December 31, 2014, and the 7-county region has a 93.8% coverage rate from January 1, 
1976, through December 31, 2014. Starting January 1, 2010, the REP was expanded to 
include a total of 27 counties.14-17 The 27-county region uses the same data linkage system 
as the REP and has an overall coverage rate of 60.9% from January 1, 2010, to December 
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13, 2014.14-17 The lower coverage rate is due predominantly to not all heath care facilities 
within the region collaborating in the REP.17 The REP has electronic indexes that include 
demographic information, diagnostic and procedure codes, health services use data, 
outpatient drug prescriptions, laboratory test results, imaging and procedure reports, and 
information about smoking, height, weight, and body mass index.14-17 The demographic, 
racial, ethnic, and socioeconomic make- up of the 27 county region REP has been shown 
to be representative of the Minnesota/Wisconsin area and to a large segment of the US 
population.17 
Study Population 
Data were collected for all Olmsted County, Minnesota residents diagnosed with 
PPCM from January 1, 1970, through December 31, 2014. PPCM cases from the 1-county 
region were broadly identified from a list of 866 women 15 55 years of age living in 
Olmsted County, Minnesota, from 1970 to 2014 with a PPCM diagnosis code (ICD-9 
674.5X, Hospital International Classification of Disease Adaptation [HICDA] 4251610, 
4251310, BRK 0234 1) or a heart failure code (ICD-9 428.X, HIC 4270110, 4279133, BRK 
23452); codes that were used for these dis- ease classifications during this time period. The 
older HICDA code was used to identify PPCM cases during the years before the use of 
ICD-9 diagnosis codes. From the original 866 patients identified with possible PPCM, 15 
cases were confirmed as PPCM. Population-level data were only available for Olmsted 
County, so the incidence of PPCM was based on Olmsted County data. 
To increase the sample size of the study, data were also collected from January 1, 
1976, through December 31, 2014, by individual record review for the 7-county and the 
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27-county regions. Because heart failure diagnosis codes had not yielded any additional 
cases of PPCM in the survey of 866 records in Olmsted County, only diagnosis codes for 
PPCM (ICD-9 674.5X) or cardiomyopathy (HICDA 4250310) were used for the expanded 
regions. From the 7- county region, we identified an additional 242 women with PPCM 
diagnoses, and a further 69 patients from the 27- county region with PPCM diagnoses. 
From these potential cases, medical record review confirmed 33 additional cases of PPCM, 
which combined with the 15 cases from Olmsted County, provided a total of 48 cases for 
the study (Fig. 5.1). 
In total, 1177 potential cases of PPCM were individually screened from all 3 
regions using a case definition for PPCM based on the criteria proposed by the National 
Heart, Lung and Blood Institute and the Office of Rare Diseases of the National Institutes 
of Health Workshop on Peripartum Cardiomyopathy1 that included (1) the development of 
cardiac failure in the last month of pregnancy or within 5 months of delivery, (2) an absence 
of an identifiable cause for the cardiac failure, (3) an absence of recognizable heart disease 
before the last month of pregnancy, and (4) a LV systolic dysfunction demonstrated by 
classical echocardiographic criteria with an EF of 45% (Fig. 5.1). 
Control patients were selected from a pool of 52,682 women 15 55 years of age 
who lived and gave birth within the 27-county region of the REP from January 1, 1970, 
through December 31, 2014. Controls were matched on a 2:1 basis by age, race, and 
number of babies born during the index pregnancy (index pregnancy refers to the 





Data regarding demographics, medical history, index pregnancy, and outcomes for 
the 48 confirmed PPCM cases and the 96 selected controls were abstracted from electronic 
and paper medical records available through the REP and entered into a Research 
Electronic Data Capture (REDCap) database.18 
Statistical Analysis 
The incidence was calculated for all Olmsted County female residents who were 
15-55 years of age and considered to be at risk for PPCM. Annual birth rates for Olmsted 
County residents were obtained from the Minnesota Health Statistics Annual Summary 
Reports.19,20 To compare cases and controls, the Student’s t test or Wilcoxon Mann 
Whitney test were used to assess differences for continuous variables with normal or 
skewed distribution, respectively. The Fisher exact test or the x2 test were used to evaluate 
categorical variables. A P value of <.05 was considered statistically significant. Categorical 
data are presented as frequency (n) and percent (%) and numeric data as mean standard 
deviation for normally distributed data and median (interquartile range) for non-normally 
distributed data, unless otherwise specified. Missing data were excluded from the analyses. 
Column total percentages are based on excluding missing data. Data were analyzed using 
Stata/IC 15.21 
Results 
 Fifteen women in the single county area of Olmsted County, Minnesota, who met 
the definition for a diagnosis of PPCM were identified. Based on vital statistics data from 
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the Minnesota Department of Health,19,20 the incidence of PPCM from 1970 through 2014 
in Olmsted County, Minnesota, was determined to be 20.3 cases per 100,000 live births. 
An additional 33 women who lived in the larger 27 county REP area and met the 
criteria for a diagnosis of PPCM were identified that, when added to the 15 cases from 
Olmsted County, provided the 48 overall number of cases for the case control study (Fig. 
5.1). Ninety-six women were identified as controls with a 2:1 matching based on age, race, 
and number of infants born during the index pregnancy. Demographics of cases and 
controls are listed in Table 5.1. The mean age of the cohort was 28 years (range15-44 years) 
(Table 5.1). The cohort was 79.2% White, 18.7% Black (a mix of African American [6.2%] 
and African immigrants [12.5%]) and 1 woman (2.1%) who identified as both Native 
American and Hispanic. Women in the PPCM cohort had a higher median body mass index 
than women in the control cohort (25.2 kg/m2vs 23.6 kg/m2, P = .01), were more likely to 
be overweight or obese (66.7% vs 41.7%, P = .005), and were more likely to have 
government-sponsored health insurance (i.e. Medicaid), whereas women in the control 
cohort were more likely to have private health insurance (53.3% vs 25.6%, P = .001) (Table 
5.1). There were no statistically significant differences in marital status, education level, 
smoking status, and his-tory of hypertension (8.3% vs 2.1%, P = .01), anxiety (25.0% vs 
10.4%, P = .03) and migraine (43.8% vs 15.6%, P< .001) compared with controls (Table 
5.2). There were no differences observed in hyperlipidemia, heart disease, cancer, 
depression, asthma, allergies, infections, diabetes, or chemical exposure between the 2 
groups (Table 5.2). Among the women for whom these data were available, women 
diagnosed with PPCM were more likely to have a history of hypertensive disorders of 
pregnancy (HDP), predominantly gestational hypertension and preeclampsia (40.0% vs 
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4.2%, P = .02), and a higher likelihood of gestational diabetes (4.8% vs 3.1%, P = .04) in 
previous pregnancies (Table 5.3).  
 Index pregnancy characteristics are listed in Table 5.4 Women in the PPCM cohort 
were more likely to have been diagnosed with HDP (56.3% vs 12.5%, P < .001) and more 
likely to have been placed on bed rest (28.2% vs 12.6%, P = .03) during their index 
pregnancy compared with women in the control group. The index pregnancies of women 
diagnosed with PPCM were less likely to have been planned pregnancies than those of 
controls (32.4% vs 54.4%, P = .03). Women in the PPCM cohort were also significantly 
more likely to have had an emergency cesarean section than women in the control cohort 
(43.8% vs 14.6%, P < .001). Women in the PPCM cohort were more likely to have had a 
cardiac indication for cesarean section than women in the control cohort (55.1% vs 7.1%, 
P = .01) (Table 5.4). Infants born to women in the PPCM cohort had a lower median 
gestational age (37 weeks vs 39 weeks, P = .004), were significantly more likely to be born 
prematurely (< 37 weeks gestation) (43.8% vs 22.9%, P = .003), had a significantly lower 
median birth weight (2445 g vs 3190 g, P= .01) and were more likely to be born at a low 
birth weight (<2500g) (45.8% vs 24.8%, P = .01). Women in the PPCM cohort seemed to 
be less likely to breastfeed, but this difference did not reach statistical significance(59.9% 
vs 75.8%, P = .06). However, the rates of breast- feeding in the PPCM cohort decreased 
significantly after diagnosis (59.9% vs 24.3%, P = .009) (Table 5.4). 
 Table 5.5 presents characteristics, including physical examination at diagnosis, 
echocardiography findings, and treatments and outcomes for the 48 cases in our cohort. 
Eleven of the women (22.9%) were diagnosed with PPCM during pregnancy and the other 




postpartum (Table 5.5). The majority of cases (41/48, 85.4%) presented with elevated 
blood pressure22 and/or heart failure symptoms (44/48, 91.7%) with 1 patient missing 
information on symptoms at diagnosis. Indications for cardiac screening in the 3 cases 
without heart failure symptoms included arrhythmias and a new heart murmur. The median 
LVEF at diagnosis was 34% (range 12% 45%) and the median LV end diastolic diameter 
was 5.7 cm (range 4.0 7.4 cm). Forty-seven of the women (97.9%) were treated with 
medications, the most common being angiotensin-converting enzyme inhibitors (87.5%, n 
= 42), diuretics (87.5%, n = 42), and beta-blockers (79.2%, n = 38) (Table 5.5). One patient 
had an intra-aortic balloon pump placed and subsequently died (Table 5.5, Fig. 5.1). This 
death was the only one in the cohort. No pacemakers or internal cardiac defibrillators were 
implanted and no patients under- went LV assist device implantation or transplantation 
during a median follow up time of 7.3 years (range 0.3 27.8 years) (Table 5.5, Fig. 5.1). 
Supplementary Fig. 1 shows the trends in LVEF of the confirmed cases over the 
first 5 years of the study. Forty- three of the women (89.6%) diagnosed with PPCM 
recovered cardiac function (LVEF 50% per follow-up echocardiography) (Table 5.5, Fig. 
5.1). The timing of the recovery ranged from 3 days to just >12 years, with the median time 
to recovery approximately 4.5 months (Table 5.5). Two women had residual cardiac 
dysfunction and no follow-up echocardiograms were recorded for 2 additional women in 
the PPCM cohort, so recovery status could not be determined (Fig. 5.1). 
Among the control cohort of 96 women, 56 (62.6%) had a total of 105 subsequent 
pregnancies, resulting in 82 (78.1%) live births, 18 (17.1%) spontaneous abortions, and 5 
(4.8%) terminations. Twenty-three of the 48 women (56.1%) diagnosed with PPCM had a 
total of 37 subsequent pregnancies resulting in 25 (67.6%) live births, 5 (13.5%) 
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spontaneous abortions, and 7 (18.9%) terminations (Table 5.6). Pregnancy termination was 
significantly higher in cases compared with controls (P = .01) (Table 5.6). Among the 
women diagnosed with PPCM, 10 (30.3%) of the subsequent pregnancies were planned, 
23 (65.2%) were unplanned, with information unavailable regarding planning for 6 
pregnancies (Table 5.6). Twenty-two of the women (95.7%) recovered cardiac function 
(LVEF of 50% per follow-up echocardiography) before subsequent pregnancy. One 
woman had no follow-up echocardiograms after index pregnancy diagnosis, so recovery 
status at subsequent pregnancy was unknown (Fig. 5.1). Fifteen women (65.2%) were on 
cardiac medication during their subsequent pregnancies (Table 5.6). The relapse rate in the 
PPCM cohort was 12.5% (n = 6), but all 6 cases recovered normal LV function after their 
relapse (Table 5.6 and Fig. 5.1). Similar rates of women in each cohort underwent 
sterilization procedures after index delivery (33.3% vs 34.4%, P = .90). 
Discussion 
The estimate of the incidence of PPCM in Olmstead County, Minnesota from 1970 
through 2014 was 20.3 cases per 100,000 live births, which is lower than previous estimates 
of 25 to 185 per 100,000 live births.5-7,9,13,23 Fifteen cases were found in Olmsted County 
and an additional 33 cases for a total of 48 cases in the larger 27 county region. However, 
owing to the lower percentage coverage rate (61%) for the REP in the 27 county region, 
PPCM incidence for the larger region could not be calculated. From an initial 1177 patients 
identified using diagnosis codes for heart failure, cardiomyopathy and PPCM, only 48 
(55%) of the 88 women with a diagnosis code for PPCM met the diagnostic criteria for 
PPCM after record review by a physician experienced with PPCM (Fig. 5.1).1 The most 
common reasons for exclusion included a LVEF of >45% and a diagnosis of other types of 
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cardiomyopathy (Fig. 5.1). Our study may reflect a more accurate population-level 
incidence than previously published studies, because all cases in this study were confirmed 
using medical record data, whereas previously published studies5-7,9,13,23 relied on diagnosis 
codes and may have overestimated the disease incidence by including women who had the 
diagnosis code for PPCM in their medical record but did not meet the diagnostic criteria 
for PPCM. 
The mean age at PPCM diagnosis in this study was28 years (Table 5.1), with 62.5% 
of cases occurring in women 30 years in contrast with previous studies that found an 
association between PPCM diagnosis and advanced maternal age.6,8,9,13 Previous studies 
reported that Black women have the highest rates of PPCM, followed by non-Hispanic 
White women, with Hispanics and Asians having the lowest rates.5,6,9,13,23-25 Based on US 
Census data, the population within the study area was 90.2 97.4% non-Hispanic White and 
1.3 3.7% Black during the study period, whereas cases in this cohort were 79.2% non-
Hispanic White and 18.8% Black, supporting previous reports that PPCM cases seem to 
occur at a higher rate among Black women compared with non-Hispanic White women.15  
Previous reports have also suggested an increased risk of PPCM with multiparty5,8-
12 and multifetal gestation.26 In the current study, we did not observe an association 
between multiparity and PPCM diagnosis, as 28 of the 48 women (58.3%) with PPCM 
were nulliparous (Table 5.3). Similar to previous studies, however, multifetal gestation 
during the index pregnancy (17.0%, n = 8 in cases) occurred at a higher rate in women 
diagnosed with PPCM compared with the national rates for multifetal gestation that ranged 
from 2.1% to 3.5% during the time period of this study.27  
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HDP have been associated with an increased risk of PPCM.26,28,29 Twenty-seven of 
the cases (56.3%) in this study were diagnosed with HDP during their index pregnancy, a 
rate significantly higher than controls (12/96, 12.5%, P .001) (Table 5.4). Preeclampsia 
was the most common HDP diagnosis among cases, occurring in 18 of the 48 women 
(37.5%) (data not shown), which is more than nine times the 4% preeclampsia rate among 
women in the United States.30 This finding aligns with previous studies that have reported 
that preeclampsia is one of the strongest risk factors for PPCM.26,31  
This study identified prior diagnoses of anxiety or migraine as novel possible risk 
factors for PPCM (Table 5.2). Anxiety may increase the risk of cardiovascular disease by 
increasing inflammation and inducing endothelial dysfunction, 2 factors that are postulated 
to play a role in the pathogenesis of PPCM.32 Migraine may also be a risk factor for 
developing PPCM, although with a small sample size of incident cases, this may also 
simply reflect migraine as a common disease state in women. It is important to note, 
however, that migraine is a known risk factor for cardiovascular and cerebrovascular 
disease, potentially increasing risk through pathways including HDP.33-35 Migraine, pre-
eclampsia, and PPCM have all been associated with vascular dysfunction owing to 
hormone imbalances and angiogenic factors including vascular endothelial growth factor, 
soluble fms-like tyrosine kinase-1, estrogen, relaxin-2, prolactin, and placental growth 
factor.33,36-41 Further investigation, including determining whether or not migraine subtype 
(with or without aura, for example) is more predictive of PPCM and whether increased 




Similar to previous studies,5,8,42,43 the findings from this study suggest that infants 
born to mothers with PPCM have an increased risk for adverse birth outcomes, including 
pre- maturity and low birthweight (<2500 g) compared with those born to mothers in the 
control cohort (Table 5.4). These adverse outcomes are important to note, because 
premature birth and low birth weight are both associated with increased infant mortality 
and a variety of developmental and medical issues for the child.44  
Another important finding in this study is that the rate of breastfeeding in women 
with PPCM decreased significantly after diagnosis (Table 5.4). Women discontinued 
breastfeeding for a variety of reasons, including their perceived compromised physical or 
mental health, not having ready access to their infants while hospitalized, a lack of 
awareness by treating physicians about the safety of cardiac medications during lactation, 
and/or a concern that breastfeeding may be detrimental to the mother’s recovery based on 
the proposed mechanistic link between PPCM and the nursing hormone prolactin.37,45 The 
World Health Organization recommends exclusive breast- feeding for 6 months and 
continued breastfeeding for 1 2 years46 because the lack of breastfeeding is associated with 
an increased risk of diabetes, ovarian and breast cancers, and postpartum depression in 
women and higher rates of mortality, infections, eczema, asthma, childhood obesity, 
diabetes, leukemia, and lower intelligence in children.47,48 Mothers with PPCM and their 
physicians would likely benefit from increased education and awareness regarding which 
cardiac medications are safe to use during lactation and that breast- feeding seems to have 
no detrimental effect on outcomes among women with PPCM according to several 
published reports.49-51 Further investigation into the short- and long- term outcomes of 
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infants born to mothers diagnosed with PPCM is necessary so that appropriate counseling 
and care can be provided to mothers and infants. 
Nearly 90% of the women with PPCM in this study recovered normal LV function 
with a median recovery time of 4.5 months (Table 5.5). It should be noted that 
approximately one- half of the women who had not recovered by year one did not have 
follow-up echocardiograms until 1 12 years after diagnosis, at which time they had 
recovered. Owing to the retrospective nature of the study, the precise timing of recovery 
was difficult to establish. However, our data suggest that cardiac function can continue to 
improve for many years after PPCM diagnosis. Guideline-directed recommendations for 
follow-up assessment of women diagnosed with PPCM would likely enhance our 
understanding regarding degree and timing of LV recovery in patients. 
In our study, 5 of 43 woman (11.6%) with PPCM who recovered LV function 
suffered a decline in cardiac function, between 6 months to 9.3 years after recovery, 
unrelated to a subsequent pregnancy (data not shown). One woman suffered cardiac 
toxicity from medications taken for an unrelated condition and recovered. A second woman 
recovered by one year and then had 2 occasions with deterioration in cardiac function 
despite remaining on cardiac medications throughout that time period with her most recent 
echocardiogram demonstrating a LVEF of 50%. Three women had discontinued all cardiac 
medications after recovery but then suffered declines in cardiac function at 3.5, 6.0, and 
9.3 years after recovery. All 3 women recovered cardiac function after cardiac medications 
were restarted. Most medical experts agree that guideline- directed medical therapy for 
heart failure should be continued indefinitely in women with PPCM who have persistent 
cardiac dysfunction. However, there is no clear consensus on how to treat women with 
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PPCM with recovered LV function.2,52Data regarding the long-term risk of cardiac 
deterioration if medications are stopped is conflicting.53,54 Two recent studies suggest that 
women with LV recovery may still have LV diastolic dysfunction, decreased exercise 
capacity, ongoing angiogenic imbalance, and residual myocardial injury.55,56 Noting that 5 
women in our PPCM cohort experienced decline in LV function after recovery unrelated 
to subsequent pregnancy high- lights the difficulty in determining the duration of medical 
treatment after recovery and the importance of long-term regular cardiac follow-up for 
women diagnosed with PPCM, including those with recovered cardiac function. 
Many women with PPCM desire to have additional pregnancies after diagnosis. 
Decisions regarding subsequent pregnancy are challenging, because all women with PPCM 
are at risk for a decrease in LV function and possibly even death. Experts agree that women 
with persistent significant cardiac dysfunction are at greatest risk for cardiac complications 
during subsequent pregnancy and should be counseled against future pregnancy, while 
women with recovered cardiac function may consider subsequent pregnancy.2,57,58 There 
are no proven risk factors for relapse during subsequent pregnancy among women with 
recovered LVEF, so careful monitoring during and after pregnancy is indicated. Although 
the sample size is small, our study results support the consensus that women diagnosed 
with PPCM with recovered cardiac function can have successful subsequent pregnancies 
(Table 5.6). Of note, 4 of the women in our study who relapsed during subsequent 
pregnancy were on cardiac medications at the time of relapse, highlighting that heart failure 
therapy does not guaran- tee freedom from relapse (Table 5.6). In addition, the large 
number of unplanned subsequent pregnancies and the higher rate of terminations in women 
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diagnosed with PPCM indicate that contraceptive counseling on an ongoing basis, not 
simply shortly after PPCM diagnosis, is critical. 
There are several limitations to this study. The small sample size prevented any 
subgroup analysis. The lack of racial/ethnic diversity in the REP compared with other 
regions of the United States may limit the generalizability of the study. Owing to the 
retrospective nature of the study, data are restricted to what is available in medical records 
and therefore the timing of subsequent echocardiograms varied between patients, adding 
uncertainty to calculations such as length of time to recovery. In addition, some cases of 
PPCM may have been missed because the REP does not have complete coverage of 
medical records for all 27 counties. This factor prevented an incidence calculation for the 
entire study area. A major strength of our study, however, is the use of data from the REP, 
a well-established, high-quality, federally funded resource for epidemiologic research. In 
addition, the use of complete medical record review to confirm the diagnosis leading to a 
well-defined cohort of PPCM cases from a specific geographical area with long- term 
follow-up is particularly noteworthy. These strengths, as well as the almost complete 
capture rate of medical records for all residents of Olmsted County, Minnesota, made it 
possible to calculate a precise incidence estimate for that area.14-16 These strengths, along 
with the verification of diagnosis by medical record review, minimized referral bias and 
misclassification, which are common in coding-based studies. This study was also 
strengthened by the range of data collected and analyzed, as well as the abundance of data 
in areas addressing knowledge gaps related to PPCM including long-term outcomes of 





The population-based incidence of PPCM was 20.3 cases per 100,000 live births in 
Olmsted County, Minnesota. Among the well-characterized cohort of women with PPCM 
in this study, a history of anxiety and a history of migraine emerged as novel risk factors. 
The majority of women recovered LV function days to years after diagnosis. A minority 
of women with recovered LV function experienced subsequent LVEF decline months to 
years after recovery. Infants of mothers with PPCM had an increased risk of prematurity 
and low birth weight. Finally, women with recovered LVEF before subsequent pregnancy 
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11Table 5.1 Maternal demographic characteristics of cases and controls* 
Patient Characteristics Case (n=48) Control (n=96) p value 
Age (y) 28 ± 7.0 28 ± 7.0 - 
Pre-pregnancy BMI (kg/m2) 25.2 (20.5-36.6) 23.6 (21.6-28.03) .01 
 BMI Category   .005 
 <25.0 16 (33.3) 56 (58.3)  
 ≥25.0 32 (66.7) 40 (41.7)  
Race/Ethnicity   - 
 White 38 (79.2) 76 (79.2)  
 American Indian 1 (2.1) 2 (2.1)  
 Black 9 (18.7) 18 (18.7)  
  African American 3 (6.2) 7 (6.2)  
  African Immigrant 6 (12.5) 11 (12.5)   
Hispanic 1 (2.1) 2 (2.1)  
Marital Status   .07 
 Single 13 (27.1) 26 (27.1)  
 Married 24 (50.0) 61 (63.5)  
 Domestic Partner 11 (22.9) 9 (6.4)  
Education    
 < High school 6 (13.3) 13 (13.7) .84 
 High school or GED 12 (26.7) 19 (20.0)  
 Some college or associate degree 15 (33.3) 36 (37.9)  
 ≥ College degree 12 (26.7) 27 (28.4)  
Health Insurance   .001 
 Private 21 (46.7) 70 (74.4)  
 Medical assistance / Medicaid 24 (53.3) 24 (25.6)  
Smoking   .16 
 At diagnosis 15 (31.2) 16 (18.0)  
 Before pregnancy 8 (16.7) 23 (25.8)  
 Never 25 (52.1) 50 (56.2)  
Alcohol Use   .44 
 At diagnosis 3 (6.5) 1 (1.6)  
 Before pregnancy 24 (52.2) 37 (57.8)  
 Never 19 (41.3) 26 (40.6)  
Drug Use   .82 
 Current 3 (6.2) 3 (3.8)  
 Past 7 (14.6) 11 (14.1)  
 Never 38 (79.2) 64 (82.1)  
Length of follow-up† (y) 7.2 (4.1 – 12.6) 12.8 (8.2 – 18.8) <.001 
Data are n (%), mean ± standard deviation, or median (interquartile range) unless 
otherwise specified. 
*Percentages are based on column totals excluding unknown data. 
†Follow-up was defined as years of medical records available for review post index 
pregnancy. Abbreviations: BMI, body mass index; GED, general educational 
development or general education diploma.  
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12Table 5.2 Medical history of cases and controls 
Comorbidity Case (n=48) Control (n=96) p value 
Hypertension 4 (8.3) 2 (2.1) .01 
Hyperlipidemia 1 (2.1) 6 (6.3) .43 
All Heart Disease*,† 3 (6.3) 7 (7.3)  .99 
Arrhythmia 3 (6.3) 3 (3.1) .39 
Other Heart Disease† 0 (0.0) 4 (4.2) .55 
Cancer‡,§ 2 (4.2) 2 (2.1) .60 
Any Mental Health Diagnosis 26 (54.2) 35 (36.5) .04 
Depression 22 (45.8) 31 (32.3) .14 
Anxiety 12 (25.0) 10 (10.4) .03 
Other Mental Health Diagnosis 15 (31.3) 18 (18.8) .10 
Asthma 11 (22.9) 18 (18.8) .66 
Allergies§ 23 (47.9) 33 (34.4) .15 
Infections 28 (58.3) 55 (57.3) .91 
Diabetes 0 (0.0) 2 (2.1) .55 
Migraines 21 (43.8) 15 (15.6) <.001 
Autoimmune Disease‖ 0 (0.0) 5 (5.2) .17 
Chemical Exposure¶ 6 (12.5) 4 (4.2) .08 
Data are n (%) or mean (range) unless otherwise specified. 
Percentages are based on column totals excluding unknown data. 
*Three cases with arrhythmia. 
†The controls with mitral valve prolapse, three controls with arrhythmia, one control with 
patent foramen ovale. 
‡Two cases had malignant melanoma, both treated only with excision. 
§One control had thyroid cancer treated with excision and iodine ablation and one control 
had laryngeal squamous cell carcinoma treated with excision.  
‖One control with ulcerative colitis, one control with Graves’ disease and three controls 
with Hashimoto’s thyroiditis. 





13Table 5.3 Obstetric history of cases and controls prior to index pregnancy* 
Obstetric history Case (n=48) Control (n=96) p value 
Parity    
 Median Parity† 1 (0-2.5) 1 (0-2.5) .34 
 Nulliparous 28 (58.3) 43 (44.8) .16 
 Primipara or multipara 20 (41.7) 53 (55.2) .16 
    
Primipara or multipara women n=20 n=53  
 
Multi-fetal gestations 0 (0.0) 0 (0.0) - 
 Hypertensive disease of 
pregnancy‡ 
8 (40.0) 4 (4.2) .02 
 Gestational diabetes§ 1 (4.8) 3 (3.1) .04 
Data are n (%) or mean (range) unless otherwise specified. 
Percentages are based on column totals excluding unknown data. 
*The index pregnancy is the pregnancy associated with initial peripartum cardiomyopathy 
diagnosis for cases and the matched pregnancy for controls. 
†Parity ranged from 0 to 6 for cases and 0 to 5 for controls. 
‡Hypertensive disorders of pregnancy includes gestational hypertension, preeclampsia, 






14Table 5.4 Index pregnancy characteristics of cases and controls* 
Characteristic Case (n=48) Control (n=96) p value 
Assisted reproduction 4 (8.3)  13 (13.5) .42 
Access to standard medical care 
during pregnancy 
27 (75.0) 78 (82.1) .36 
Planned Pregnancy 11 (32.4) 50 (54.4) .03 
Single Parenting 10 (20.8) 21 (23.1) .96 
Hypertensive disease of pregnancy 27 (56.3) 12 (12.5) <.001 
Gestational diabetes  2 (4.4) 9 (9.5) .50 
Antibiotic use during pregnancy 21 (70.0) 53 (56.4) .19 
Bed rest 11 (28.2) 12 (12.6) .03 
Tocolytic therapy  2 (4.3) 11 (11.6) .22 
Method of delivery   .001 
 Spontaneous vaginal 16 (33.3) 59 (61.5) .001 
 Assisted vaginal 6 (12.5) 12 (12.5) .99 
 Planned caesarian section 5 (10.4) 11 (11.5) .85 
 Emergency caesarian section 21 (43.8) 14 (11.6) <.001 
Indication for caesarean section    
 Cardiac 11 (55.4) 1 (7.1) .01 
 Obstetric 10 (47.6) 13 (92.9)  
Number of neonates    
 Single 40 (83.3) 80 (83.3) - 
 Twins 7 (14.9) 14 (14.9)  
 Triplets 1 (2.1) 2 (2.1)  
Neonate sex   .68 
 Male 23 (41.8) 51 (45.1)  
 Female 32 (58.2) 62 (54.9)  
Gestational age (wks) 36 (23-39) 37 (37-40) .004 
 Premature (< 37 weeks) 21 (43.8) 22 (22.9) .003 
Birthweight (g) 2,445 (2012-3459) 3,190 (2550-3562) .01 
 Low birth weight (<2,500 g) 22 (45.8) 28 (24.8) .01 
Breastfeeding    
  Yes 22 (59.5) 69 (75.8) .06 
Breastfeeding in cases only    
  After delivery 22 (59.5) - .009 
  Post diagnosis 9 (24.3) -  
Data are n (%) or median (interquartile range) unless otherwise specified. 
Percentages are based on column totals excluding unknown data. 
*The index pregnancy is the pregnancy associated with initial peripartum cardiomyopathy 




15Table 5.5 Disease characteristics of women diagnosed with PPCM (n=48) 
Disease Characteristic Value 
Timing of Diagnosis* (days) 4 (0 - 12) 
 During pregnancy 11 
 Postpartum 37 
Clinical Features  
 Blood pressure  
  Systolic (mmHg) 140 (126 - 154) 
  Diastolic (mmHg) 89 (79 - 104) 
  Elevated
†
 41 (85.4) 
 Heart rate (bpm) 




 14 (29) 
 Signs suggestive of left heart failure§  
  Yes 36 (75.0) 
  Unknown 2 (4.2) 
 
Signs suggestive of right heart failure¶  
  Yes 33 (68.8) 
  Unknown 5 (10.4) 
Echocardiograph Parameters 
 EF (%) 34 (24 – 40) 
 LVEDD (cm) 5.7 (5.1 – 6.0) 
 LVESD (cm) 4.5 (4.1 – 4.0) 
 Ventricular septal wall thickness (cm) 1.0 (0.9 – 1.1) 
 Posterior wall thickness (cm) 0.9 (0.9 – 1.1) 
 RV enlargement
‡
 9 (18.8) 
 RV hypokinesis
‖
 16 (33.3) 
 LA volume index (mL/m2) 34 (27 – 38) 
 Valvular heart disease#,
‖
 20 (41.7) 
 Pericardial effusion
‖
 20 (41.7) 
Treatments 
 Treatment with medication 47 (97.9) 
  ACE inhibitor 42 (87.5) 
  Angiotensin II receptor blocker 2 (4.2) 
  Beta blocker 38 (79.2) 
  Diuretic 42 (87.5) 
  Blood thinner 17 (35.4) 
  Bromocriptine 0 (0.0) 
  Vasodilator 10 (20.8) 
  Anti-arrhythmic 10 (20.8) 
  Calcium channel blocker 2 (4.2) 
  Nitroglycerin 3 (6.3) 
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  Potassium 4 (8.3) 
  Magnesium sulfate 4 (8.3) 
 Mechanical circulatory support 0 (0.0) 
 Cardiac device implantation** 1 (2.1) 
 VAD 0 (0.0) 
Outcomes  
 Length of follow-up after diagnosis (y) 7.3 (4.1 – 12.2) 
 Transplant 0 (0.0) 
 Death 1 (2.1) 
 Left ventricular recover††,‡‡ 43 (89.6) 
 Persistent cardiac dysfunction§§ 2 (4.2) 
Data are n (%) or median (interquartile range) unless otherwise specified. 
Percentages are based on column totals excluding unknown data. 
*Diagnosis timing ranged from 2 days before delivery to 185 days (6 months) 
postpartum with 7 women diagnosed on the day of delivery. 
†
Elevated blood pressure as defined as a systolic blood pressure of ≥140 mm Hg and/or a 
diastolic blood pressure of ≥90 mm Hg as in the 2020 International Society of 
Hypertension Global Hypertension Practice Guidelines.22 
‡
Seven missing. 
§Rales, wheezing, pulmonary edema. 
¶Jugular venous distension, ascites, peripheral edema. 
‖
Eight missing. 
#Designation of valvular heart disease was based on echocardiogram interpretations and 
included disease categorized as mild/moderate, moderate, moderate/severe, or severe. 
Valvular disease was found in just the mitral valve in 11 patients and in just the tricuspid 
valve in 6 patients. An additional 2 patients had disease in both the mitral and tricuspid 
valves and 1 patient had disease in the mitral, tricuspid, and pulmonary valve. 
**Intra-aortic balloon pump. 
††Left ventricular recovery defined as a left ventricular ejection fraction of ≥50% by 
echocardiogram. 
‡‡Recovery time ranged from 3 days to just >12 years with a median of 4.5 months. Two 
patients had residual dysfunction, 1 died, and 2 had no follow-up echocardiogram, so the 
official recovery status is not known, but both were functionally recovered. 
§§Persistent cardiac dysfunction defined as a left ventricular ejection fraction of ≤50%. 
Abbreviations: ACE, angiotensin-converting enzyme; bpm, beats per minute; EF, ejection 
fraction; LA, left atrial; LVEDD, left ventricular end diastolic diameter; LVESD, left 
ventricular end systolic diameter; RV, right ventricle; VAD, ventricular assist device. 
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16Table 5.6 Obstetric and cardiac outcomes of subsequent pregnancy of 
cases and controls 
Outcomes Case (n=48) Control (n=96) p value 
Number of women w/ subsequent 
pregnancies 
23 (56.1) 56 (62.6) 
.46 
Subsequent pregnancies† (n=37) (n=105)  
 Planned 10 (30.3) ‡ - 
 Unplanned 23 (69.7) ‡ - 
Pregnancy outcome     
 Delivered 25 (67.6) 82 (78.1) .20 
 Spontaneous abortion 5 (13.5) 18 (17.1) .80 
 Terminated 7 (18.9) 5 (4.8) .01 
Women on cardiac medication 15 (65.2) ‡  
 Beta Blocker§ 14 ‡  
 Calcium channel blocker 1 ‡  
 Digoxin 1 ‡  
Maternal Outcome    
 Relapse¶ 6 (12.5) ‡ - 
  
On cardiac medication at 
time of relapse 
4 (66.7) ‡ 
 
 Recovery after relapse‖ 6 (100.0) ‡ - 
Sterilization 16 (33.3) 33 (34.4) .90 
Data are number (%) unless otherwise specified. 
Percentages are based on column totals excluding unknown data. 
*For 7 cases and 7 controls subsequent pregnancy status is unknown. 
†For 4, subsequent status, no data are available regarding planning of pregnancy. 
‡Data either not applicable or not obtained. 
§One woman was treated with both a beta blocker and a calcium channel blocker. 
¶Relapse defined as decrease in the left ventricular ejection fraction to ≤45%. 












6Figure 5.1 Patient cohort with outcomes. 
From an initial cohort of 1177 women, 48 cases of peripartum cardiomyopathy (PPCM) 
were con- firmed. 47 out of 48 women survived. One woman received an intra-aortic 
balloon pump and subsequently died. There were no transplants in this cohort. 43 women 
recovered cardiac function (left ventricular ejection fraction of 50% on echocardiogram), 
2 had residual left ventricular dysfunction, and 2 had no follow-up echocardiograms so the 
recovery status could not be determined, but both were functionally recovered. At least 22 
of the recovered women had subsequent pregnancies, as well as 1 woman whose recovery 
status was unknown. One woman with unknown recovery status (functionally recovered) 
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had 1 subsequent pregnancy and did not relapse symptomatically, but no echocardiogram 
was conducted. Six of the recovered cases relapsed (12.5% rate of relapse) with at least 1 





7Supplemental Figure 5.1 Trends in LVEF for confirmed cases of PPCM.  
Data for the first 5 years post diagnosis are included in the graph, although follow-up 
echocardiograms are available for some patients up to 25.6 years after diagnosis. The time 
to recovery ranged from 3 days to just over 12 years based on echocardiography with an 
average time to recovery of just under one year. One patient died without recovery, two 
patients had residual dysfunction, and two patients did not have follow-up 

















% LVEF - First 5 years of follow up only
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Chapter 6: The Potential Relationship between Air 
Pollution Exposure and Peripartum Cardiomyopathy 
 
In 2014, air pollution was identified as the largest single environmental health risk 
factor for death worldwide and was related to multiple adverse health outcomes including 
cancer, respiratory diseases, and CVDs.1,2 One type of air pollution, particulate matter 
(PM) was found to be responsible for 3.2 million deaths in 2010 and was reported to be the 
9th leading cause of disability adjusted life-years worldwide.3,4 PM can be of various sizes 
and arises from a variety of sources. PM is generally classified by size into 3 categories 
using the mean aerodynamic diameter of the particles. The largest particles are termed 
“coarse PM” or PM10 and consist of particles between 2.5µm and 10µm. Smaller particles 
that are <2.5µm are called “fine PM” or PM2.5. And finally, “ultrafine particles” are 
<0.1µm in size. PM10 particles are mainly composed of soil and road dust suspended by 
wind or moving vehicles, construction activity like grinding and digging, and road wear of 
brake pads on vehicles. PM2.5 is predominantly a byproduct of combustion of fossil fuels 
created by vehicles and power plants, or through the burning of coal, oil, and wood for 
industrial and residential heating. Outdoor pollution (especially PM2.5) is found inside 
buildings and therefore exposure to outdoor pollution may occur indoors. In low-income 
countries, indoor air pollution is greater than in high-income nations due to the common 
use of fossil fuels (i.e., coal, wood, biomass) for cooking and heating homes, schools, and 
the work place.1,2,5,6 
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In an effort to reduce adverse health effects related to ambient air pollution, many 
countries as well as the World Health Organization (WHO) have released exposure 
guidelines for each major air pollutant including PM. The US Environmental Protection 
Agency (EPA) sets the annual mean exposure limit in the US for PM2.5 at 12µg/m
3 while 
the WHO sets the limit at 10µg/m3.1,7 While EPA and WHO guidelines have helped to 
reduce ambient air pollution, the reality is that levels of PM2.5 regularly exceed these 
guidelines in most large cities in the US and in many places throughout the world.2,6,8 
Importantly, even the lowest levels of PM2.5 have been found to cause adverse health 
effects, suggesting that there is no safe minimum exposure level for PM2.5.
1,2,6,9 
Epidemiological studies have established a causal relationship between ambient 
PM2.5 exposure and CVD.
4-6,9 Both short and long-term exposure to PM2.5 increases the 
risk of ischemic heart disease, MI, stroke, arrhythmia, and heart failure and increases the 
risk of hospitalization and mortality due to CVD.6 Although the underlying 
pathophysiological mechanisms are still being investigated, PM2.5 is believed to promote 
CVDs, including cardiomyopathy, through two main mechanisms.5,6,9,10 The first 
mechanism is that air pollution activates the pulmonary autonomic nervous system leading 
to increased blood pressure which promotes endothelial dysfunction and hypertension, 
resulting in poor cardiac output and heart failure. (Figure 6.1) Secondly, PM2.5 also 
activates ROS, causing an inflammatory response in the lungs that leads to endothelial 
dysfunction, elevated blood pressure, hypertension and heart failure (Fig. 6.1). The most 
recent Integrated Science Assessment for Particulate Matter (ISA for PM) the U.S. 
Environmental Protection Agency11 also suggest similar mechanisms in their chapter on 
cardiovascular disease. (Figure 6.2) 
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The clear overlap in proposed mechanisms for CV dysfunction caused by air 
pollution and those proposed for prolactin suggest that PM may act as a trigger to increase 
the risk of PPCM in susceptible individuals. We hypothesize that PM could act a co-factor 
in triggering PPCM by contributing to oxidative stress (as a source of ROS) and endothelial 
dysfunction that may lead to cardiomyopathy (see Figure 6.3).12 To our knowledge, no one 
has examined whether PM is a risk factor for PPCM. Chapter Seven presents a case study 
using the cohorts described in Chapter Four to examine the ability of three commonly 
available methodologies (air monitoring, traffic density, and distance to major roadways) 
to ascertain the role of PM2.5 exposure in the development of PPCM, the challenges that 
prevented each method from being fully applied, policy-based recommendations that 
would allow studies to successfully determine whether PM2.5 exposure leads to increased 
susceptibility to developing PPCM and recommendations that could strengthen the human 
health protection required by the Clean Air Act (CAA). The specific components of Aim 
2 needed to be modified for Aim 2 because of challenges that arose in being able to 
determine PM exposure for the study. These challenges are presented as a case study in 
Chapter Seven. Because of the challenges the sub aims for Aim 2 of this research project 
were modified to: a) Identifying and comparing different methodologies for measuring air 
pollution exposure in rural areas, and b) creating a case study of these methodologies using 
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8Figure 6.1 Potential biological pathway for the role of air pollution 
exposure (including PM2.5) in the development of heart failure, 
cardiomyopathy, and peripartum cardiomyopathy.  
Exposure to air pollution can lead to systemic oxidative stress (i.e., reactive oxygen 
species) as well as an imbalance in the autonomic nervous system. These physiological 
changes affect multiple factors including endothelial function, blood pressure, cardiac 
output, and heart rate, which may result in cardiomyopathy or heart failure. Figure adapted 
from11 Cosselman, K. E., Navas-Acien, A., & Kaufman, J. D. (2015). Environmental 
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9Figure 6.2 Biological pathways for cardiovascular effects following 
short-term exposure to PM2.5. 
 
HR = heart rate; HRV = heart rate variability; PM2.5 = particulate matter with a nominal 
mean aerodynamic diameter less than or equal to 2.5 μm.  
 
Note: The boxes above represent the effects for which there is experimental or 
epidemiologic evidence related to short-term PM2.5 exposure, and the arrows indicate a 
proposed relationship between those effects. Solid arrows denote evidence of essentiality 
as provided, for example, by an inhibitor of the pathway or a genetic knockout model used 
in an experimental study involving PM2.5 exposure. Shading around multiple boxes is used 
to denote a grouping of these effects. Arrows may connect individual boxes, groupings of 
boxes, and individual boxes within groupings of boxes. Progression of effects is generally 
depicted from left to right and color coded (gray = exposure; green = initial effect; blue = 
intermediate effect; orange = effect at the population level or a key clinical effect). Here, 
population-level effects generally reflect results of epidemiologic studies. When there are 
gaps in the evidence, there are complementary gaps in the figure and the accompanying 
text below.  










10Figure 6.3 Proposed mechanism for the role of PM2.5 in PPCM. 
PM2.5 could increase susceptibility to PPCM by increasing oxidative stress leading to 
increased reactive oxygen species and / or by causing endothelial dysfunction, which are 
part of the currently accepted mechanism for the development of PPCM. Abbreviations: 
STAT3, signal transducer and activator of transcription 3; PGC-1α, proliferator-activated 
receptor-gammacoactivator-1α; sFlt1, soluble Fms-like tyrosine kinase 1; 16Kd, 16-kDa 
form of prolactin; MnSOD, manganese superoxidedimutase; CathD, cathepsin D; PRL, 
prolactin; VEGF-A/B, vascular endothelial growth factors; ROS, reactive oxygen species. 
Figure adapted from Arany, Z., & Elkayam, U. (2016). Peripartum Cardiomyopathy. 











Chapter 7: A Case Study on Strengthening the Clean 
Air Act: Peripartum Cardiomyopathy and the 




*Note: The formatting of this manuscript differs from the other three manuscripts 
presented in this dissertation because it has been formatted for submission to The 
Environmental Law Reporter (ELR). The ELR is a legal publication that addresses the legal 
and/or policy aspects of environmental issues and as such has a different formatting style 




The Clean Air Act (CAA)i is one of the fundamental laws of the United States 
protecting public health, welfare, and the environment by setting air quality standards and 
regulating air pollutant emissions from both stationary and mobile sources. One of the 
central components of the CAA is the requirement that the U.S. Environmental Protection 
Agency (EPA) must develop health based primary and secondary national ambient air 
quality standards (NAAQS) for “criteria pollutants” that include 6 common air pollutants 
or pollutant groups: sulfur dioxide, particulate matter (PM2.5 and PM10), nitrogen dioxide, 
 





carbon monoxide, ozone, and lead. The NAAQS must be set at levels that protect public 
health with an adequate margin of safety and to protect public welfare from any known or 
anticipated adverse effect.1 The CAA requires that the EPA review the scientific data for 
each of these criteria pollutants and revise the NAAQS in relation to any new data as 
necessary every 5 years. The responsibility for attaining and maintaining these standards 
is placed with the states, and each state must provide plans and updates on progress to the 
EPA.  
For particulate matter (PM) the EPA regulates and has set standards for both coarse 
particulate matter between 2.5 and 10 micrometers in diameter (PM10) and fine particulate 
matter with a diameter less than 2.5 micrometers (PM2.5). For PM10, which generally 
includes particles created by traffic-related road dust, agricultural operations, construction, 
industrial processes, and biomass burning, the current primary (health-based) 24-hour 
standard is 150 µg/m3.1 PM2.5, on the other hand, can either be primary (emitted directly 
from sources including vehicles, smokestacks, and fires) or it can be secondary (formed 
when other gaseous emissions from vehicles, power plants, industry, and others react in 
the atmosphere). In urban areas the PM2.5 comes predominantly from primary sources while 
in many rural areas secondary sources of PM2.5 account for the majority of PM2.5.
2 For 
PM2.5 there are two primary standards including the 24-hour standard at 35 µg/m
3 and the 
annual standard of 12 µg/m3.1 Secondary standards (welfare-based) are set at the same 
limits as the primary standards, except for the PM2.5 annual standard which is set at 15 
µg/m3.1  
Across the spectrum of PM size, the scientific evidence for a relationship between 





causality determinations for multiple adverse health effects including respiratory, 
cardiovascular, metabolic, nervous system, reproductive and developmental, cancer, as 
well as increased mortality - all linked by research to PM2.5. The most recent Integrated 
Science Assessment for Particulate Matter (ISA for PM), completed in 2019, concluded 
that there is a causal relationship determination between both short and long-term PM2.5 
exposure and cardiovascular effects and mortality.2 These finding were based on 
epidemiological studies that consistently showed positive associations between exposure 
and increased admissions to emergency departments and hospitalizations for ischemic 
heart disease, heart failure, and cardiovascular mortality as well as results from controlled 
human exposure studies and animal toxicological studies which provided biological 
plausibility including endothelial dysfunction, increases in blood pressure, and conduction 
abnormalities. 2 
The EPA does not include information on many specific cardiac conditions which 
could have a link to PM2.5 exposure including the many types of cardiomyopathy. Figure 
7.1a depicts potential biological pathways through which PM2.5 exposure could lead to 
heart failure and cardiomyopathy. PM2.5 exposure can lead to systemic oxidative stress as 
well as an imbalance in the autonomic nervous system. These physiological changes affect 
multiple factors including endothelial function, blood pressure, cardiac output, and heart 
rate, which can contribute to the development of cardiomyopathy and other types of heart 
failure.1,3-5 One type of cardiomyopathy, peripartum cardiomyopathy (PPCM), can have a 
profound effect on women of child-bearing age. PPCM is a form of heart failure with no 
known cause that occurs towards the end of pregnancy or in the months following 





recovery to persistent dysfunction, transplant, and death.6 The cause of PPCM is not fully 
understood but is most likely multi-factorial with research suggesting that hormones of late 
pregnancy cause a vasculotoxic environment that in susceptible women leads to the 
development of PPCM. Hypertensive disease of pregnancy (HDP), one of the biggest 
known risk factors for PPCM, has been found to be related to air pollution exposure 
including PM2.5.
7-12 However, as far as we know no one has studied the possibility of a 
relationship between PM2.5 exposure and the development of PPCM.  
We postulate that PM2.5 exposure could increase susceptibility to PPCM in some 
women. Figure 7.1b depicts a model of how PM2.5 exposure could increase susceptibility 
to PPCM by promoting oxidative stress and endothelial dysfunction. In this case study, we 
examine the ability of three commonly available methodologies (air monitoring, traffic 
density, and distance to major roadways) to ascertain the role of PM2.5 exposure on a 
population level cohort of patients with PPCM from the federally funded Rochester 
Epidemiology Project (REP).13-17 We further highlight issues preventing each method from 
being fully applied to understand the relationship of PM2.5 exposure the development of 
PPCM. We then make policy-based recommendations that would allow studies to 
successfully determine whether PM2.5 exposure leads to increased susceptibility to 
developing PPCM as well as related recommendations, such as including additional health 
endpoints like hypertensive disease of pregnancy, cardiomyopathy, and PPCM, that would 








Materials and Methods 
Human Subjects 
 The project was approved by both the Mayo Clinic and Olmsted Medical Center 
Institutional Review Boards and conformed to the principles set forth in the Declaration of 
Helsinki 1975, as revised in 2013. All patients involved in the study provided written 
informed consent to allow the use of their medical records for research purposes as part of 
the Rochester Epidemiology Project. Patients who had not previously consented to 
participate in research through the REP were excluded from the study. 
Study Population 
The study population has been described in detail previously.18 Briefly, this study 
utilized data from the Rochester Epidemiology Project13-17,19 identifying women diagnosed 
with PPCM (cases) and controls matched on a 2:1 basis by age, race and number of babies 
born during the index pregnancy (pregnancy related to initial PPCM diagnosis) for cases 
and the matched pregnancy in each control. We geocoded residential addresses, at time of 
diagnosis for cases and time of matched delivery for controls.ii We could not geocode the 











In this case study we examined three methods of estimating exposure to PM2.5 
including EPA air monitoring data as a direct measure of PM2.5 as well as traffic density 
and distance to major roadway as surrogate measures for traffic related PM2.5 exposure.  
Results 
Part I: Air Monitoring 
Data for location of air monitors was obtained from the Air Quality System (AQS) 
Monitoring Network, EPA OAR OAQPS. iii There are 129 AQS PM2.5 monitors located at 
87 unique sites in or around the 27-county study area that are or were active during the 
study time frame of 1970 to 2014. (Figure 7.2a) The residential addresses of the women in 
this study are shown in Figure 7.2 as dark stars for cases and light stars for controls. 
Initially, ArcGIS Near tool was used to identify the closest monitor to each geocoded 
residential address. Analysis of the near data showed that all subjects with mappable 
residential addresses were closest to one of 11 monitors at 9 unique locations within the 
region of the REP (which incorporates an area of southeastern Minnesota and southwestern 
Wisconsin) (Table 7.1). However, as seen in Figure 7.2 and based on AQS data the dates 
each monitor was active varies greatly and the monitor location closest to each residential 
address might not have been collecting data at the time of interest (i.e., date of PPCM 
diagnosis for cases or delivery date of index pregnancy for controls). 
 
iiiInformation at: https://edg.epa.gov/metadata/catalog/search/resource/details.page?uuid=%7B7BF467D5-A5D7-427B-
B896-5674A15B55B4%7D Data retrieved from: https://www.epa.gov/outdoor-air-quality-data/interactive-map-air-





The next step was to match each case and control to the nearest monitor that was 
active at the time of interest for each woman in the study. The AcrGIS Near Table Tool 
was used to identify the 10 closest monitors in order of increasing distance (i.e., straight 
line distance) to each geocoded residential address. Microsoft Excel and StataIC 15. 21 
were used to identify the closest monitor that was active as the time of interest (diagnosis 
for cases and delivery of index pregnancy for controls). This resulted in matches for 120 
women’s addresses to 17 monitors in 15 unique locations (Table 7.1). The remaining 24 
women could not be matched to active monitors as the times of interest for each of these 
women occurred between 1971 to 1997, before the first monitors in this area were active 
on 4/4/1997 (Figure 7.3 and Table 7.1). The locations of the 19 monitors used for the two 
types of matching in this study are shown in Figure 7.2b. The parameters for each of these 
monitors are listed in Table 7.1, and the active date range for each of the monitors is 
depicted visually in Figure 7.3. Continuous data are presented as median (interquartile 
range (IQR)). To compare cases and controls the Mann-Whitney U Test for non-normally 
distributed data was applied. A p value <0.05 was considered statistically significant. Data 
were analyzed using StataIC 15. 21. For the 120 women with date matched monitors, the 
distance from residential address to monitor ranged from 0.3 – 405.1 km with a median 
distance of 10.0 km (IQR 4.5 – 52.5 km). Cases median distance to date matched monitors 
was significantly further than the median distance for controls (42.9 vs 8.6 km, p = 0.01). 
(Table 7.2) However, the range of distances for controls was larger (0.85 – 103.0 km for 
cases vs 0.3-405.1 km for controls) with controls living up to 405.1 km from the nearest 
active monitor due to the locations of the only active monitors in the early years of 





Studies on the relationship between exposure to PM2.5 and hypertensive disorders 
of pregnancy use varying distances from EPA monitors from subject’s residential address 
varying from 5 km to 20 km with one study combining data from multiple monitors within 
50 km.20-24 Studies on the relationship between PM2.5 and heart failure or heart disease use 
similar distance ranges, but most are conducted in larger metropolitan areas and average 
multiple monitors togetheriv, methodology that cannot be applied in a rural area. In this 
rural study area, the median distance to date-matched monitors was 10km, but distances 
were as large as 103 km for cases and 405 km for controls (Table 7.2). In addition, for 
many data points with large distances the location of the monitor was not environmentally 
similar the location of the subject’s residence. For example, some rural residential 
addresses matched by date to monitors in urban Milwaukee, WI. The use of these data 
would likely lead to misclassification bias and possibly shift the study results towards the 
null.  
In addition, due to the matching design of the cohort used for this study, matched pairs 
must be dropped from the analysis if they are missing exposure data. For this study19 
case/control sets (57 women total) would need to be dropped from the analysis based on 
dates of interest for either the case or controls occurring before monitoring began. Due to 
the high number of cases and controls with no monitoring data available (40% of the 
cohort), analysis of PM2.5 levels from monitoring data could not be completed for this study 
population.  
 
iviv See studies included in: U.S. EPA. Integrated Science Assessment (ISA) for Particulate Matter (Final Report, Dec 





Part II: Surrogate options 
Surrogate option 1 - Distance to Major Roadway  
 Distance to major roadway is a commonly used surrogate for measuring air 
pollution exposure related to traffic. Euclidean straight-line distance to major roadway at 
each residential address was calculated as a proxy for traffic exposure using the NEAR 
function in ArcGIS. Because the study spanned a wide range of years obtaining data for 
each time of interest was not possible. Data for earlier years was only available as PDFs 
from each states Department of Transportation, and not as electronic files that could be 
used in ArcGIS.v Due to this limitation we chose to use road segments from the 2019 
TIGER/line Roads National Geodatabase with exposure categories based on MAF/TIGER 
Feature Class Codes (MTFCC) classifications assigned by the Census Bureau.vi,vii (Figure 
7.4). Major roadways were initially defined as those designated as MTFCC S1100 primary 
roadways (limited-access highways that connect to other roads only at interchanges 
including interstate highways and other highways with limited access). Exposure zones for 
traffic-related air pollution range from 50 to 1500 meters (m) from highways and major 
roadways with the most highly affected area occurring between 300 – 500 meters.viii We 
examined residential distance to S1100 roadways using the following cutoff points: 250 m, 
500m, and 1,000m.ix These buffer sizes were selected based the Health Effects Institute 
 
v In addition, due to COVID shutdowns and work from home orders the PDF files were not accessible during the time 
when this study was conducted. 
vi2019 TIGER/Line Shapefiles (machine readable data files) / prepared by the U.S. Census Bureau, 2019 - files and 
information (as well as those from other years) are available at: https://www.census.gov/geographies/mapping-
files/time-series/geo/tiger-line-file.2019.html 
vii 2019 TIGER/Line Shapefiles Technical Documentation / prepared by the U.S. Census Bureau, 2019 – see appendix 
E for MTFCC code definitions available at: https://www.census.gov/programs-surveys/geography/technical-
documentation/complete-technical-documentation/tiger-geo-line.2019.html 
viii Exposure zones vary by pollutant and meteorological conditions. See HEI Panel on the Health Effects of Traffic 
Related Pollution. 2010. Traffic-Related Air Pollution: A Critical Reivew of the Literature on Emissions, Exposures, 
and Health Effects. HEI Special Report 17. Available at www.healtheffects.org 





(HEI) report,25 distance used in previously published studies of hypertensive disease of 
pregnancy26-28 or heart disease,29 and the information that PM2.5 concentration appears to 
reach background levels around 900 meters from roadways.30 To compare cases and 
controls, Chi-squared (X2) or Fisher’s exact test were used to evaluate categorical 
variables. A p value <0.05 was considered statistically significant. Categorical data are 
presented as frequency (n) and percent (%). Data were analyzed using StataIC 15.31  
The initial analysis, using the standard definition of major roadway as those roads 
classified as MTFCC S1100, did not show any significant difference in distance from 
residential address to major roadway between cases and controls and the diagnosis of 
PPCM for any of the chosen buffer sizes (Table 7.3). However, it is difficult to draw 
conclusions based on these results as the number of study subjects that lived within any 
buffered distance of MTFCC S1100 roadways is very small due to the rural location of the 
study which contains very few roadways with this classification (Figure 7.4 and Table 7.3). 
Considering the predominantly rural geography of the study area we also conducted a 
separate analysis where major roadways were defined as those designated as MTFCC 
S1100 or MTFCC S1200 secondary roadways (main arteries that are not limited access, 
generally U.S. highway, state highway, or county highway systems). Figure 7.4 shows the 
locations of MTFCC S1100 and S1200 designated roads in and near the study area. Using 
this broader definition of major roadways also did not find any association between 
distance to major roadway and diagnosis of PPCM (Table 7.3). The EPA defines “near a 
major roadway” as within 500-600 feet (about 152-183 meters).x Similarly, previous 
 
xSee: US EPA Office of Transportation and Air Quality. Near Roadway Air Pollution and Health: Frequently Asked 





studies which have found positive associations between distance to major roadway and 
various hypertensive disease of pregnancy or cardiovascular outcomes using distance 
between 50 – 200 meters.26-28,32-39 In this study, less than 5% of cases and controls in this 
study lived within 200 meters of a major roadway. (Table 7.3). In addition, in rural areas 
traffic is often not the main source of particulate matter pollution.xi It is likely that this 
method may be a better surrogate in urban areas where a higher concentration of residential 
addressed are within 200 meters of a major roadways and traffic emissions are a bigger 
source of particulate matter pollution. 
Surrogate Option 2 - Traffic Density / Annual Average Daily Traffic (AADT) 
 Annual Average Daily Traffic (AADT) is an estimate of the total number of 
vehicles using a section of roadway (in both directions) on any given day of the year.xii 
AADT is a commonly used surrogate for traffic-related air pollution exposure. 26,27,33,40-47 
A review of air pollution measurement methods suggests that traffic density measured at a 
specific location could possibly be a more accurate measure than centrally monitored air 
pollution, especially when the central monitors are located further from the address of 
interest,29 a concern in this predominantly rural study area, as shown in the distance to 
monitor results in part I of this case study. As with distance to major roadway, because the 
study spanned a wide range of years obtaining data for each time of interest was not 
possible. Data for earlier years would only be availed as PDFs and not as electronic files 
that could be used in ArcGIS. In addition, data specific to time of pregnancy/diagnoses was 
 
xi In rural areas, such as in this study, sources of air pollution differ from urban areas with traffic generally playing less 
of a role and additional sources including agriculture and residential wood burning playing larger roles. For example, in 
Minnesota – the largest source of directly emitted from combustion sources comes from residential wood burning.40  
xii Further information on AADT and how it’s measured and calculated can be found at the Minnesota Department of 





not available as traffic counts are conducted in cycles where either 1/3 of roadway sections 
are counted every 3 years or where 1/6 of roadway sections are counted every 6 
years.xiii.Due to this limitation we chose to use AADT data from the 2018 Highway 
Performance Monitoring System Public Release data from the U.S., the most recent year 
of data available, from the Department of Transportation Federal Highway Administrations 
Office of Highway Policy Information.xiv  
 In this study we examined AADT both as a continuous variable and as a categorical 
variable using the volume group /AADT ranges defined by The U.S. Department of 
Transportation Federal Highway Administrations Office of Highway Policy Informationxv 
which are shown in Table 7.4. We also examined these data using the U.S. Department of 
Transportation designated cut point of 125,000 vehicles per day to define a major 
roadway.xvi To compare cases and controls Wilcoxon rank sum test was used for the 
analysis where AADT was treated as a continuous variable and Fisher’s exact test was used 
for the analysis where AADT was treated as a categorical variable. A p value <0.05 was 
considered statistically significant. Categorical data are presented as frequency (n) and 
percent (%) and numeric data as median (interquartile range) for non-normally distributed 
data, unless otherwise specified. Data were analyzed using StataIC 15.31 
 
xiii In addition, also only some are Continuous Counts Stations (CCS) with 24/7 traffic counting 365 days of the year at 
a limited number of locations. The rest are called short term counts – 48-hour counts (2 full 24-hour days) are required 
for HPMS data and then have calculations are done using the CCS data to covert the counts to AADT. See: U.S. 
Department of Transportation Federal Highway Administration Office of Highway Policy Highway Performance 
Monitoring System Field Manual (Dec 2016) sections 4-51 to 4-52 and 5-3 to 5-8. Available at: 
https://www.fhwa.dot.gov/policyinformation/hpms/fieldmanual/hpms_field_manual_dec2016.pdf 
xiv Dataset is HPMS ARNOLD 2018 HPMS Public Release from the U.S. Department of Transportation Federal 
Highway Administration Office of Highway Policy. Data available at 
https://www.fhwa.dot.gov/policyinformation/hpms/shapefiles.cfm 
xv See U.S. Department of Transportation Federal Highway Administration Office of Highway Policy Highway 
Performance Monitoring System Field Manual (Dec 2016) available at: 
https://www.fhwa.dot.gov/policyinformation/hpms/fieldmanual/hpms_field_manual_dec2016.pdf 





 ArcGIS Pro was used to create multiple ring buffers around each residential address 
to identify the roadway section with the highest AADT within each buffer distance. The 
same distances were used and chosen for the same reasons as those used for distance from 
major roadway in part II of this case study which included buffers of 100, 250, 500, and 
1,000 meters. Figure 7.5 shows the traffic density data used for this study with Figure 7.5a 
depicting traffic density data in and around the study area and Figure 7.5b illustrating that 
that there are no road segments with AADT volume of 125,000 cars or higher within the study area. 
We first examined traffic density as a continuous variable with results shown in Table 7.5. 
The median AADT appeared to increase with increasing buffer size in both the cases and 
controls (Table 7.5). Contrary to our hypothesis, our results suggest that controls live near 
roads with higher traffic density then cases, although this difference was only significant 
using a 1000m buffer (Table 7.5). There are many limitations to these data. As mentioned 
in the methods, we could not obtain data specific to the time of interest for each case or 
control. In addition, states are not required to report section level AADT for all roadsxvii 
and, in this rural area, when using smaller buffer sizes, we found that many study 
participants had no road segments with recorded AADT data with the selected buffers 
making it hard to draw any conclusion from the 100m and 250m buffer data (Table 7.5). 
At 500m and 1000m most participants had data available for analysis, but the same issues 
related timing of data used and frequency of actual collection (as noted in methods) applies 
to these results as well.  
 
xvii States are not required to report section level AADT for non-Federal-Aid, non-NHS (National Highway Safety 
System) roadways so AADT for every road is not available (generally this includes only smaller roads – minor 
collectors and local roads) p 1-3 table 1.1 of the U.S. Deptment of Transportation Federal Highway Administration 






 Results treating AADT as a categorical variable are shown in Table 7.6. There were 
no significant relationships between highest AADT level and diagnosis of PPCM at any 
buffer distance examined. However, most of the higher AADT volume groups, which are 
the ones usually considered as significant exposures, have no or very low values as this 
rural study area does not have roads with these higher levels of traffic (Figure 7.5, Table 
7.6). Due to the lack of participants living near high traffic density roads it is hard to draw 
any conclusions from these findings. 
Discussion and Policy Recommendations 
The Rochester Epidemiology Project is a collaboration of health care providers in 
southeast Minnesota and Southwest Wisconsin sharing medical information with 
researchers by linking medical records data together allowing for population-based 
research can be conducted.13-17,19 The design of the Rochester Epidemiology Project (REP) 
provides a rare opportunity to study relationships between environmental exposures, such 
as air pollution, and disease outcomes at a population level with increased generalizability 
compared to single center or multi-center cohort studies. However, as this case study 
demonstrates, this federally funded, potentially high impact resource, cannot currently be 
leveraged to study the effect of air pollution on health outcomes, such as PPCM, primarily 
because of the lack of pollution monitors in this rural region of the U.S. Below we will 
discuss the issues identified through this case study and make policy recommendations that 
could address these issues to improve the ability of future research to undertake exposure 
studies using the REP. Addressing these limitations would also ultimately improve the 





 Data limitations prevented the full application and analysis of all three of the 
currently available methods to assess PM2.5 exposure examined in this case study. Of the 
three approaches air pollution monitors are the preferred method to determine this 
relationship as the monitors measure ambient levels of pollution accounting for all sources, 
which is particularly important in rural areas where traffic may not be the primary source 
of PM2.5. However, monitoring networks in the U.S. generally focus on areas with high 
population density and have minimal resources (i.e., few monitors) in rural areas, which 
makes it difficult to use monitoring data to measures health effects of pollution exposure 
in rural areas, such as in this case study. Because direct exposure could not be measured 
using air monitoring data for this study, we examined two commonly used surrogate 
measures; distance to major roadway and traffic density as other means to measure the 
effect of PM2.5 exposure on the development of PPCM in this population. The biggest 
limitation to both of these methods is that they are surrogate measures for traffic-related 
pollution and do not take into account other sources of PM2.5 in the environment, which in 
rural areas (such as this study location) may contribute more to PM2.5 than traffic such as 
agricultural sources and residential woodburning. xviii However, it was important to examine 
these surrogates, despite this their limitations, to determine if they could measure PM2.5 
exposure and its potential effect on the development of PPCM. However, neither of these 
surrogate measures led to useable results. We found that the cases and controls in this case 
study lived in rural areas with smaller roads, lower traffic density, and this likely related to 
lower traffic emissions. Thus, traffic-related pollution is not likely to be a major source of 
 
xviii In rural areas, such as the area of this case study, sources of air pollution differ from urban areas with traffic 
generally playing less of a role and additional sources including agriculture and residential wood burning playing larger 
roles. For example, in Minnesota – the largest source of directly emitted from combustion sources comes from 
residential wood burning. See Smith, AJ. et al., The air we breathe the state of Minnesota’s air quality 2019. Minnesota 





PM2.5 exposure for this study population. In rural areas, such as the REP region used in this 
study, monitoring data would provide the most accurate measure as it would account for 
all sources of PM2.5 levels including agriculture and residential woodburning, key 
contributors in rural areas. However, as this case study shows, current monitoring is not 
sufficient to assess health effects due to too few monitors for PM2.5 in this rural area. Below 
we present four policy recommendations to address this gap that could improve 
understanding of the role of PM2.5 on adverse health outcomes, such as PPCM, as examined 
in this study. 
1. Design monitoring with research in mind 
 The CAA requires the EPA to set NAAQS to protect human health with an adequate 
margin of safety based on 5-year reviews of available scientific data. While the NAAQS 
are set based on scientific evidence reviewed in the required ISAs, the required monitoring 
is specifically to assess if states are meeting the NAAQS required levels. Monitoring for 
air pollutants, including PM2.5, are set in the CAA.xix These requirements are based on 
population counts and on the 3-year design value for each area, whether it is ≤ or ≥ and of 
the PM2.5 NAAQS values. With higher population and areas with 3-year design value 
≥85% of any PM2.5 NAAQS requiring more monitors. Providing high quality data to 
improve research related to the health effects of exposure is not the aim of the CAA, even 
though the NAAQS are set based on the results from scientific research. Monitoring should 
be designed and implemented with the goal of improving and increasing data available for 
research, not just to assess attainment. This would require a more complete network of 
monitoring throughout the US, including rural areas which have different sources of air 
 





pollution, such as the area in this case study (the area of the REP) where monitor data could 
not be applied due to lack of monitoring in rural areas. The monitors currently used can 
effectively assess air quality, but are too distant to monitor all neighborhoods and it is 
possible for specific locations to not meet the NAAQS set levels even though monitoring 
(which may only occur at a regional level) shows that the levels of air pollution are safe. 
In addition, often, monitors are installed in new areas to establish if those areas are meet 
the NAAQS standards and if these areas meet the standards, then those monitors are often 
discontinued so that the resources can be focused on another area. To further research, 
monitors need to be continually active throughout the network. We saw in this case study 
that the monitors in the area were active at a range of different times (Figure 7.1 and Table 
7.3) which impedes research over larger areas as well as in more rural areas. Both of these 
changes would increase the availability of high-quality data allowing for better studies on 
the health effects of PM2.5 (and other air pollutants) which would improve the science used 
to set the NAAQS thereby increasing the protection of human health as required by the 
CAA. 
2. Increased focus on non-urban areas 
 Monitoring and remediation generally focus on urban areas that have the highest 
population density, highest density of roads, highest levels of traffic, largest number of 
industrial air pollution sources, and highest levels of air pollution. While more people live 
in urban areas, the population in rural areas have demographic and economic differences 
from urban areas that may increase their susceptibility to the adverse health effects of air 
pollution. For example, using this study’s geographical area, while only about 26% of MN 





levels of education, higher rates of unemployment, lower median earnings, and higher rates 
of poverty.48,xx Older populations are already included in the EPA’s “At-Risk” 
classification due to a known increase risk to adverse health outcomes from exposure to air 
pollution including PM2.5. However, both within Minnesota and the United States as a 
whole, people with lower incomes or social economic disadvantages are more likely to live 
in areas with air pollution levels that are above the NAAQS guidelines.49,xxi In addition, 
non-white populations also face an increased risk of adverse effects from air pollution 
along with higher rates of factors such as low socioeconomic status that also increase 
susceptibility to adverse health effects from air pollution exposure.xxii In the population 
used for this case study, rates of PPCM were increased in non-white women and in women 
with lower social economic status.18,xxiii These are two groups with a known increased risk 
for adverse health effects from air pollution exposure; however, as shown in this case study, 
due to the lack of focus on monitoring in rural areas the effect of air pollution on these 
populations cannot be studied effectively.  
 
3. Add pregnant women to the list of “at-risk” populations 
 NAAQS are intended to “Accurately reflect the latest scientific knowledge useful 
in indicating the kind and extent of all identifiable effects on public health or welfare which 
may be expected from the presence of [a] pollutant in the ambient air.” xxiv However, the 
 
xxSee: Rural Health Information Hub. Minnesota State Guide. https://www.ruralhealthinfo.org/states/minnesota. Last 
updated 1/22/2019. Last accessed 2/20/2021 
xxi See: Minnesota Pollution Control Agency. Disproportionate impacts in Minnesota. Available at: 
https://www.pca.state.mn.us/air/disproportionate-impacts-minnesota. Last accessed 2/20/2021. 
xxii For more information see the website: Dispariaties in the Impact of Air Polltion from the American Lung 
Association available at: https://www.lung.org/clean-air/outdoors/who-is-at-risk/disparities  
xxiii Using medical assistance as a surrogate for social economic status. See ref 18. 





EPA does not include pregnant women in the “At-Risk Populations” under the CAA.50, A 
recent study presents a clear case for including pregnant women in this classification based 
on associations of hypertensive diseases of pregnancy(HDP), one of the biggest risk factors 
for PPCM, and air pollution.12 HDP is a leading cause of maternal morbidity and mortality 
during the perinatal period leading to disease and death in young women. In addition, the 
development of HDP is associated with exposure to air pollution.7-12 In the 2019 ISA for 
PM the EPA acknowledged for the first time that PM2.5 exposure during the perinatal 
period may affect maternal health during pregnancy, including contributing to the 
development of HDP.2,xxv Exposure to air pollution, including PM2.5, is associated with 
adverse birth outcomes, including low birth weight, preterm birth, and still birth.51 More 
research is needed into emerging adverse health outcomes, including HDP and PPCM, to 
further support the importance including pregnant women as a susceptible group. The 
addition of maternal health endpoints in the ISA for PM (and other air pollutants) could 
help guide the CAA reviews and ultimately strengthen the protection from NAAQS 
standards for this very large group of particularly vulnerable young women. 
 
4. Increased funding 
 Significant changes to the current monitoring system and resulting data cannot be 
made without sufficient funding in place to continually support them. Funding needs to be 
secured for increased monitoring, handling and analyzing the data, grants to support the 
 
xxv On page 9-11 and in figure 9-2 of the 2019 ISA for PM the EPA notes that PM2.5 exposure may contribute to 
adverse events during pregnancy like HDP but do not consider these as specific health endpoints – only as steps within 
the presented plausible biological pathways leading to the adverse birth outcome endpoints. U.S. EPA. Integrated 
Science Assessment (ISA) for Particulate Matter (Final Report, Dec 2019). U.S. Environmental Protection Agency, 





state and local governments designing and implementing the monitoring, and to fund 
research with the resulting improved data. One of the main funding sources for monitoring 
comes from federal grants and matched state funds. However, in recent years congress has 
repeatedly tried to reduce the funding designated for state and local air quality grants.xxvi 
Without sufficient funding the available monitoring data will continue to be insufficient 
for high quality research into the health effect of air pollution exposure. In the most recent 
ISA for PM the EPA notes that research into many health effects is limited and that more 
data are needed. Without improved data the EPA cannot complete its duty of “…protecting 
human health with an adequate margin of safety…” one of the key requirements of the 
CAA. New funding will need to be designated, above what is currently in place, for real, 
significant changes to be made. 
Conclusions 
 In this case study we attempted to determine whether exposure to PM2.5 contributes 
to the development on PPCM in a population level cohort using the Rochester 
Epidemiology Project employing three commonly used methods to measure pollution 
exposure: monitoring, distance to major roadway, and traffic density. However, we found 
that in the rural area where the study and control cohort lived the current monitoring 
network was not sufficient to measure the effect of PM2.5 exposure on adverse health 
outcomes for PPCM. Additionally, surrogate methods for exposure to PM2.5 based on 
traffic-based measures did not find a relationship between PM2.5 and increase diagnosis of 
PPCM. This may be due however to these measures not being suitable in rural areas due to 
 
xxviWhile they have not been successful in the last few years, for fiscal years 2019, 2020, and 20121 they tried to 
decrease the budget for air grants by about $76 million (about 33%) each year. More detail can be found on the 






the predominant sources of or PM2.5 coming from non-traffic related sources such as 
agriculture. The CAA requires the EPA to establish science-based exposure standards for 
PM2.5 and other air pollutants (NAAQS standards) to protect public health with an adequate 
margin of safety. The most recent ISA for PM concludes that there is a casual relationship 
between PM2.5 and specific cardiovascular health effects based on the currently available 
scientific data. However, data are lacking for the relationship between PM2.5 and PPCM. 
This omission leaves women of reproductive age, a large population that is potentially 
more susceptible particularly during pregnancy, out of the considerations used in setting 
the NAAQS required by the CAA. A monitoring system driven by scientific needs, 
increased focus on rural areas, an inclusion of pregnant women in the “at-risk” designation, 
and increased funding to support each of these items are needed to strengthen human health 
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✓ 55-079-0010 Milwaukee WI 4/4/1997 10/2/1998 4 km to 50 km 24 hours Every 6th day 
 ✓ 55-055-0008 Waterloo WI 1/1/1999 3/4/2003 100 m to 500 m 24 hours Every 3rd day 
✓ ✓ 27-037-6018 Hastings MN 4/24/1999 12/29/2003 4 km to 50 km 24 hours Every 3rd day 
 ✓ 19-033-0019 Mason City IA 7/1/1999 8/4/2004 missing 24 hours Every 3rd day 
✓ ✓ 27-047-5401 Albert Lea MN 10/1/1999 6/30/2001 4 km to 50 km 24 hours Every 6th day 
✓ ✓ 19-063-0003 Estherville IA 1/1/2000 12/29/2004 missing 24 hours Every 3rd day 
 ✓ 27-139-0505 Shakopee MN 1/1/2000 7/22/2018 500 m to 4 km 24 hours Every 3rd day 
✓ ✓ 27-109-5008 Rochester 1 MN 1/7/2000 6/29/2019 500 m to 4 km 24 hours Every 3rd day 
 ✓ 27-037-0470 Apple Valley MN 10/3/2000 6/29/2019 500 m to 4 km 24 hours Every 3rd day 
✓  27-103-5109 N. Mankato MN 10/3/2000 9/10/2001 missing 24 hours Every 6th day 
 ✓ 19-147-1002 Emmetsburg IA 1/1/2005 6/29/2020 50 to hundreds km 24 hours Every 3rd day 
✓ ✓ 55-063-0012 La Crosse 1 WI 12/7/2005 3/27/2018 50 to hundreds km 24 hours Every 6th day 
 ✓ 27-163-0446 Bayport MN 5/17/2007 12/27/2009 100 m to 500 m 24 hours Every 6th day 
✓ ✓ 55-035-0100 Eau Claire 1 WI 3/17/2009 3/28/2011 4 km to 50 km 24 hours Every 6th day 
✓ ✓ 55-063-0012 La Crosse 2 WI 7/14/2010 3/31/2020 50 to hundreds km 1 hour Daily 
✓ ✓ 27-109-5008 Rochester 2 MN 1/1/2011 3/31/2020 500 m to 4 km 1 hour Daily 
 ✓ 55-035-0014 Eau Claire 2 WI 4/1/2011 3/27/2018 50 to hundreds km 24 hours Every 6th day 
✓  27-169-5220 Winona MN 1/1/2014 12/31/2014 500 m to 4 km 1 hour Daily 
 





18Table 7.2. Distance to monitor matched using date of interest 
 All (n = 120) Cases (n = 43) Controls (n = 77) p value 
Median (IQR) 10.0 (4.5 – 52.5) 42.9 (5.9 – 63.7) 8.6 (4.1 – 29.0) 0.01 
Range 0.3 – 405.1 0.85 – 103.0  0.3 – 405.1  







19Table 7.3 PM2.5 exposure from traffic using distance to major roadway as a 
proxy for traffic exposure.  
Categorya Distance (m) Cases n (%) Controls n (%) p value 
S1100 Primary 
Roadsb,c 
< 250 2 (4%) 3 (3%) 0.66 
 < 500 3 (7%) 12 (13%) 0.39 
 < 1000 7 (15%) 23 (24%) 0.28 
     
S1100 Primary & 
S1200 Secondary 
Roadsb,c,d 
    
 < 250 11 (24%) 17 (18%) 0.40 
 < 500 16 (35%) 40 (42%) 0.40 
 < 1000 32 (70%) 70 (75%) 0.61 
a Exposure categories are based on MTFCC classifications and data is from the 2019 
TIGER/line Roads National Geodatabase. Source for exposure categories: 2019 
TIGER/Line Shapefiles Technical Documentation prepared by the U.S. Census Bureau, 
2019 – see appendix E for MTFCC code definitions available at: 
https://www.census.gov/programs-surveys/geography/technical-documentation/complete-
technical-documentation/tiger-geo-line.2019.html  
b2 cases and 1 control are not included because addresses could not be mapped. 
cS1100 Primary roads include interstate highways and all other highways with limited 
access (connecting to other roads only at interchanges and not at-grade intersections). 
dS1200 Secondary Roads are main arterials that are not limited access (usually connect to 
many other roads with at-grade intersections) including U.S. highways, state highways, 
county highways. 
Abbreviations: MAF/TIGER Feature Class Codes, MTFCCC; PM2.5, fine particulate 






20Table 7.4. AADT Volume Groupsa 
Group AADT Volume 
1 Under 500 
2 500 - 1,999 
3 2,000 - 4,999 
4 5,000 - 9,999 
5 10,000 - 19,999 
6 20,000 - 34,999 
7 35,000 - 54,999 
8 55,000 - 84,999 
9 85,000 - 124,999 
10 125,000 - 174,999 
11 175,000 - 249,999 
12 250,000 and more 
aSource: U.S. Department of Transportation Federal Highway Administration Office of 
Highway Policy Highway Performance Monitoring System Field Manual (Dec 2016) 











21Table 7.5 Effect of traffic density by buffer size, treating AADT as a 
continuous variable 
Abbreviations: AADT – average daily traffic density 
 
 
Buffer size (m) Total n Observations Missing Median IQR p value 
100 144 47 97 8,031 2,471 – 11,896 0.24 
250 144 98 46 8,348 4,200 – 12,921 0.08 
500 144 127 17 9,700 4,700 – 20,233 0.38 






22Table 7.6 Effect of traffic density by buffer size, treating AADT as a categorical variable 
Group AADT Volume 

















1 Under 500 0 (0) 1 (1.0) 0 (0) 1 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 
2 500 - 1,999 3 (6.3) 5 5.2) 3 (6.3) 6 (6.3) 4 (8.3) 6 (6.3) 3 (6.3) 3 (3.1) 
3 2,000 - 4,999 4 (8.3) 3 (3.1) 12 (25.0) 7 (7.3) 7 (14.6) 19 (19.8) 5 (10.4) 10 (10.4) 
4 5,000 - 9,999 3 (6.3) 12 (12.5) 9 (18.8) 24 (25.0) 10 (20.8) 18 (18.8) 8 (16.7) 11 (11.5) 
5 10,000 - 19,999 3 (6.3) 8 (8.3) 7 (14.6) 14 (14.6) 11 (22.9) 19 (19.8) 12 (25.0) 24 (25.0) 
6 20,000 - 34,999 0 (0) 5 (5.2) 1 (2.1) 8 (8.3) 4 (8.3) 13 (13.5) 8 (16.7) 22 (22.9) 
7 35,000 - 54,999 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0) 1 (1.0) 2 (4.2) 2 (2.1) 
8 55,000 - 84,999 0 (0) 0 (0) 1 (2.1) 3 (3.1) 1 (1.0) 10 (10.4) 2 (4.2) 14 (15.6) 
9 85,000 - 124,999 0 (0) 0 (0) 1 (2.1) 0 (0) 2 (4.2) 2 (2.1) 2 (4.2) 7 (7.3) 
10 125,000 - 174,999 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
11 175,000 - 249,999 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
12 250,000 and more 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
n/a missing 35 (72.9) 62 (64.6) 14 (29.1) 32 (33.3) 9 (18.8) 8 (8.3) 6 (12.5) 3 (3.1) 
 p value  p = 0.33 p = 0.09 p = 0.60 p = 0.50 









11Figure 7.1 Potential Biological Pathways for Heart Failure, 
Cardiomyopathy, and Peripartum Cardiomyopathy post exposure to air 


















12Figure 7.1a Mechanism for the role of air pollution exposure in the 
development of cardiomyopathy and heart failure. 
Exposure to air pollution can lead to systemic oxidative stress (i.e., reactive oxygen 
species) as well as an imbalance in the autonomic nervous system. These physiological 
changes affect multiple factors including endothelial function, blood pressure, cardiac 
output, and heart rate, which may result in cardiomyopathy or heart failure. 
Abbreviations: BP, blood pressure; PM2.5, fine particulate matter with diameter less than 
2.5 micrometers Figure adapted from: Cosselman, K. E., Navas-Acien, A., & Kaufman, J. 
D. (2015). Environmental factors in cardiovascular disease. Nat Rev Cardiol, 12(11), 
627-642. doi: 10.1038/nrcardio.2015.152   
Air Pollution 
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13Figure 7.1b Proposed mechanism for how PM2.5 could increase susceptibility to 
PPCM. 
Exposure to PM2.5 may increase oxidative stress leading to increased reactive oxygen 
species and / or may cause endothelial dysfunction, both of these pathways are part of the 
currently accepted mechanism for the development of PPCM. Abbreviations: STAT3, 
signal transducer and activator of transcription 3; PGC-1α, proliferator-activated 
receptor-gammacoactivator-1α; sFlt1, soluble Fms-like tyrosine kinase 1; 16Kd, 16-kDa 
form of prolactin; MnSOD, manganese superoxidedimutase; CathD, cathepsin D; PRL, 
prolactin; VEGF-A/B, vascular endothelial growth factors; ROS, reactive oxygen species. 
Figure adapted from Arany, Z., & Elkayam, U. (2016). Peripartum Cardiomyopathy. 












14Figure 7.2 Study area with PM2.5 monitoring locations and residential addresses. 
 
15Figure 7.2a All Monitors in or around the study area. 
The counties colored darker blue are the 27 counties included in the Rochester Epidemiology Project and the lighter blue are other 
MN or WI counties. Red push pins signify the locations of the 129 AQS PM2.5 monitors at 87 unique sites located in or around the 
study area that are or have been active at any time during the study’s time frame. Location of cases are indicated by dark stars and 
locations of controls by the light stars. Abbreviations: AQS, Air Quality System; MN, Minnesota; PM2.5, particulate matter with 







16Figure 7.2b Monitors used in this study. 
Locations of 19 PM2.5 monitoring stations included in this case study are marked by red push pins. Location of cases are indicated by 
dark stars and locations of controls by the light stars. Monitors that are outside of the direct study area are included on the map when 
these monitors matched cases or controls as the “closest monitor” or “closest monitor with data from appropriate date”.  






17Figure 7.3 Active data ranges for each of the 19 PM2.5 monitoring locations included in this study. 


























18Figure 7.4 Major Roadways using MTFCC Classifications. 
S1100 Primary Road Road/Path Features (Orange) are limited-access highways that connect to other roads only at interchanges and 
not at at-grade intersections. This category includes Interstate highways, as well as all other highways with limited access (some of 
which are toll roads). Limited-access highways with only one lane in each direction, as well as those that are undivided, are also 
included under S1100. S1200 Secondary Road Road/Path Features (green) are main arteries that are not limited access, usually in the 
U.S. highway, state highway, or county highway systems. These roads have one or more lanes of traffic in each direction, may or may 
not be divided, and usually have at-grade intersections with many other roads and driveways. They often have both a local name and a 





19Figure 7.5 Average annual daily traffic (AADT) density maps for the study area 
 
20Figure 7.5a Average Annual Daily Traffic estimates for road segments in and near the study area. 






21Figure 7.5b Only road segments with AADT volume of 125,000 cars or higher.  
There are no road segments with average annual daily traffic (AADT) volume >125,000 with in the predominantly rural study area. 





Chapter 8: Conclusions 
 
 
 Peripartum Cardiomyopathy (PPCM) can have a profound effect on previously 
healthy young women as well as their families. The cause of PPCM is not fully understood, 
but it is most likely multifactorial and driven by a vasculotoxic environment caused by late 
pregnancy hormones. Susceptibility to PPCM may also be increased by other factors such 
as oxidative stress, inflammation, infection, and anti-angiogenic molecules. One well 
known environmental source of inflammation and oxidative stress that is linked to the 
development of multiple types of cardiovascular disease is air pollution including PM2.5. 
Based on the known associations between PM2.5 exposure and multiple types of 
cardiovascular disease as well as the potential mechanistic overlaps in pathophysiology we 
hypothesized that exposure to PM2.5 during pregnancy and post-delivery may increase the 
risk of developing PPCM. 
 To investigate our hypothesis a case-control cohort was created using the Rochester 
Epidemiology Project (REP). Previous studies of PPCM either relied on diagnosis codes 
to identity cases or were limited to the information available in the institution(s) medical 
records. Using the REP as the data source for our cohort allowed us to create, to our 
knowledge, the first population level study of PPCM with complete medical record review 
to confirm diagnosis. The REP is a unique, data rich, long standing resource for conducting 
epidemiology studies and we envisaged leveraging all the strengths of the REP to study the 





 The first part of this dissertation, presented in Chapter 2, was a clinically focused 
literature review of PPCM including subsections on the case definition, epidemiology, 
pathophysiology, genetics and risk factors, diagnosis, biomarkers, treatment, outcomes, 
subsequent pregnancy, additional clinical concerns, knowledge gaps, and clinical care 
points. This manuscript was published in Cardiology Clinics: Douglass EJ, Blauwet LA. 
Peripartum Cardiomyopathy. Cardiology Clinics 2021;39(1):119-142. DOI: 
10.1016/j.ccl.2020.09.008.  
 The two studies presented in Chapters 4 and 5 of this dissertation present the first, 
to our knowledge, population level epidemiology studies of PPCM that use complete 
medical record review to confirm diagnosis. After full medical record review only 55% 
(48/88) of women with diagnosis codes for PPCM in their medical records were confirmed 
to have PPCM. This result supports our decision to create a new cohort from the REP 
database to reduce misclassification bias in the cohort used to conduct the environmental 
epidemiology study proposed in Aim 2 of this dissertation. 
 First, we created a cohort of residents residing in Olmsted County, MN which has 
the most complete coverage of any county included in REP at 99.9%, with the data 
presented in Chapter 4. Based on this cohort of 15 women the incidence rate of PPCM in 
Olmsted County, MN from 1970-2014 was calculated to be 20.3 cases per 100,000 live 
births.1 The women in this study had complete cardiac recovery post diagnosis. There were 
multiple subsequent pregnancies with a 26% relapse rate, but all of these women fully 
recovered with none developing persistent cardiac dysfunction or needing device therapy 
or transplant. Using the data from this study we identified five potential novel risk factors 





small sample size of the Olmsted County cohort (n=15) we next expanded our study to the 
entire 27 county region of the Rochester Epidemiology Project. For the expanded study we 
also identified controls at a 2:1 ratio to be used for the epidemiology case-control study as 
well as the air pollution analysis. We matched controls on race, age, and number of babies 
born during the index pregnancy for a total of 48 cases and 96 controls. These results of 
the epidemiology study of cases and controls are presented in Chapter 5 as a manuscript 
that was published in the Journal of Cardiac Failure: Douglass EJ, et al. A Case-Control 
Study of Peripartum Cardiomyopathy Using the Rochester Epidemiology Project. J Card 
Fail. 2021 Feb;27(2):132-142. doi: 10.1016/j.cardfail.2020.12.021. Epub 2021 Jan 1. 
PMID: 33388468.  
 This larger epidemiology case-control study found that women with PPCM had a 
higher median BMI and were more likely to be overweight or obese. They were also more 
likely to have government-sponsored healthcare and unplanned pregnancies compared to 
controls who had higher rates of private insurance and planned pregnancies. As in previous 
studies of PPCM, hypertensive disease of pregnancy during index pregnancy was a major 
risk factor. The study further supports the finding that prior diagnosis of migraines 
(p<0.001) and anxiety (p=0.03) may be novel risk factors for PPCM. The study also found 
an impact on the infants born during the index pregnancies that infants born to women with 
PPCM had lower birth weights and were more likely to be born at an earlier gestational 
age (i.e., premature). The diagnosis, treatment, and outcomes of the 48 women were also 
presented in this manuscript with the majority (89.6%) having recovered cardiac function, 
with only 1 death and no transplants. There were multiple subsequent pregnancies in both 





unplanned subsequent pregnancies and more likely to end their pregnancies in 
terminations. All but one of the women with PPCM had recovered cardiac function prior 
to subsequent pregnancy and while there was 12.6% relapse rate, all of the women 
recovered full cardiac function post relapse.  
 The second aim of this dissertation was to test the hypothesis that exposure to 
elevated levels of PM2.5 during pregnancy increases the risk of developing PPCM. We 
chose to create a cohort from the REP as it presents a unique opportunity to study 
relationships between environmental exposure and disease outcomes at a population level 
with increased generalizability compared to single or multi -center studies and to examine 
the effect of PM2.5 exposure on the development of PPCM. However, due to limitations in 
air monitoring availability in rural areas, this hypothesis was not able to be tested with the 
planned study design. Instead, in Chapter 7, we present a manuscript of a case study of 
problems with current monitoring tools and how this hypothesis could be addressed if more 
complete data were available. We then provide policy recommendations to address the 
issues that were identified.  
 We initially attempted to measure PM2.5 exposure using data from the US EPA 
AQS Monitoring Network by matching each study participant to the nearest PM2.5 monitor 
that was active at the time of interest for each person (diagnosis date for cases and delivery 
date of index pregnancy for controls) using ArcGIS Pro. During this part of the study the 
following issues that prevented completion of the aim using monitoring data were 
identified: 1) 24/144 women did not have any monitoring data available as their dates of 
interest occurred before the first monitoring began in the study area, 2) the distance to 





405.1 km with a median distance of 10.0 km, 3) due to the large distance between some 
residential addresses and monitoring locations the geographical locations would not be 
similar potentially leading to differential misclassification of exposure as controls lived 
further from monitors then cases, and 4) due to the matching design of the study the 24 
women missing monitoring data would result in 19 case/control sets (57 women total) 
being dropped from the study significantly reducing the sample and possibly introducing 
bias. These four issues prevented us from being able to complete an analysis using EPA 
monitoring data for the exposure measure. 
 As a next step we identified two alternate methods to evaluate Aim 2 using two 
commonly used surrogate measures of air pollution/ PM2.5 as exposure measures: distance 
to major roadway and traffic density. The first method used was distance to major roadway, 
which has been used in many published research studies.2-13 When obtaining data for this 
option from the MN and WI Departments of Transportation we discovered that only recent 
years were available in a format that could be used in ArcGIS Pro and the other dates were 
only available as PDFs (which were not accessible due to COVID restrictions). To 
complete the case study, we choose to use data from 2019 which is the most recent year of 
ArcGIS Pro compatible data available accepting that there would potentially be non-
differential misclassification bias due to changes in roads over time. We were able to use 
the data from 2019 to demonstrate how this type of analysis could be used if more complete 
data were available. However, while the initial analysis using distance to primary roadway 
did not show any significant difference in distance to major roadway between cases and 
controls, we felt that it was difficult to draw any conclusions from these data as only 3-





address this limitation, we completed a second analysis with major roadway defined as 
either primary or secondary roadways, which also did not find any significant difference 
in distance to major roadway between cases and controls. 
 The second surrogate measure used to estimate exposure to PM2.5 was annual 
average daily traffic (AADT) which is also commonly used in previously published 
studies.2,3,7,14-21 We attempted to identify the road with the highest AADT within specific 
buffered distances of each residential address treating AADT both as a continuous and a 
categorical variable. When considering AADT as a continuous variable the results 
suggested that controls may live closer to higher traffic density roads, but only using a 
1000m buffer; the categorical data found no significant difference in highest traffic density 
level between cases and controls. These data also had a number of limitations that made it 
difficult to draw conclusions including: 1)we could not obtain data from every year of 
interest for the study (again they were only available as PDFs) and had to use data from 
just one year leading to potential non-differential misclassification, 2) traffic counts were 
only conducted on each road segment once every 3 or 6 years depending on the location so 
that data were not available for matching the date of interest in this study, 3) within the 
predominantly rural study area there were no roads with AADT >125,000 which is the cut-
off point used by the U.S. DOT to define major roadway, 4) when treating AADT as a 
continuous variable a large number of study participants had no roads with measured data 
within the smaller buffer sizes, and 5) when treating AADT as a categorical variable most 
of the higher AADT volume group categories (which are generally considered as 
significant exposure levels) have no, or very low, values in this predominantly rural area. 





density) highlighted by our results, was that in rural areas, like the study area, traffic was 
often not the main source of PM2.5 air pollution limiting the appropriateness of using these 
surrogates to measure PM2.5 air pollution exposure in this study population.  
 The manuscript which is going to be submitted to the Environmental Law Reporter 
in Chapter 7 also addressed Aim 3 of the dissertation, which discussed the public health 
implications and potential policy opportunities that arise from the results of Aim 2. Based 
on the results of our case study traffic-based surrogates for PM2.5 do not appear to be good 
measures of exposure in this rural population and PM2.5 air monitoring would be the most 
accurate exposure metric. However, the current level of EPA monitoring in rural areas is 
not sufficient to assess relationships between PM2.5 exposure and potential resulting health 
effects such as PPCM. This assessment gap also makes it difficult to determine whether 
PM2.5 levels required by the Clean Air Act to protect human health are within an adequate 
margin of safety. To address these concerns we made the following policy 
recommendations: 
1) Design monitoring with research in mind to improve the quality and 
accessibility of data to further research and not just to measure attainment which 
would include increasing monitoring locations while also keeping all previous 
monitors active continuously, 
2) Increase the focus of monitoring and remediation not only for urban areas but 
also for non-urban areas where populations have geographical and economic 
differences that may lead to altered susceptibility to the adverse health effects 





3) Add pregnant women to the list of EPA designated “at-risk” populations as 
current research in the field supports this and doing so could increase protection 
for this very large group of particularly vulnerable women, 
4) Increase funding available for monitoring, data acquisition and analysis, 
providing funding to state and local governments tasked with designing and 
implementing the monitoring, and fund research that uses these monitoring 
tools to assess the impact of pollution on human health. 
 Each of these 4 policy recommendations would help strengthen the human health 
protection from PM2.5 exposure required by the CAA. The most recent Integrated Science 
Assessment for PM from the US EPA concludes that there is a casual relationship between 
exposure to PM2.5 and specific cardiovascular health effects, and for the first time that 
exposure to PM2.5 during pregnancy may affect maternal health,
22 but more data are needed 
to draw a conclusion particularly related to pregnant women. However, as the case study 
in this dissertation shows, currently available monitoring tools are hindering research to 
generate the additional data needed by the US EPA to draw a conclusion about the effects 
of PM2.5 exposure on maternal health during pregnancy. The omission of endpoints like 
PPCM from the US EPA’s analysis leaves pregnant women, a large population with 
potentially increased susceptibility, unprotected. Increased funding to develop and 
implement a monitoring system based on scientific and not just compliance measurement 
needs would allow the US EPA to increase protection of human health from air pollution 
including PM2.5 exposure to pregnant women, and all other populations. Without these 
changes the US EPA may fail to meet its duty to protect human health with an adequate 








1. Douglass EJ, Cooper LT, Jr., Morales-Lara AC, et al. A Case-Control Study of 
Peripartum Cardiomyopathy Using the Rochester Epidemiology Project. Journal of 
cardiac failure 2021;27(2):132-142. DOI: 10.1016/j.cardfail.2020.12.021. 
2. Malmqvist E, Jakobsson K, Tinnerberg H, Rignell-Hydbom A, Rylander L. 
Gestational diabetes and preeclampsia in association with air pollution at levels 
below current air quality guidelines. Environmental health perspectives 
2013;121(4):488-93. DOI: 10.1289/ehp.1205736. 
3. Yorifuji T, Naruse H, Kashima S, Murakoshi T, Doi H. Residential proximity to 
major roads and obstetrical complications. The Science of the total environment 
2015;508:188-92. DOI: 10.1016/j.scitotenv.2014.11.077. 
4. Yorifuji T, Naruse H, Kashima S, et al. Residential proximity to major roads and 
preterm births. Epidemiology 2011;22(1):74-80. (In eng). DOI: 
10.1097/EDE.0b013e3181fe759f. 
5. Grahame TJ, Schlesinger RB. Cardiovascular health and particulate vehicular 
emissions: a critical evaluation of the evidence. Air quality, atmosphere, & health 
2010;3(1):3-27. (In eng). DOI: 10.1007/s11869-009-0047-x. 
6. Hart JE, Puett RC, Rexrode KM, Albert CM, Laden F. Effect Modification of Long-
Term Air Pollution Exposures and the Risk of Incident Cardiovascular Disease in 






7. Wu M, Ries JJ, Proietti E, Vogt D, Hahn S, Hoesli I. Development of Late-Onset 
Preeclampsia in Association with Road Densities as a Proxy for Traffic-Related Air 
Pollution. Fetal diagnosis and therapy 2016;39(1):21-7. (In eng). DOI: 
10.1159/000381802. 
8. Fuks KB, Weinmayr G, Foraster M, et al. Arterial blood pressure and long-term 
exposure to traffic-related air pollution: an analysis in the European Study of 
Cohorts for Air Pollution Effects (ESCAPE). Environmental health perspectives 
2014;122(9):896-905. DOI: 10.1289/ehp.1307725. 
9. Fuks K, Moebus S, Hertel S, et al. Long-term urban particulate air pollution, traffic 
noise, and arterial blood pressure. Environmental health perspectives 
2011;119(12):1706-11. DOI: 10.1289/ehp.1103564. 
10. Weaver AM, Wellenius GA, Wu WC, Hickson DA, Kamalesh M, Wang Y. 
Residential distance to major roadways and cardiac structure in African Americans: 
cross-sectional results from the Jackson Heart Study. Environmental health : a 
global access science source 2017;16(1):21. DOI: 10.1186/s12940-017-0226-4. 
11. Kingsley SL, Eliot MN, Whitsel EA, et al. Residential proximity to major roadways 
and incident hypertension in post-menopausal women. Environmental research 
2015;142:522-8. DOI: 10.1016/j.envres.2015.08.002. 
12. Kirwa K, Eliot MN, Wang Y, et al. Residential proximity to major roadways and 
prevalent hypertension among postmenopausal women: results from the Women's 
Health Initiative San Diego Cohort. Journal of the American Heart Association 





13. Sorensen M, Hoffmann B, Hvidberg M, et al. Long-term exposure to traffic-related 
air pollution associated with blood pressure and self-reported hypertension in a 
Danish cohort. Environmental health perspectives 2012;120(3):418-24. DOI: 
10.1289/ehp.1103631. 
14. Olsson D, Mogren I, Eneroth K, Forsberg B. Traffic pollution at the home address 
and pregnancy outcomes in Stockholm, Sweden. BMJ open 2015;5(8):e007034. 
DOI: 10.1136/bmjopen-2014-007034. 
15. Pereira G, Haggar F, Shand AW, Bower C, Cook A, Nassar N. Association between 
pre-eclampsia and locally derived traffic-related air pollution: a retrospective 
cohort study. Journal of epidemiology and community health 2013;67(2):147-52. 
(In eng). DOI: 10.1136/jech-2011-200805. 
16. van den Hooven EH, Jaddoe VW, de Kluizenaar Y, et al. Residential traffic 
exposure and pregnancy-related outcomes: a prospective birth cohort study. 
Environmental health : a global access science source 2009;8:59. (In eng). DOI: 
10.1186/1476-069x-8-59. 
17. Wu J, Wilhelm M, Chung J, Ritz B. Comparing exposure assessment methods for 
traffic-related air pollution in an adverse pregnancy outcome study. Environmental 
research 2011;111(5):685-92. (In eng). DOI: 10.1016/j.envres.2011.03.008. 
18. Kan H, Heiss G, Rose KM, Whitsel EA, Lurmann F, London SJ. Prospective 
analysis of traffic exposure as a risk factor for incident coronary heart disease: the 
Atherosclerosis Risk in Communities (ARIC) study. Environmental health 





19. Janssen NA, Schwartz J, Zanobetti A, Suh HH. Air conditioning and source-
specific particles as modifiers of the effect of PM(10) on hospital admissions for 
heart and lung disease. Environmental health perspectives 2002;110(1):43-9. 
(http://www.ncbi.nlm.nih.gov/pubmed/11781164). 
20. Lipfert FW, Wyzga RE, Baty JD, Miller JP. Traffic density as a surrogate measure 
of environmental exposures in studies of air pollution health effects: Long-term 
mortality in a cohort of US veterans. Atmospheric Environment 2006;40(1):154-
169. DOI: https://doi.org/10.1016/j.atmosenv.2005.09.027. 
21. Medina-Ramon M, Goldberg R, Melly S, Mittleman MA, Schwartz J. Residential 
exposure to traffic-related air pollution and survival after heart failure. 
Environmental health perspectives 2008;116(4):481-5. DOI: 10.1289/ehp.10918. 
22. U. S. Environmental Protection Agency. U.S. EPA. Integrated Science Assessment 







































































































































































































































Erika J. Douglass, MPH, DrPH 





Doctor of Public (DrPH), Environmental Health and Engineering  2012-2021 
 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland   
 Honors: Health, Human Resources & Services Public Health Training Grant 2012- 
   2013 
   Environmental Health Sciences Student Org. DrPH representative 2012-2014 
 
Master of Public Health       2010-2011  
 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland   
 Certificate: The Risk Sciences and Public Policy 
 Capstone: Sex Differences in Vitamin D Binding Protein are Associated with Increased 
 Myocarditis in Men and Male Mice. 
 
Bachelor of Art, Major Biochemistry & Minor German    1999-2003 
Occidental College - Los Angeles, California     
 Honors: Truman Scholarship (4 years)  
 Occidental College Tenure Track Neurobiologist Search Committee 
 
 
WORK EXPERIENCE  
Cardiovascular Research Liaison       2015-current 
Mayo Clinic, Jacksonville, FL        
• Appointment to the Division of Cardiovascular Diseases to help develop and facilitate a 
translational research program for the department. 
• Developed and lead monthly Cardiovascular Research Conference for the department. 
• Coordinated Fellows research experiences and projects. 
• Assist in the development and implementation of human subjects research for the 
department including protocol development, IRB applications, study coordination, and 
funding proposals. 
• Liaise with other units that support research – including the Clinical Trials Unit, Office of 
Special Projects Administration, Institutional Review Board, and Health Sciences 
Research. 
• Liaise with outside vendors and organizations. 
 
Research Trainee        2015 
Mayo Clinic, Rochester, MN        
• Appointment to the Division of Cardiovascular Diseases to conduct research on the 
incidence, risk factors, environmental associations, and outcomes of Peripartum 






Research Assistant          
Children and Nature Network, Minneapolis, MN     2014-2015  
• Conducted comprehensive literature review on the effects of exposure to nature on 
children’s physical health and created annotated bibliography of identified peer-reviewed 
studies. 
•  Produced written research summary synthesizing collected information and identifying 
gaps and future directions for research. 
 
Teaching Assistant        2013-2013 
Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 
• Food & Waterborne Disease - contributed to writing of exams, interacted with students 
by email, in person, and in the classroom setting to enhance their learning experience, 
and administered and graded exams. 
• Professional Epidemiology Methods I – co-taught lab sessions, conducted office hours 
regularly to assist students, interacted with students individually and in a class setting, 
graded class reports. 
 
ASPH/EPA Environmental Health Fellow     8/2011-8/2012 
Association of Schools of Public Health /US Environmental Protection Agency, Washington, D.C 
• Co-Author on EPA report America’s Children and the Environment-Third Edition, 
published January 2013. 
• Collaborating with EPA researchers in Washington, Boston, and Research Triangle Park 
to develop web-based tools for community level cumulative risk assessment. Developing 
a model for including health outcomes in the Community-Focused Exposure and Risk 
Screening Tool (C-FERST) using Asthma as the health outcome. Helping to develop the 
modeling function of Community Cumulative Assessment Tool (CCAT) and working on 
a case study to apply the tool to a community for the first time. These tools and models 
will be used to assist communities in identifying, prioritizing, for community level health 
concerns.  
 
Research Specialist        6/2011-9/2011 
Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 
• Conducted immunological research on the role of vitamin D and vitamin D binding 
protein in an animal model of autoimmune myocarditis. 
• Developed standard operating procedures for the research group including for PCR, gel 
electrophoresis, and mouse genetic typing. 
• Contributed to data analysis and manuscript writing. 
 
Certified Clinical Research Coordinator - Cancer Institute   7/2007-6/2010 
Benaroya Research Institute, Seattle, Washington 
• Recruitment coordinator – screened medical records of every patient seen in the clinic 
daily to identify potential study participants and then present research studies to identified 
patients. 
• Coordinate Genitourinary Oncology trials - Complete all aspects of clinical trials 
including study start up, recruitment, informed consent process, coordinate participant 
visits, meet with patients in a clinical setting, collect and manage data, and process and 






Clinical Research Assistant - Type I Diabetes Institute   1/2007-7/2007 
Benaroya Research Institute, Seattle, Washington 
• Performed duties to support the conduction of clinical trials including managing a type I 
diabetes registry, conducting patient visits, acting as a phlebotomist, processing 
specimens, conducting outreach at health fairs and other events, and completing internal 
review board submissions. 
 
Research Scientist – Immunology      6/2003-1/2007 
University of Washington, Seattle, WA 
• Executed directed research regarding the innate immune response to Pseudomonas 
aeruginosa including the development of transgenic mice expressing human genes. 
• Conducted management duties including: general lab organization, chemical inventory, 
supply and equipment procurement, safety standards enforcement and waste 
management. 
• Developed proficiency in animal and laboratory techniques including PCR, RTPCR, 
ELISA, LUMINEX, DNA and RNA isolation, flow cytometry, western blots, 
transgenics, bacterial cloning, and cell culture. 
 
Teaching Assistant         2001-2003 
Occidental College, Los Angeles, CA 
• Prepared and instructed laboratory classes with the professors, graded examinations and 
laboratory reports, led review sessions, and peer-advised up to 50 students on course 
material for Organic Chemistry, Introduction to Molecular Biology, and Molecular 
Biology classes. 
 
Research Intern - Summer Undergraduate Research Program   2001 
University of Texas Medical Branch, Galveston, TX 
• Conducted molecular research to enhance the understanding of how certain molecules 
work to protect proteins from damage during freezing or dehydration. 




Computer Skills:  Microsoft Office Products (Word, Excel, Access, and PowerPoint), 
STATA, ArcGIS Pro, REDCap 
Languages:   English (fluent), German (fluent) 
Memberships:   American Association of Immunologists (2016-2017) 
American Public Health Association (2011-2015) 
   Organization for the Study of Sex Differences (2011-present) 
Sigma Xi - National Scientific Research Fraternity (2001-2013) 
Association of Clinical Research Personnel (2007-2011) 
Southwest Oncology Group (2007-2010) 
Awards & Honors:  U.S. Public Health Service Training Grant, JHSPH & NIH (2012-2013) 
Certificate of Appreciation, Clinical Research Program, Benaroya 
Research Institute (2008) 
Truman Scholarship, Occidental College (1999-2003) 
Sealy Center for Structural Biology Award (2001) 





Selected Volunteer:  Mayo Clinic Florida - American Heart Association Heart Walk   
   Communications Chair (2015-2021)  
   Why Not Us Foundation – Project HERO (2014-2015) 
Johns Hopkins Bloomberg School of Public Health Green Student Group 
 (2010-2013) 
JH-U-Turn (The Really Big Super Cheap Hopkins Garage Sale) (2011) 
   Johns Hopkins Bloomberg School of Public Health Career Fair   
   Volunteer (2011) 
   Amara Parenting and Adoption Agency Board Intern (2005-2006) 
Exceed Board of Directors Program (2005-2006) 
Habitat for Humanity – Occidental College Chapter (2000-2003)  
PUBLICATIONS 
Peer-reviewed 
Douglass EJ, Blauwet LA. (2021) Peripartum Cardiomyopathy. Cardiology Clinics, 2021-02-01; 
39 (1): 119-142. doi: 10.1016/j.ccl.2020.09.008. 
 
Douglass EJ, Cooper LT, Morales-Lara AC, Adedinsewo DA, Rozen TD, Blauwet LA, 
Fairweather D. (2021) A Case-Control Study of Peripartum Cardiomyopathy Using the Rochester 
Epidemiology Project. Journal of Cardiac Failure. 27 (2):132-142. doi: 
10.1016/j.cardfail.2020.12.021. 
 
Bruce AJ, Pincelli TP, Heckman MG, Desmond CM, Arthurs JR, Diehl NN, Douglass EJ, Bruce 
CJ, Shapiro SA. (2020) A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to 
Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. Dermatologic Surgery. 
46(6):826–832. doi: 10.1097/DSS.0000000000002168. 
 
Coronado MJ, Bruno KA, Blauwet LA, Tschöpe C, Cunningham MW, Pankuweit S, van Linthout 
S, Jeon ES, McNamara DM, Krejčí J, Bienertová-Vašků J, Douglass EJ, Abston ED, Bucek A, 
Frisancho JA, Greenaway MS, Hill AR, Schultheiss HP, Cooper LT Jr, Fairweather D. (2019) 
Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis. J 
Am Heart Assoc. Jan 22;8(2): e008968. doi: 10.1161/JAHA.118.008968. PubMed PMID: 
30638108; PubMed Central PMCID: PMC6497352. 
 
Vuky J, Pham HT, Warren S, Douglass E, Badiozamani K, Madsen B, Hsi A, Song G. (2012) 
Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated 
Radiation Therapy (IMRT) in High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. Mar 
15;82(4):e609-15. Epub 2011 Dec 28.  
Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, Woods AS, Gowda DC. 
(2005) Induction of proinflammatory responses in macrophages by the 
glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, 
glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol 
Chem. Mar 4; 280(9):8606-16. 
Not peer reviewed  
Axelrad D, Adams K, Chowdhury F, D’Amico L, Douglass E, Hudson G, Lam J, Lorenz A, 





America’s Children and the Environment, Third Edition. US Environmental Protection Agency. 
January 2013. 
 
PUBLICATIONS UNDER REVIEW 
 
Adedinsewo DA, Johnson PW, Douglass EJ, Attia, IZ, Phillips SD, Goswami RM, Yamani MH, 
Connolly HM, Rose CH, Sharpe EE, Blauwet LA, Lopez-Jimenez F, Friedman PA, Carter RE, 
Noseworthy PA. (2021) Detecting Cardiomyopathies in Pregnancy and the Postpartum Period with 
an Electrocardiogram-Based Deep Learning Model. JACC Submitted May 2021. Under Review 
 
Krishnarao K*#, Bruno KA*, Di Florio DN, Hill AR, Cornell LF, Tan W, Geiger XJ, Douglass 
EJ, Fairweather D#, Yamani MH#. (2021) Endothelin 1 upregulation predicts chemotherapy-
induced cardiotoxicity in patients with breast cancer. JACC. Submitted April 2021. Under Review* 




Bruno KA, Cooper LT, Mathews JE, Douglass EJ, Brandt JE, Bucek A, Coronado MJ, Fairweather 
D. Sex differences in the effect of vitamin D on inflammatory heart disease: protective in women 
but damaging in men Cardiology. 2017; 137:294. 
 
Fairweather D, Bruno KA, Mathews JE, Coronado MJ, Douglass EJ, Hill AR, Frisancho JA, Bucek 
A, Blauwet LA, Cooper LT. Sex differences in biomarkers of heart failure Cardiology. 2017; 
137:260.  
 
Stafford K, Cooper L, Douglass E, Brandt J, Bucek A, Coronado M, Kew R, Fairweather D. Sex 
differences in the effect of vitamin D on inflammatory heart disease: protective in women but 




Douglass EJ, Fairweather D, Blauwet LA. A population level epidemiological study of peripartum 
cardiomyopathy in a27 county region surrounding Olmsted County, Minnesota. (2018) Presented 
at the International Congress of Cardiac Problems in Pregnancy, Bologna, Italy on February 23.  
 
Douglass EJ, & Fairweather D. Sex Differences in Vitamin D Binding Protein are Associated with 
Increased Myocarditis in Men and Male Mice. (2011) Presented at Johns Hopkins Bloomberg 
School of Public Health, MPH Capstone Symposium on May 14. 
 
POSTERS 
Adedinsewo D, Siddiqui H, Attia Z, Cohen-Shelly M, Douglass E, Noseworthy P, Carter R. 2021. 
Title: Performance of a Deep Learning Model on Digitized Paper ECGs. Poster presented by 
Adedinsewo at 2021 Mayo Clinic AI Symposium held virtually May 17-18. 
Bruno KA, Douglass EA, Salomon G, Jain A, Cooper LT, Coronado MJ, Kew RR, Fairweather D. 





Translational Animal Model Reveals Mechanism. Poster presented by Bruno KA at the Heart 
Failure Society of America Annual Meeting held Virtually on September 30-October 6. 
 
Whelan E*, Bruno KA, Coronado MJ, Blauwet LA, Douglass EJ, Abston ED, Bucek A, Frisancho 
JA, Greenaway MS, Hill AR, Cooper LT, Fairweather D. 2019. Title: Elevated sera sST2 predicts 
heart failure in men under the age of 50 with clinically suspected myocarditis. Poster presented by 
Whelan E at the University of North Florida Showcase of Osprey Advancements in Research and 
Scholarship held in Jacksonville, FL on April 3. 
 
Bruno KA, Mathews JE, Greyer HD, Molina FA, Hill AR, DiFlorio DN, Scott AJ, Yang AL, 
Cooper LT, Hoyne JB, Douglass EJ, Brandt JE, Bucek A, Coronado MJ, Fairweather D. 2018. 
Title: Translational studies of sex differences in vitamin D/ vitamin D receptor on myocarditis. 
Poster presented by Bruno KA at the Celebration of Women’s Health Research held in Rochester, 
MN on October 18.  
 
Bruno KA, Mathews JE, Douglass EJ, Hill AR, Cooper LT, Hoyne JB, Fairweather D. 2018. Title: 
Sex differences in Vitamin D alter inflammation during heart disease. Poster presented by Bruno 
KA at the American Heart Association: Basic Cardiovascular Sciences Scientific Sessions (BCVS) 
held in San Antonio, TX on July 30-August 2. 
 
Bruno KA, Coronado MJ, Blauwet LA, Douglass EJ, Abston ED, Bucek A, Frisancho JA, 
Greenaway MS, Hill AR, Cooper LT, Fairweather D. 2018. Title: Elevated sera sST2 predicts heart 
failure in men under the age of 50 with clinically suspected myocarditis. Poster presented by Bruno 
KA at the Florida Chapter of the American Academy of Cardiology Annual Meeting held in 
Orlando, FL on August 17-19 
 
Di Florio DN*, Douglass EJ, Bruno KA, Hill AR, Mathews JE, Haley WE, Fairweather D. 2018. 
Title: Sex differences in vitamin D and urinary stone diseases. Poster presented by Bruno KA at 
the National Kidney Foundation held in Austin, TX on April 10-14. 
 
Sousou JM*, Bruno KA, DiFlorio DN, Hill AR, Mathews JE, Morales C, Douglass EJ, 
Rahinduwage H, Petrikovics I, Hoyne JB, Cooper LT, Fairweather D. 2018. Title: Vitamin D 
deficient diet decreases cardiac function during myocarditis in females, Poster presentation at 
Organization for the Study of Sex Differences Annual Meeting held in Atlanta, GA on April 30-
May 3. 
 
Mease AA*, Bruno KA, Di Florio DN, Douglass EJ, Haley WE, Fairweather D. 2018. Title: 
Cardiac involvement in urinary stone disease: sex differences in vitamin D, Poster presented by 
Mease AA at the Organization for the Study of Sex Differences Annual Meeting held in Atlanta, 
GA on April 30-May 3. 
 
Di Florio DN*, Douglass EJ, Bruno KA, Hill AR, Mathews JE, Haley WE, Fairweather D. 2018. 
Sex Differences in Vitamin D and Urinary Stone Diseases. Poster presented by Di Florio DN at the 







Douglass E, Fairweather D, Blauwet L. A 2017. Title: population level epidemiological study of 
peripartum cardiomyopathy in Olmsted County, Minnesota. Poster presented at the Celebration of 
Women’s Health at Mayo Clinic in Rochester, Minnesota on October 18. 
 
Bruno KA, Mathews JE, Greyer HD, Molina FA, Hill AR, DiFlorio DN, Scott AJ, Yang AL, 
Cooper LT, Hoyne JB, Douglass EJ, Brandt JE, Bucek A, Coronado MJ, Fairweather D. 2017. 
Title: Translational studies of sex differences in vitamin D/ vitamin D receptor on myocarditis. 
Presented by Bruno KA, at the Celebration of Women’s Health at Mayo Clinic in Rochester, 
Minnesota on October 18. 
 
Stafford K, Cooper L, Douglass E, Brandt J, Bucek A, Coronado M, Kew R, Fairweather D. 2013. 
Title: Vitamin D receptor signaling reduces inflammation in female mice with myocarditis, but 
increases inflammation in males: implications for translation studies, Poster presented by Stafford 
K at Organization for the Study of Sex Differences held in Weehawken, NY on April 25-27. 
  
Stafford K, Molina F, Clifford M, Douglass E, Cooper L, Brandt J, Bucek A, Fairweather D. 2013. 
Title: Vitamin D receptor signaling reduces inflammation in female mice with myocarditis, but 
increases inflammation in males: implications for translation studies, Poster presented by Stafford 
K at Society for Women’s Health Research held in Washington, DC on July 19. 
 
Stafford K, Cooper L, Douglass E, Brandt J, Bucek A, Coronado M, Kew R, Fairweather D. 2013. 
Title: Sex differences in the effect of vitamin D on inflammatory heart disease: protective in women 
but damaging in men, Poster presented by Stafford K at American Association of Immunologists 
held in Honolulu, Hawaii on May 3 - 7. 
 
Stafford K, Douglass E, Cooper L, Bucek A, Coronado M, Brandt J, Fairweather D. 2013. Title: 
Vitamin D receptor signaling reduces inflammation in female mice with myocarditis, but increases 
inflammation in males: implications for translation studies. Poster presented by Stafford K at Heart 
Failure Society of America held in Orlando, FL on September 22-25. 
 
Erika J. Douglass, Michael J. Coronado, Adriana Bucek, Douglas W. Mahoney, Jo D. Carryer, 
Leslie T. Cooper Jr, and DeLisa Fairweather. 2012. Title: Sex Differences in Vitamin D Binding 
Protein are Associated with Increased Myocarditis in Men and Male Mice. Poster presented at the 
8th International Congress on Autoimmunity in Granada, Spain May. 
 
Erika J. Douglass, Michael J. Coronado, Adriana Bucek, Douglas W. Mahoney, Jo D. Carryer, 
Leslie T. Cooper Jr, and DeLisa Fairweather. 2012. Title: Sex Differences in Vitamin D Binding 
Protein are Associated with Increased Myocarditis in Men and Male Mice. Presented at the 
Organization for the Study of Sex Differences 6th Annual Meeting in Baltimore. MD June 7-9. 
 
Stafford K, Cooper L, Douglass E, Brandt J, Bucek A, Coronado M, Kew R, Fairweather D. 2012. 
Title: Sex differences in the effect of vitamin D on inflammatory heart disease: protective in women 
but damaging in men. Poster presented by Stafford K at Organization for the Study of Sex 







Katlyn A Stafford, Erika J. Douglass, Jessica E. Brandt, Adriana Bucek, Michael J. Coronado, 
Richard R. Kew, Leslie T. Cooper Jr., and DeLisa Fairweather. Vitamin D receptor increases 
coxsackievirus B3 myocarditis. Poster presented by Stafford K at the Organization for the Study of 
Sex Differences 6th Annual Meeting in Baltimore. MD June 7-9. 
 
Axelrad D, Adams K, Chowdhury F, D’Amico L, Douglass E, Hudson G, Lam J, Lorenz A, 
McCoy E, Miller G, Newhouse K, Nweke O, Cantor Paster D, Sturza J, Underhill L, Weber K. 
2011. Title: Children's environmental health in the United States: Indicators from America's 
Children and the Environment. Poster presented by Axelrad DA at the American Public Health 
Association 139th Annual Meeting in Washington, DC. 
 
Douglass E, Auton M, and Bolen DW. 2001. How Does Glycerol Enable Organisms to Survive 
Environmental Stress? Poster presented at 2001 Summer Annual Research Program Poster Session, 
University of Texas Medical Branch, Galveston TX, August. 
